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ZUSAMMENFASSUNG 
Myxobakterien haben sich als sehr nützliche Naturstoffproduzenten erwiesen, da sie eine 
Vielzahl von Sekundärmetaboliten mit einzigartigen Strukturen liefern. Diese Naturstoffe 
besitzen darüber hinaus häufig biologische Aktivität und weisen neuartige Wirkmechanismen 
auf. 
Diese Arbeit vermittelt erste Einblicke in den Wirkmechanismus des myxobakteriellen 
Metabolits Prätubulysin. Synthetisches Prätubulysin und einige Derivate davon sind in 
größeren Mengen verfügbar und wurden im Zuge dieser Arbeit charakterisiert. Durch diese 
Bioaktivitätsstudien konnte eindeutig gezeigt werden, dass Prätubulysine zu einer 
Depolymerisation von Mikrotubuli führen und im Weiteren einen mitotischen Arrest und 
Apotose in kultivierten Säugerzellen induzieren. Durch vergleichende Studien mit mehreren 
synthetischen Analoga konnten darüber hinaus wichtige Struktur-Aktivitäts-Beziehungen 
hergeleitet werden.  
Ein weiteres Thema dieser Arbeit war die Implementierung von High-Content-Screening für 
die bioaktivitätsgeleitete Aufreinigung von Sekundärmetaboliten aus Myxobakterien. Im 
Laufe der Untersuchungen wurden so über 30 neue Chondramid-Derivate in Extrakten von 
Chondromyces sp. gefunden und zum Teil isoliert. Die biologische Evaluierung der 
Reinstoffe, die eine Polymerisation von G-Aktin induzieren, erbrachte wichtige Struktur-
Aktivitäts-Beziehungen. Außerdem lieferten zellbasierte und in vitro-Studien im Falle von 
bromierten Analoga Hinweise auf ein vermeintliches zweites zelluläres Target. 
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ABSTRACT 
Myxobacteria have proven to be highly valuable as sources of natural products since they 
produce a variety of secondary metabolites with unique structures. These natural products 
often exhibit astonishing biological activities with a new mode-of-action.  
This thesis provides new insights into the mode-of-action of the myxobacterial metabolite 
pretubulysin. Synthetic pretubulysin and some of its derivatives, which are available in gram-
scale quantities, were characterized and bioactivity studies clearly showed the compounds’ 
ability to depolymerize microtubules. Pretubulysin treatment consequently leads to mitotic 
arrest and the induction of apoptosis in cultured mammalian cells. Furthermore, important 
structure-activity relationships were elucidated by comparing several synthetic analogs.  
Another topic of this thesis was the implementation of high-content screening for bioactivity-
guided isolation of secondary metabolites from myxobacteria. For this purpose, 
Chondromyces sp. extracts were subjected to several in-depth cell-based assays, which 
resulted in the discovery of over 30 new chondramide derivatives. Compounds of this class 
are described to target actin filaments with a phalloidin-like binding mode. In addition to 
structure-activity relationship insights, the biological evaluation of purified compounds 
provided evidence for a putative second target for some brominated analogs of this exciting 
class of natural products. 
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INTRODUCTION 
1.1 NATURAL PRODUCTS 
Traditionally, the main sources of natural products (NPs) are soil bacteria, fungi, and higher 
plants. In the last decades, cyanobacteria and marine organisms were additional resources of 
particular interest.[1] The term natural product is thereby commonly defined as a compound 
derived from natural sources, which mostly exhibits some biological activities.[2] The 
definition is not clear-cut and ‘natural product’ is most often referred to as secondary 
metabolite, thus, describing naturally produced compounds that have no direct role in growth, 
development, and reproduction of the host. Secondary metabolites are rather involved in for 
instance, signaling, defense, cellular communication, differentiation, and sporulation. By this, 
the survival rate of the producer is improved in competition with other co-existing species.[3] 
A prominent example is Pseudomonas aeruginosa, the major pathogen in the lung of cystic 
fibrosis (CF) patients. Due to its ability to form biofilms and excrete toxic metabolites the 
Gram-negative bacterium has a competitive advantage against other colonizing bacteria.[4] In 
addition, it has been shown that instead of only creating a niche, P. aeruginosa interacts with 
other human-associated pathogens, like Candida albicans, via homoserine lactone, one of its 
quorum sensing molecules.[5, 6, 7] 
Contrary to the categorization of NPs as survival factors, the enormous structural diversity of 
natural product scaffolds and the high number of seemingly inactive metabolites (such which 
did not show activity in the assays performed) found with some producers, may be explained 
by the ‘Screening Hypothesis’. Fundamentally, this model is based on the assumption that any 
potent biological activity is a rare feature for any molecule to possess.[8, 9] Any organism that 
is able to produce its own chemically diverse ‘screening library’ at low cost, and by this, 
enhance the chance to produce metabolites with useful and potent biological activity, would 
be evolutionary favored.[9] 
1.1.1 NATURAL PRODUCTS AND PHARMACEUTICAL INDUSTRIES 
NPs have been used for millennia by humans to meet medical needs. For instance, in 
Traditional Chinese Medicine (TCM), which is an integral part of the Chinese culture, drugs 
are derived from natural sources, like herbal medicines, which are administered as complex 
mixture customized to each patient.[10] However, in Western pharmaceutical industry drug 
formulations of purified compounds have become more typical in the last century, and 
research on NPs as novel therapeutics reached its peak in the period 1970-1980.[2, 11] 
Introduction 
 
2 
Especially for the treatment of infections caused by bacterial pathogens, NP or NP-derived 
drugs were regarded as the ‘magic bullets’, but with the advancement of high-throughput 
screening (HTS) pharmaceutical companies de-emphasized NPs and instead, used chemical 
libraries in their screening campaigns where tens of thousands of small molecules are 
screened per week.[2] This reflects one of the major drawbacks when it comes to NPs: low 
production yields and issues with continuous supply.[12, 13] The classic case for the ‘supply 
issue’ is taxol (or paclitaxel), which was first isolated in 1969 from Taxus brevifolia (Pacific 
yew) bark (Figure 1-1).[14] Taxol acts by promoting tubulin polymerization and stabilizing 
microtubules, and its clinical activity against ovarian cancer was first reported in 1989.[15, 16] 
By that time, the NP was only available from the bark of the Pacific yew, which was subject 
of the ‘taxol supply crisis’.[17, 18] Despite the initiation of large bark collection programs, 
semisynthetic approaches were developed and Bristol-Myers Squibb is now producing this 
blockbuster drug by plant tissue culture.[19] 
 
Figure 1-1: Taxus brevifolia leaves and chemical structure of taxol (paclitaxel). 
In addition to the supply issue from biological sources, synthetic routes towards NP scaffolds 
are often very complex and far from being economical, as again seen in the case of taxol.[20, 21] 
Ideally, chemical synthesis creates a rapid access to NPs with reasonable yields in only a few 
practical synthetic steps.[22] 
Despite these apparent drawbacks, NPs still play a significant role in the field of drug 
discovery and development of novel pharmaceuticals, particularly as anticancer and 
antiinfective agents, but also as immunosuppressive, cholesterol-lowering, and other drugs. 
As reviewed by Newman and Cragg recently, over 25% of all drugs approved between 1981 
and 2010 are NPs or directly NP-derived. If one would also take into account the large 
by J. Hollinger
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number of totally synthetic NP mimics or drugs with a NP pharmacophore, the total 
proportion of NP-like drugs would be >50% (Figure 1-2).[23] 
 
 
Figure 1-2: Sources of all new drugs approved between 1981 and 2010. 
In total, 1355 new chemical entities (NCE) were approved in the period 1981 to 2010. 
NP: natural product; NP-derived: mostly semisynthetic NP variant; Biological: large 
peptides or proteins; Vaccine: biological preparation to improve immunity to certain 
diseases; Synthetic: totally synthetic drug; NP-inspired: NP mimics and totally 
synthetic with NP pharmacophore (adapted from ref. [23]). 
Although the process of drug discovery with NPs requires more patience and is generally 
slower than with pure synthetic libraries, hits derived from NP libraries or from bioactivity-
guided isolation approaches, are often higher quality leads.[2] Mainly the advantages of 
chemical diversity and numerous biological activities (NP scaffolds are seen as ‘privileged 
structures’) countervails against the issues mentioned above, especially as much higher hit 
rates can be expected.[11, 12, 13] It is also noticeable that out of thirteen natural product-related 
drugs approved between 2005 and 2007, five represent new classes of pharmaceuticals, which 
reflects the chemical diversity of natural products, and is a positive indicator that NPs still 
provide a good value to human medicine.[24] In addition to chemical diversity per se, NPs are 
optimized in terms of possible protein interactions. In general, protein families belong to a 
finite number of structural elements (folds), and similar folds can even be found in proteins 
that are apparently different in their amino acid sequences. Due to their biosynthetic origin, 
NPs are optimized to interact with these common recognition elements within the protein 
structural arrangements.[25, 26] In virtue of three-dimensional structure similarities of proteins, 
even of proteins from different pharmacological classes, NPs are able to interact with a 
NP / NP-derived
26.8%
‚Biological‘
14.9%
Vaccine
5.9%
Synthetic
28.6%
Synthetic
(‚NP-inspired‘)
23.8%
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variety of biological target molecules and often modulate multiple signal transduction 
pathways.[26, 27] 
Nevertheless, major pharmaceutical companies mostly abandoned R&D programs on natural 
products over the last 20-30 years, and it seems unlikely that ‘Big Pharma’ will return to its 
former NP programs soon, as required investments are large. R&D is expected to rather be 
undertaken by smaller biotechnology companies or academia. This movement was mainly 
driven by business objectives, since it seemed more feasible to generate hits from large HTS 
libraries at much lower costs than with tedious NP discovery campaigns.[2, 28] However, this 
paradigm shift did not meet expectations and the overall success rates of compounds in 
phase I clinical trials were rather low.[29] This finding may partly be explained by the fact that 
many effective and successful drugs do not act on single molecules but interact with multiple 
receptors or enzymes, like kinase inhibitors in anticancer therapy. These drugs can target 
multiple pathways by inhibition of several key kinases and in turn, interact with major 
signaling pathways involved in cancer cell progression.[28, 30, 31] 
Typical HTS screening libraries do not appear to be the optimal strategy when it comes to 
assays that cover a broader range of biological interactions (phenotypic screening). Instead, 
privileged structures of NPs, like natural non-ribosomal peptides (NRPs) and polyketides 
(PKs)[32], seem preferred for these purposes, not only due to their inherent multiple binding 
domains. In order to compromise between efficient screening strategies using NP scaffolds 
and the aim of low costs, work has mainly been focussed on biological evaluation of pre-
fractionated simplified mixtures of crude extracts.[33] Major hurdles in the context of 
screening these mixtures have been overcome. Thus, lead generation from NPs is strongly 
accelerated in terms of technological advances in detection and structural elucidation, novel 
robust screening assays, as well as fermentation and process development.[28, 34] 
1.1.2 MICROBIAL PRODUCERS 
Mixtures of plant ingredients have widely been used in ancient medicine, but the isolation of 
morphine from opium produced by Papaver somniferum was one of the most important 
discoveries in medicine of the 19th century.[35, 36] Since then, isolation of single active 
ingredients from plant sources was commonly accomplished, enabling the administration of 
precise dosages. By now, ca. 100,000 bioactive metabolites have been described from higher 
plants.[37] Regarding microbial producers, the serendipitous discovery of penicillin from 
Penicillium fungi in 1929 by Fleming[38] initiated the era of antibiotics (with the period 
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1950 to 1960 entitled the ‘Golden Era’ in antibiotics discovery) and, in turn, a tremendous 
screening of microorganisms for new bioactive compounds. [1, 39] 
From a retrospective point of view, filamentous actinomycetales species (especially 
Streptomyces sp.) are the most productive source among the microbial producers. 
Actinomycetes are extensively studied and produce numerous bioactive secondary 
metabolites, with over 10,000 reported compounds, that make up approximately 45% of all 
bioactive microbial metabolites.[37] Nevertheless, success rates of discovering novel chemical 
entities from these microorganisms with potent biological activity decreased with time.[40] 
Furthermore, the fact that for instance the aminoglycoside antibiotic streptomycin, which was 
discovered in the 1940s, is produced by about 1% of soil actinomycetes, significantly hampers 
bioactivity-guided isolation of new antibiotics. Bioactivities of NCEs (new chemical entities) 
might be masked by the presence of known metabolites.[41] However, current attempts focus 
on the development of smart screening techniques, innovative enrichment methods of soil and 
marine sediments, more feasible fermentation strategies, genome mining for the discovery of 
novel chemotypes from ‘cryptic’ gene clusters, and combinatorial biosynthesis.[41, 42] 
Complementary to these efforts, actinomycetes from so far underexplored sources in terms of 
microbial diversity, like the marine environment, have been actively investigated in recent 
decades. For instance, members of the genus Marinispora or Salinispora have proven to be a 
promising source of new antibiotics, as e.g. the proteasome inhibitor salinosporamide, which 
is currently in phase I clinical trials as anticancer agent, is produced by 
Salinispora tropica. [43, 44, 45, 46] 
Besides Streptomyces sp. and rare actinomycetes (non-Streptomyces actinomycetales species), 
fungal species, in particular ascomycetes, several other filamentous fungi, and endophytes, are 
the second rich source of bioactive secondary metabolites, which include toxins as well as 
antibiotics.[37] Fungal secondary metabolite classes comprise mainly NRPs, PKs, or mixed 
NRP/PKs; less abundant compared to plant metabolites are terpenes and alkaloids.[47] With 
the availability of fungal genomes many efforts have been made to characterize fungal gene 
clusters in terms of regulation, activate silent clusters, and more generally, apply genome 
mining approaches for the discovery of new NPs.[47, 48] The total diversity of fungal species is 
estimated to be 1.5-1.6 million, based on a global extrapolation of sampled fungal 
communities in and around plant and soil ecosystems from Western Europe. Nevertheless, the 
total number of species is probably even much higher when taking into account that many 
unknown species of fungi from unusual habitats, like the marine environment, were not 
covered.[49, 50, 51] Amongst fungal species, endophytes have been extensively investigated in 
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the last years as to NP isolation, and the balanced antagonism between fungal virulence and 
plant defence has been proposed to be one reason for a rich secondary metabolism.[52] After 
transmission of the fungus to the host plant, which occurs either horizontally (via airborne 
spores) or vertically (via seeds), microorganisms reside in internal plant tissues in a quiescent 
state without causing apparent disease symptoms.[53] Growth in this habitat involves 
continuous metabolic interaction, thus, endophytic fungi reveal a great potential as sources of 
new biologically active NPs.[54] Interestingly, it was also found that endophytic fungi are 
capable of producing NPs originally known from plants, a fact which might be explained 
either by direct supply of the metabolites from the fungus to the plant or gene transfer from 
plant to microbe or vice versa.[55]  
The third group of microbial NP producers, which accounts for ca. 17% of all microbial 
secondary metabolites, are unicellular bacteria, with Bacillus and Pseudomonas species as the 
most frequent producers. In recent decades, also cyanobacteria, myxobacteria, and marine 
organisms are increasingly recognized.[1, 37] 
1.1.3 ROLE OF MYXOBACTERIA 
Myxobacteria were initially recognized because of their unusual growth characteristics, 
cooperative social behaviour, and unique developmental life cycle. The soil-dwelling δ-
proteobacteria of the order Myxococcales can be found in various habitats, preferentially in 
places that are rich in microbial life and organic matter. Several dozen genera of myxobacteria 
have been isolated worldwide mainly from terrestrial soils, but also from marine sediments[56], 
freshwater/saltwater, tree bark, animal dung, and anaerobic[57] and hypothermic[58] habitats. 
Particularly numerous isolates originate from subtropical and tropical zones with moderate to 
warm temperatures (Figure 1-3).[59, 60, 61, 62] 
Myxobacteria are distinguished from other bacteria mainly by two features: they move by 
gliding on solid surfaces in swarm-like patterns, and upon starvation conditions they form so-
called fruiting bodies containing resting cells.[63] Many species, like Myxococcus xanthus[64], 
live prey other microorganisms (Figure 1-4). This cooperative feeding is facilitated by the 
gliding movement across solid surfaces, where individual cells organize in waves which travel 
in a rippling-like motion[65]. The movement is thereby generated by two genetically distinct 
motility systems[66]; the social (S) motility system is characterized by type IV pili that interact 
with components of the M. xanthus exopolysaccharide (EPS) matrix[67], and the 
adventurous (A) motility system allows movement of individual cells although usually 
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employed in the swarm context.[68, 69] During cooperative feeding (‘wolf-pack’ behaviour[64]) 
other microbial species are degraded as prey by secretion of antibiotics and exoenzymes.[62, 70] 
As swarming cells collide under starvation conditions they aggregate in mounds culminating 
in the formation of fruiting bodies that typically harbor 104 to 106 individual cells. Vegetative 
cells that are usually rod-shaped (4-12 µm long and 0.7-1.2 µm wide) undergo a cellular 
morphogenesis within the fruiting body resulting in shortened and fattened stress-resistant 
myxospores. A new life cycle is started from these resting cells once nutrients are available 
and myxospores germinate to develop new swarms (Figure 1-5). This process is regulated by 
sophisticated extra- and intracellular signaling mechanisms.[61, 63, 70]  
 
Figure 1-3: Global distribution of myxobacteria. 
White spots mark sampling sites of soils that were used for the isolation of 
myxobacterial strains (adapted from ref. [60]). 
 
Figure 1-4: Cooperative feeding of Myxococcus xanthus. 
A swarm of M. xanthus cells (left) consumes a colony of E. coli (right) by gliding in a 
swarm-like pattern and degradation of the prey organism (image by J. Berleman and 
J. Kirby, taken from ref. [62]). 
movement
M. xanthus E. coli
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Figure 1-5: Schematic myxobacterial life cycle. 
Vegetative cells move by gliding, form a swarm and some species (suborder 
Cystobacterineae) act as predatory collective on other microbes (I) by surrounding the 
prey, degradation, and consummation of the prey bacteria (II). Nutrient poor 
conditions trigger a changed cell movement, i.e. formation of waves and aggregation 
to moulds (III). This finally culminates in the formation of fruiting bodies (IV), which 
typically measure 20-1000 µm in height. These contain stress-resistant myxospores 
that germinate when nutrients are present (graphics are adapted from ref. [71]; images 
by Dr. R. O. Garcia). 
One class of secondary metabolites that accounts to some extent for the developmental life 
cycle of myxobacteria, particularly M. xanthus, are the yellow DKxanthenes. The 
physiological role of these pigments in sporulation was found in the mid 90s[72, 73] and 
genome-sequencing of M. xanthus strain DK1622 finally enabled, amongst others, the 
identification of the DKxanthene biosynthetic gene cluster. Targeted inactivation of the 
corresponding PKS and NRPS genes then indeed provided evidence that DKxanthenes are 
required for spore germination of M. xanthus (Figure 1-6).[74] 
 
myxospores
gliding colony vegetative cells
fruiting bodies
I
II
III
IV
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Figure 1-6: Influence of DKxanthene on fruiting body formation of M. xanthus. 
The chemical structure of a DKxanthene derivative, a common secondary metabolite 
found in almost all Myxococcus xanthus strains, is displayed in the upper panel. Upon 
targeted gene inactivation in strain DK1050, fruiting body formation was found to be 
delayed (lower panel). In addition, the efficiency of sporulation could be restored in 
the deficient mutant to ca. 25% of wildtype level by supplementation with 
DKxanthene-534 (not shown).[74] 
Besides these fascinating ecological and developmental aspects, myxobacteria have gained 
increasing attention also with respect to biotechnological application as multi-producers of 
NPs.[75] Within the last three decades, the proteobacteria have become an outstanding source 
of NPs with unique structures, broad spectrum of activities, and mostly complete novel 
mechanisms of action (Figure 1-7). Reported activities, in turn, include antifungal, 
antibacterial, cytotoxic, but also antiviral, immunosuppressive, antiplasmodial/antimalarial 
activities, plus some others.[76, 77] A continuous research programme at the HZI (Helmholtz 
Centre for Infectious Research, Braunschweig, Germany; formerly German Research Centre 
for Biotechnology GBF) revealed that strains of the genus Sorangium, Myxococcus, and 
Chondromyces are the most frequent producers within the collection that comprises several 
thousand strains. Nannocystis and Corallococcus were found to be rather poor producers of 
bioactive secondary metabolites.[78] 
So far, myxobacterial strains have yielded at least 70 core structures reported in literature and 
some 500 derivatives. These are mainly PKs, NRPs, PK/NRP hybrids, terpenoids, alkaloids, 
and phenyl-propanoids.[76, 79, 80] With regards to reported biological activities, antibacterial 
(29%) and antifungal (54%) activities are predominant, most likely explained by the 
competitive pressure in the natural habitat. However, cellular targets and mechanisms of 
action are rather unusual compared to NPs from other sources.[61, 77] 
DKxanthene-534
6 h                  12 h                  18 h                   24 h                  48 h
M. xanthus
WT
M. xanthus
DKxanthene-
deficient 
mutant
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Figure 1-7: Selected antibiotic secondary metabolites isolated from myxobacteria. 
Stigmatellin is produced by Stigmatella aurantiaca Sg a15 and was found to be active 
on fungi and some selected Gram-positive bacteria by inhibiting complex bc1 of the 
repirartory chain.[81, 82] The highly cytotoxic archazolids were isolated from 
Archangium gephyra Ar 3548 and Cystobacter sp. and were shown to be specific 
inhibitors of V-ATPase, an increasingly recognized putative novel target in cancer 
therapy.[83, 84, 85, 86] The broad-spectrum antifungal agent ambructicin produced by 
Polyangium cellulosum subsp. fulvum interferes with osmoregulation by targeting the 
HOG pathway.[87, 88, 89] Soraphens were initially isolated from Sorangium cellulosum 
strain So ce10 because of their strong antifungal activity by inhibiting the anticancer 
target acetyl CoA carboxylase (ACC).[90, 91, 92, 93] Epothilones from 
Sorangium cellulosum So ce90 are microtubule stabilizers that act in a similar manner 
as taxanes. The latter compounds represent one of the highlights in myxobacterial 
natural product research, as epothilone B’s semisynthetic analogue ixabepilone was 
approved in 2007 for clinical treatment of advanced breast cancer in the 
United States.  [94, 95, 96] Maracin and its α-chlorinated alkene analog maracen were also 
isolated from S. cellulosum strains because of their strong and specific activity on 
mycobacteria.[97] 
Stigmatellin
antifugal
respiratory chain inhibitor (complex I)
Ambruticin
antifugal
interference with osmoregulation
Archazolid
cytotoxic
V-ATPase inhibitor
Soraphen
antifungal/anticancer
ACC inhibitor
Maracin
antibacterial
(mycobacteria)
Epothilone
antifungal/cytostatic
promotes tubulin polymerization
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The further establishment of myxobacteria as prolific NP suppliers and the exploitation of 
their biosynthetic potential are currently being pursued using a panel of chemical, biological 
and genomics-based methods.[78, 98] Especially the increasing availability of genome data of 
several myxobacterial strains has facilitated efforts towards the isolation of novel NPs. 
Myxobacterial genomes are very large, comprising 9-13 Mb, and have a high average GC 
content of approximately 70%. The model strain Sorangium cellulosum So ce56 has so far the 
largest bacterial genome, with a size of 13.0 Mb. In addition, usually around 8-10% of the 
sequence information is dedicated to genes encoding enzymes that are involved in secondary 
metabolism.[99, 100] By this, the biosynthetic potential of myxobacteria at least equals that of 
sequenced streptomycetes, such as the model organism Streptomyces coelicolor.[101, 102] 
Several biosynthetic gene clusters have already been identified from myxobacteria, whereas 
attempts towards NP isolation focus on heterologous expression and manipulation of the 
underlying megasynthetase systems, elucidation of their regulation, and activation of silent 
gene clusters.[101, 103] For instance, the model organism in myxobacterial research on 
developmental and ecological aspects, Myxococcus xanthus DK1622, was regarded as a rather 
poor secondary metabolite producer. Complete genome sequencing then revealed in total at 
least 18 biosynthetic gene clusters encoding PKS, NRPS, and PKS/NRPS hybrid systems. 
Detailed efforts in the last seven years have revealed this species to produce at least eight 
different families of NPs.[71, 77, 104] 
1.2 NEW LEAD STRUCTURES FROM MICROBIAL SOURCES 
In the past few decades, the process of identifying and purifying NPs from microbial sources 
has not changed significantly. Basically, crude extracts are prepared from microbial 
fermentations followed by bioactivity-guided fractionation, either employing whole cell - or 
in vitro protein assays, and de novo structural elucidation. In the outcome, NPs are the source 
of a large fraction of the current pharmaceutics available against human disease.[2] However, 
rapid identification of novelty in structure to find new leads (dereplication) in general remains 
one of the major issues when it comes to the discovery of NCEs. One criticism about NP 
screening campaigns is the high rate of repeated rediscovery of already known compounds 
arising from limitations in analytical techniques but more considerably from bias in screening 
programs themselves. Screening campaigns for antibiotics were focused only on a limited set 
of microbial sources, with Streptomyces as the best studied genus and, as a consequence, most 
frequent producer. Compounds isolated from streptomycetes historically play a very 
Introduction 
 
12 
prominent role in NP research since more than 50% of antibiotics available were isolated 
from Streptomyces sp. in the ‘Golden Era’.[11, 77, 105, 106] 
Besides the continuous improvement of analytical methods, engineered biosynthesis, and 
metabolome mining approaches, a partial shift from highly abundant and readily culturable 
microorganisms to unusual taxonomic groups of bacteria and more exotic species from 
extreme and/or underexplored natural environments took place in the last decades. Recent 
examples are novel bioactive NPs isolated from extremophiles[107], fungal endophytes[108], or 
organisms from the deep sea[109] (Figure 1-8). However, existing microbial collections are 
also considered as a rich source of new NCEs when employing genomics approaches for the 
activation of silent gene clusters or production enhancement.[2, 110, 111] In addition, 
extremophiles are not expected to be a rich source for secondary metabolites as competition in 
their habitats is usually limited. We have therefore focused our approaches on bacterial 
producers from highly diverse samples.[79] 
 
 
Figure 1-8: Examples of microbial NPs derived from diverse natural habitats. 
Cytotoxic berkazaphilones were isolated from a Penicillium species that was collected 
from a depth of 270 m in the Berkley Pit Lake, a former mine, filled with acidic, 
metal-sulfate contaminated water.[112] The antimicrobial (activity against MRSA and 
Mtb) abyssomycin is produced by a rare actinomycete (Verrucosispora sp.) collected 
from the deep sea of Japan.[113, 114] The potent antineoplastic agent camptothecine that 
interferes with DNA topoisomerase I was isolated from the plant 
Camptotheca acuminate and later on, also found to be produced by an endophytic 
fungus.[115] 
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1.2.1 SCREENING PROCESS 
In the traditional workflow of NP isolation from microbial sources (Figure 1-9) crude extracts 
are prepared from small-scale cultivation batches. These extracts are then subjected to MS 
screening and the primary biological screening on e.g. antimicrobial, cytotoxic, or antiviral 
properties. Upon dereplication, extracts with unknown NPs are fractionated by 
chromatographic techniques and those fractions are again tested on their biological activity. 
Once the active target compounds are defined, the microorganism is production-optimized for 
the target compound and fermented in larger scale for subsequent NP purification, de novo 
structure elucidation, further activity tests, and mode-of-action (MoA) studies.[116] For 
industrial use this process is regarded as too time-consuming and expensive. To overcome 
these hurdles, HTS may be applied for both, primary and secondary activity screening of 
crude extracts and fractions, respectively. In primary testing, the main issue is the complexity 
of extracts that often contain fluorescent or colored contaminants, which interfere with the 
assay read-out. Furthermore, samples might be insoluble in aqueous solution, be unstable as a 
mixture, or individual concentrations of active constituents are too low to be detected in HTS. 
Even if a robust screen yields hits in first instance reproduction of the results and access and 
examination of the biological resource are critical.[1] It is believed that a better flexibility, 
higher quality, and tailor-made lead-finding strategies in HTS may circumvent some of these 
obstacles.[117] 
Mainly two different approaches evolved over the last years: the use of targeted smart screens 
and automated pre-fractionation with online chemical profiling of crude samples. The former 
strategy was successfully applied e.g. in the discovery of novel broad-spectrum antimicrobial 
agents that target conserved and essential enzymes of the fatty acid synthesis. In a differential-
sensitivity whole cell two-plate agar diffusion assay over 250,000 microbial crude extracts 
were screened against a WT S. aureus strain and a hypersensitive mutant bearing a plasmid 
that produces antisense RNA to target fatty acid synthesis enzymes. The overall hit rate was 
exceptionally high (0.1%) and finally led to the discovery of platensimycin A and 
platencin. [118, 119, 120] 
Even more efficient, with regards to accelerating the screening and purification process, are 
methods that employ sophisticated pre-fractionation techniques. The construction of such 
large fraction libraries has the advantage of reduced complexity of the test material and often 
also accounts already for a physicochemical characterization prior to the application of 
bioassays.[11, 121, 122, 123, 124] 
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Figure 1-9: Schematic workflow of bioactivity-guided isolation of NPs from microbial sources. 
Crude extracts from microbial sources are tested on biological activity either in in 
vitro or whole cell screens. In parallel, the chemical profile is determined for 
exclusion of already known NPs, ideally by dereplication against existing databases. 
This is followed by several cycles of fractionation and repeated activity testing. 
Finally, novel NPs are purified and structurally elucidated.  
Due to significant improvements in analytics (detection, separation, structure elucidation) 
crude extracts from natural sources now seem to be accessible by HTS technologies. In 
addition, nearly all biochemical and cell-based assays can be translated to a high-throughput 
format. The most important recent technology, which might affect evolution of HTS 
campaigns, is HCS (high-content screening). Using HCS it is expected to achieve hits with 
greater physiological relevance and by this, determine higher quality leads. Currently, HCS is 
mostly applied in secondary screens, structure-activity relationship (SAR) -, target 
validation -, hit-to-lead optimization -, and mode-of-action studies, although it is expected that 
this methodology might move at least to some extent to primary compound screening. This 
trend is thereby accompanied by a shift from steadily increasing library sizes to smaller, more 
focused, and target-specific libraries.[125, 126, 127, 128]  
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In contrast to HTS, the HCS technology is based on automated fluorescence imaging 
technology and provides spatial and temporal information on a single cell basis within a 
population in the context of structural and functional integrity. A wide variety of assays can 
be developed, such as signal transduction -[129], GPCR (G-protein-coupled receptor) -[130], 
organelle function -[131], RNAi -[132], or toxicity [133] screens. By this, HCS can be integrated 
into workflows typical for a broad range of research fields and is applied for instance in 
oncology -[134], cardiovascular -[135], and stem cell[136] research using either endpoint (fixed 
cells) or live cell imaging techniques. More recently, HCS has also found its way into early 
drug discovery, such as cellular assays on antiviral replication[137] or in vivo toxicity studies 
on zebrafish[138]. 
However, most HCS applications rely on multiplexing several probes within one assay. As a 
result, these multiparametric screens produce scientifically complex data, which is highly 
beneficial for in-depth research on small molecule effectors and their impact on cellular 
processes. Early in the hit development process, either from NPs or synthetic compounds, it is 
possible to gain detailed information of a compound’s MoA and to facilitate SAR studies. 
Nevertheless, in NP crude extract screening it is assumed that HCS may be unsuitable because 
of the added complexity during deconvolution of various observations, which might be caused 
by different compounds in an extract or even result from synergistic effects.[2] Significant 
achievements in HCS small molecule library screens nevertheless encouraged researchers to 
apply robust HC screens for the characterization of crude extracts. Current examples are the 
development of a rapid HCS assay on cell cycle inhibition induced by treatment with crude 
extracts from myxobacterial origin[139] or HC live cell imaging of marine-derived extracts for 
the discovery of new antimalarials[140].  
1.2.2 MICROBIAL NATURAL PRODUCTS AND THERAPEUTIC APPLICATIONS 
In general, microbial NPs are either employed as molecular probes to study cellular functions 
of key proteins or further developed as lead structures in almost every therapeutic area of 
human disease. Over 16,500 microbial metabolites are reported to exhibit antibiotic 
activity.[37] Presumably due to their origin, microbial NPs are particularly successful for the 
treatment of infectious disease as antibacterial and antifungal agents. Amongst NCEs that 
were reported in the period 1981 to 2010, nearly 55% of in total 147 compounds were either 
NPs or directly NP-derived, whereas a major part is from microbial sources.[23] Although NP 
research in large pharmaceutical companies declined, emerging resistance, as seen with 
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Mycobacterium tuberculosis (MDR-TB and XDR-TB), again fosters the development of 
drugs with novel targets from natural sources or to engineer existing scaffolds.[141] 
The second large group of drugs developed from microbial NPs is cytostatic compounds used 
in cancer chemotherapy. Remarkably, over 60% of anticancer drugs in the last 30 years have 
originated from NPs.[23] These comprise mainly agents that interfere with eukaryotic cell 
division and proliferation by targeting e.g. topoisomerases, kinases, microtubules, or 
DNA.[142] The search for novel agents for cancer therapy is thereby, amongst others, 
motivated by the apparent heterogeneity of cancer cells, which in general complicates 
effective treatment strategies. Furthermore, some tumors acquire chemo-resistance, whereas 
for instance overexpression of classical MDR (multidrug resistant) proteins, such as P-gp (P-
glycoprotein) or MRP (Multidrug Resistance Protein), is strongly correlated to resistance.[143] 
Current therapeutic applications of NPs have expanded into immunosuppressive (e.g. 
rapamycin, isolated from Streptomyces sp., inhibits mTOR[144]), cholesterol-lowering (e.g. the 
fungal metabolite lovastatin inhibits HMG-CoA reductase[145]), anthelmintic/antiparasitic (e.g. 
ivermectin from Streptomyces sp. blocks glutamate-gated anion channels[146]), and 
antidiabetic agents (e.g. exendin-4, a hormone found in the saliva of Heloderma suspectum, 
acts as a GLP-1 agonist[147]). 
Other therapeutic areas, where NPs or NP-derived drugs are part of the pharmacopoeia, are 
inflammation, neurological diseases, cardiovascular diseases and endrocrinology, and some 
others.[2] 
1.3 NATURAL PRODUCTS AND CANCER THERAPY 
As reviewed by Newman and Cragg in 2012[23], over 60% of anticancer drugs in the last 
30 years have originated from natural products. Particularly NPs from plant sources have been 
exceptionally successful as anticancer agents. Since the Vinca alkaloids vinblastine and 
vincristine entered the market in early 1960s, numerous other chemotherapeutics derived from 
plant secondary metabolites have been launched for the treatment of various cancerous 
diseases.[148] This may partly be attributed to a long history of use of relevant plants in 
traditional medicine. For example podophyllotoxin, isolated from a resin (podophyllin) 
produced by species of the genus Podophyllum, has been used in folk medicine for centuries 
and amongst other indications was found to be topically effective for skin cancers. Its 
semisynthetic derivative etoposide was later on developed as an anticancer agent and acts by 
inhibiting topoisomerase II activity (Figure 1-10).[149, 150] 
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Besides plants as sources of novel anticancer agents, mainly compounds from terrestrial 
microorganisms and marine-derived NPs made their way into clinics. In the period 
2005-2007, 23 lead compounds from plant origin, 17 from microbial sources, and 9 isolated 
from marine organisms were in oncology clinical trials.[24] 
 
 
Figure 1-10: The plant-derived anticancer agent etoposide. 
Podophyllotoxin is a lignan produced by several Podophyllum spp. and has a long 
history in traditional medicine. The semi-synthetic derivative etoposide was developed 
for clinical use as a topoisomerase II inhibitor for the treatment of cancer. 
1.3.1 THERAPEUTIC TARGETS 
At the outset of modern NP research, novel bioactive compounds were basically isolated 
following rather unspecific broad-spectrum bioactivity screens. This resulted in a significant 
number of new NPs, which are applied in treatment of various diseases. However, second 
generation cancer chemotherapeutics are more likely to be discovered in robust and 
particularly specific screens by which the limited use of non-selective toxic agents is 
circumvented. Recently, novel functional genomics approaches provide increasingly 
sophisticated knowledge of biological processes that underlie the malignant transformation of 
normal cells. By this, tumors can be classified according to their key abnormal pathways and 
novel ‘druggable’ targets within these networks can be identified and in turn, by using tailor-
made, target-specific screens, highly selective sets of lead structures can be established.[151] 
The main targets of current anticancer drugs are DNA, key effector kinases, and tubulin. 
Chemotherapeutics of the first class either directly interfere with DNA or target proteins that 
play a role in DNA repair mechanisms, such as topoisomerases. By reducing the enhanced 
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capacity of many cancer cells to repair critical lesions, e.g. DSBs (DNA double-strand 
breaks), enhanced chemoresistance observed with such tumors can be countervailed. Novel 
strategies to combat drug resistance may rely on using chemosensitizers, such as PARP 
[poly(ADP-ribose) polymerase] inhibitors, in combination with already established 
topoisomerase inhibitors, DNA-alkylating agents, or radiation therapy. These combinations 
can cause severe genomic instability in tumor cells ultimately resulting in cell 
death.[152, 153, 154] 
Many signaling cascades have been identified that are to some extent dysregulated in cancer 
tissue and the development of selective kinase inhibitors, such as small molecule inhibitors of 
cell cycle regulating cyclin-dependent kinases (CDKs), is one of the prime targets in 
anticancer research. Nevertheless, highly selective blocking of single kinases has been 
associated with only limited responses in clinical trials. Thus, simultaneous inhibition of 
several receptor tyrosine kinases (RTKs) and/or downstream serine/threonine kinases may 
improve overall clinical success rates. This can be either be achieved by combination 
therapies of selective inhibitors or novel therapeutics that target multiple key signaling 
pathways, such as the multikinase inhibitor sorafenib.[30, 155, 156] 
Among the aforementioned decisive cellular targets, microtubules have played a major role, 
especially since the first Vinca alkaloids entered the market 50 years ago. Moreover, 
chemotherapeutics belonging to this compound class continue to be highly valuable as part of 
the pharmacopoeia for cancer treatment.[24, 148] In mammalian cells, microtubules are crucial 
for trafficking, signaling, migration, and proliferation. Most importantly, the suppression of 
these dynamics by small molecules ultimately results in mitotic arrest and, in turn, the 
inhibition of cell proliferation and the induction of apoptosis. The search for novel 
microtubule-interacting compounds is primarily motivated by the need to overcome the 
typical resistance acquired to these drugs and the neurotoxicity of these compounds.[157] 
Other therapeutic targets include for instance proteasome inhibition[158], antiangiogenic 
therapies[159], modulation of hypoxia-inducible factor 1 (HIF-1)[160], and V-ATPase 
inhibition[86]. 
In addition to extensive research efforts in the elucidation of novel molecular cancer targets, 
the development of antibody-drug conjugates (ADCs) represents a growing research field. 
This approach might be of special interest when it comes to NPs or NP-derived drugs since 
these molecules are often not optimized to bind to one specific target but interact with 
different cellular targets. This intrinsic feature is often beneficial in multi-targeted therapy but 
may also lead to unwanted off-target effects. Coupling of rather unspecific, yet potent 
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cytotoxic agents (‘payload’) to specific antibodies greatly contributes to the reduction of 
collateral damage to surrounding tissue and may foster a renaissance of NPs in cancer 
therapy.[28, 161] Generally, lead optimization includes the design of suitable linkers and the 
selection of antibodies, as in the case of the highly potent antineoplastic agent 
monomethylauristatin E (synthetic dolastatin analog) that has been approved as an ADC in 
2011. The active component was coupled to antibodies either directed against CD30 antigen 
or a glycoprotein overexpressed in cancer cells via a valine-citrulline peptide linker. After 
receptor-mediated cellular uptake of the ADC, the linker is cleaved by lysosomal proteases 
and the active agent thus triggers apoptosis induction through G2/M cell cycle arrest.[162, 163] 
1.3.2 THE EUKARYOTIC CYTOSKELETON 
The eukaryotic cytoskeleton plays a crucial role during mitosis and cell division, controls 
intracellular transport mechanisms of organelles and cell movement, and accounts for 
mechanical stability of the cell. The main components are actin microfilaments, intermediate 
filaments, and microtubules (Figure 1-11), whereas each of these classes has a large dedicated 
set of accessory proteins.[164] 
 
Figure 1-11: Components of the eukaryotic cytoskeleton. 
A) Intermediate filaments. B) Actin microfilaments. C) Microtubules. (Micrographs: 
courtesy of R. Craig (A), R. Wade (B), and R. Quinlan (C); all images and graphics 
were taken from ref. [164]). 
Among these three major systems, intermediate filaments (IFs) are probably the least 
studied with respect to their function and structure. These rope-like fibers are made of IF 
proteins and have a diameter of around 10 nm. The IF proteins differ largely in amino acid 
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sequence and are encoded by approximately 75 genes, which in turn, are regulated in a cell- 
and tissue-specific fashion. This results in an enormous diversity of IFs although they share 
common structural motives. α-Helical domains build coiled-coil dimers, which then form 
staggered tetramers; eight of theses tetramers are packed together into rope-like filaments, 
which form the IF consisting of in total 32 α-helical domains. Due to this three-dimensional 
arrangement, IFs are especially resistant to bending or stretching forces. Although IFs were 
initially considered as rather static cytoskeletal elements with only little subunit exchange, 
current studies provide evidence that association and turnover of IFs are mainly regulated by 
rapid phosphorylation events. By this, IFs do not only account for mechanical resistance of 
cells but play also a specific role in locomotion. Based on the protein composition, four major 
types of IFs are distinguished: nuclear lamins, vimentin-like proteins, keratins, and neuronal 
IFs.[164, 165, 166] 
The other two major cytoskeletal components, actin filaments and microtubules, are involved 
in signaling and are critical for cell motility, maintenance of cell shape, transport mechanisms, 
cytokinesis, and mitosis. For the treatment of cancer, particularly antimitotic agents directly 
targeting microtubules are well established chemotherapeutics.[167] However, no actin-
targeting drug is currently in clinical use, although both, tubulin and actin, have been thought 
to be valid anticancer targets.[168, 169] 
The dynamic microtubule structures are composed of α,β-tubulin heterodimers that are 
constantly assembled and disassembled as the microtubules oscillate between growing and 
shortening phases. While α- and β-tubulin are regular building blocks of microtubules, γ-
tubulin has a more specific role as it associates with other proteins to form the γ-TuRC 
(tubulin ring complex) within the MTOC (microtubule organizing center) at the centrosome 
where single tubulin heterodimers are constantly assembled. By this, microtubules are 
polarized, with the minus-end capped by the γ-TuRC and anchored at the MTOC and the 
plus-end localized at the periphery of the cell. The polar protofilaments form together a 
bundle-like, hollow cylinder structure with a diameter of approximately 25 nm, which is 
composed of 13 protofilaments. One of the most important properties of microtubules is their 
dynamic instability[170]. When microtubule subunits polymerize, tubulin dimers with bound 
GTP are added at the plus-end of the growing polymer, followed by hydrolysis of β-tubulin 
bound GTP to GDP. Since this hydrolysis is delayed with respect to further subunit addition, 
a GTP-tubulin cap is formed. Upon loss of this cap (‘catatstrophe’) by e.g. slowed down 
subunit addition, a rapid depolymerization of the microtubule is induced. At some time later, 
the microtubule might regain its GTP-tubulin cap (‘rescue’) and begin to grow again. These 
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rapid dynamics are crucial for instance in cell division processes, such as chromosomal 
movements in anaphase[171]. However, destabilization and stabilization are extrinsically 
regulated mostly by MAPs (microtubule-associated proteins) that bind to microtubules. One 
such is XMAP215[172, 173] that stabilizes the growing end of a microtubule and suppresses the 
frequency of catastrophes. It has been proposed that XMAP215 acts as a template for head-to-
tail oligomerization of multiple tubulin dimers and by this, facilitates the delivery of those 
preassembled protofilaments to the microtubule plus-end (tubulin shuttle model). However, 
current research also provides evidence for non-templating but tip tracking mechanisms, 
which might either occur via treadmilling or surfing. In contrast, proteins of the kinesin 
superfamily, such as MCAK[174], oppose this action by removing the GTP-tubulin cap from 
growing microtubules. In a ‘diffuse and capture’ mechanism, the depolymerase MCAK 
couples ATP hydrolysis to the removal of GTP and triggers catastrophes at both microtubule 
ends.[175, 176, 177] 
Actin microfilaments determine the cell shape and polarity and are necessary for locomotive 
processes. The filaments are constituted of single subunits of actin, a protein which is highly 
conserved and the most abundant in most eukaryotic cells. In total, three main isoforms are 
known, including α-actin of cardiac, skeletal, and smooth muscle cells, and β- and γ-actin of 
nonmuscle and muscle cells. Similar to tubulin, actin permanently alternates between 
monomeric or globular (G-actin) and filamentous (F-actin) states. Actin subunits thereby bind 
ATP and assemble head-to-tail to form polarized protofilaments, whereby two of these 
filaments twist around each other two build up a right-handed 7-9 nm diameter helix.[164] 
These actin filaments are relatively flexible but are cross-linked and bundled within the cells 
by various accessory proteins, such as α-actinin and filamin, that both enhance the stiffness of 
F-actin networks.[178] De novo nucleation of actin filaments primarily occurs at the plasma 
membrane and is catalyzed by a number of proteins, including actin-related proteins (ARPs). 
Especially the Arp2/3 complex plays a central role in the regulation of actin assembly, 
dynamics and cross-linking. The initial association of G-actin molecules to form dimers and 
trimers (nucleation centers), followed by the conversion of ATP to ADP, is energetically less 
favorable than the elongation of already existing filaments. Similar to γ-TuRC in the MTOC, 
the Arp2/3 complex forms a pseudo ‘barbed end’ (minus-end), which mimics an actin trimer, 
and by this allows rapid elongation at the ‘pointed end’ (plus-end). Furthermore, it is possible 
that the bound Arp complex attaches to another actin filament resulting in a branched network 
with new filaments growing at a 70° angle relative to the initial filament.[179, 180] As a 
consequence of permanent ATP hydrolysis and differences in the free energy of subunit 
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association and dissociation reactions, a phenomenon referred to as ‘treadmilling’ is observed 
with actin filaments. In steady-state, filament growth at the pointed end is exactly balanced 
with filament shrinkage at the barbed end, leading to rapid cycles of subunits between the 
cytosol (G-actin) and the filaments (F-actin), while the overall length of filaments remains 
constant.[164] As with microtubules, complex assembly of actin microfilaments is not only 
determined by inherent characteristics of actin polymerization but is tightly regulated by a 
large set of actin-binding proteins (ABPs). The most abundant ABP is thymosin β4 which 
binds to soluble G-actin and by this prevents polymerization resulting in a reservoir of 
unassembled monomeric actin in the cytoplasm. Upon de-sequestration by for instance 
profilin, which competes with thymosin β4 in actin-binding, polymerization is promoted 
again. Additionally, the filament elongation is facilitated due to configurational changes of the 
actin subunit upon profilin-binding that delivers polymerization-competent actin to the 
growing filament.[181, 182, 183] However, certain severing and capping proteins, such as gelsolin, 
can negatively impact the growth of actin microfilaments. Gelsolin[184] is regulated by Ca2+ 
and PIP2 and binds to actin filaments rapidly prior to severing. The actin conformation within 
the protofilament is changed and filaments are broken by gelsolin. Once an actin filament has 
been severed, gelsolin remains attached to the barbed end and acts as an effective capping 
protein, which prevents further filament growth.[164, 175, 185] 
1.3.3 MYXOBACTERIAL METABOLITES 
In a comprehensive review on myxobacterial secondary metabolites by Weissman and Müller 
in 2010[76], the authors list in total 67 compound families that have been published at that 
time. Out of those, 31 NP classes have a cytotoxic activity towards mammalian cells. 
Although some of the underlying cellular mechanisms remain undiscovered, for most 
compounds (given in brackets) targets have been identified and include V-ATPase (apicularen 
and archazolid[84]), mitochondrial F1-ATPase (cruentaren[186]), DNA (saframycin Mx1[187]), 
protein synthesis (gephyronic acid[188]), proteasome (argyrin[189]), and nuclear export complex 
formation (ratjadon[190]). Notably, six distinct compound classes that are produced by 
myxobacteria have been found to directly interfere with the eukaryotic cytoskeleton 
(Figure 1-12) by either stabilizing or destabilizing microtubules (epothilone[95], disorazol[191], 
and tubulysin[192]) or actin filaments (chivosazol[193], chondramide[194], and rhizopodin[195]). 
Especially the microtubule-targeting drugs have been the subject of concerted efforts to 
elucidate their biosynthesis, total synthesis, and semi-synthesis in order to improve their 
pharmacological properties and yields.[196, 197] 
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As mentioned above, a semisynthetic analog of the microtubule-stabilizer epothilone B 
(ixabepilone) has already been approved by the FDA in 2007 for the clinical treatment of 
advanced breast cancer in the United States.[96] Although having a similar binding pattern as 
taxane, cross-resistance with epothilone is not observed.[198] It is the first example of an NP 
exclusively produced by myxobacteria, which has been developed for clinical use. In addition, 
other modified epothilones and epothilone B are currently progressing clinical trials.[24] 
 
Figure 1-12: Myxobacterial secondary metabolites acting on the eukaryotic cytoskeleton. 
Tubulysins, epothilones, and disorazols act on microtubules and chondramides, 
rhizopodin, and chivosazols act on actin filaments. The compounds can be classified 
either as stabilizers (epothilones and chondramides) or destabilizers (all others) of 
their respective target structures. Images show cytoskeletal structures in green (left: 
microtubules; right: actin microfilaments) and nuclei in blue.  
Despite the encouraging pre-clinical evaluation of tubulysin A[199], which acts by destabilizing 
microtubules, a major hurdle for the further development of this compound class is its supply. 
Fermentation yields only several mg per L and downstream-processing includes multiple 
chromatographic steps. Also total synthesis cannot be achieved so far on a reasonable and 
thus, economic scale.[200, 201] With the discovery of one of its biosynthetic precursor 
molecules, referred to as ‘pretubulysin’ (Figure 1-13), and successful total synthesis of this 
NP, the supply issue can now be circumvented due to a practical chemical synthesis that 
yields the product in multigram quantities. Pretubulysin lacks the N,O-acetal and acetoxy 
functionalities of the amino acid tubuvalin in the original NP.[202] Nevertheless, it could be 
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shown that these moieties are not crucial for biological activity and first reports demonstrate 
that pretubulysin might be developed, instead of tubulysins themselves, as an effective 
antineoplastic and antiangiogenic drug.[203, 204] 
 
Figure 1-13: Chemical structures of tubulysin D and pretubulysin. 
Biosynthesis studies revealed the presence of a precursor molecule (pretubulysin) that 
is released from the PKS/NRPS assembly line and undergoes post-assembly acylation 
and oxidation reactions to form tubulysins. Due to the lacking N,O-acetal and acetoxy 
moieties, pretubulysin can be synthesized in multigram quantities and currently 
undergoes pre-clinical studies. (Mep: N-methylpipecolic acid; Ile: isoleucin; Tuv: 
tubuvaline; Tup: tubuphenylalanine). 
Disorazols act like tubulysins by destabilizing microtubules and show extraordinary high 
activity (picomolar range) against a variety of cancer cell lines.[197] Studies on the specific 
targeting of disorazoles to cancer cells are currently ongoing, as for instance applied for 
disorazol Z. The NP was coupled to an LHRH (luteinizing hormone-releasing hormone) 
agonist peptide that binds to the respective receptors mainly expressed on cancer cells. Upon 
binding and internalization of the conjugate, the linker is cleaved spontaneously and the 
payload (disorazol Z) is released. First in vivo results were encouraging and demonstrated that 
using this approach disorazol’s tumor suppression activity can be further increased.[205] 
Research on myxobacterial NPs targeting the actin cytoskeleton has been mainly focused on 
unraveling their biosynthetic origin and total synthesis. Although migration of cancer cells, 
which might also be inhibited by actin-targeting cytostatic drugs, has become an extensively 
studied target in the last years, NPs of this class are rather believed to be suitable as molecular 
probes and their medicinal potential remains uncertain.[168] 
Especially the chondramides are believed to be suitable as effective probes for studying actin 
dynamics. These cyclodepsipeptides were originally isolated from terrestrial strains of 
Chondromyces crocatus and interestingly, showed high structural similarity to 
jasplakinolide/jaspamide isolated from marine sponges.[194, 206, 207] Members of both 
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compound families are able to induce actin polymerization and share a common binding site 
on F-actin, similar to that of the mushroom toxin phalloidin.[208, 209, 210] However, total 
synthesis of chondramides enabled researchers to further develop them as valuable fluorescent 
tools to study actin dynamics. In contrast to commonly applied phalloidin probes, 
chondramides are cell permeable and thus, can be applied in non-permeabilized cells.[211, 212] 
1.4 SCOPE OF THE WORK 
The aim of this thesis was the biological characterization of pretubulysin as a novel putative 
lead structure in cancer therapy and in addition, the development of smart screening 
techniques for myxobacterial crude extracts or compounds.  
In the first part of this work, pretubulysin, a synthetically accessible precursor of the tubulysin 
compound family was biologically characterized. A variety of cell-based and in vitro studies 
was applied to compare its antimitotic potency with that of the parent compounds tubulysins 
A and D. Additionally, other synthetic derivatives and precursor molecules were examined, 
which enabled structure-activity relationship insights. The presented study aimed to provide 
an initial characterization of pretubulysin and build the basis for upcoming in-depth pre-
clinical studies on pretubulysin as a novel antineoplastic agent. 
The second part of the work was intended to deal with the activity-guided isolation of novel 
chondramide derivatives. In routine screening of new myxobacterial isolates, it was found that 
Chondromyces sp. SBCm007 extracts show exceptionally high cytotoxicity against 
mammalian cell lines. Desirably, not only high-abundance molecules should be isolated, but 
also less frequently produced natural products with interesting novel activity profiles. In order 
to account for this, high-content screening techniques were adjusted to be suitable for crude 
extract and fraction screening. Coupling fermentation strategies directly to the process of 
bioactivity-guided isolation via HCS it was possible to isolate a number of novel chondramide 
derivatives. These were further characterized and compared to already known derivatives in 
some biological assays. 
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MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 COMPOUNDS  
The reference compounds epothilone B, disorazol A, tubulysins A and D, and chondramides 
A~D were kindly provided by the Microbial Drugs research group (MWIS) at the Helmholtz 
Centre for Infection Research (HZI, Braunschweig, Germany).  
Pretubulysin and its derivatives were synthesized and kindly provided by Dr. J. L. Burkhart, 
Dr. A. Ullrich, and Dr. Mengxia Xue (group of Prof. Dr. U. Kazmaier at Saarland University, 
Institute for Organic Chemistry).  
Chondramide derivatives produced by Chondromyces sp. SBCm007 were purified by 
S. Hüttel in our research group in the course of this study. 
2.1.2 CHEMICALS  
All chemicals were of reagent grade quality and were obtained from commercial sources and 
used without further purification unless otherwise noted. 
2.1.3 CELL LINES AND PRIMARY CELLS 
The L3.6pl cell line was kindly provided by Prof. Dr. C. J. Bruns (Department of Surgery, 
Clinic Großhadern, LMU Munich, Germany).[213] Other cell lines were obtained from the 
American Type Culture Collection (ATCC) and the German Collection of Microorganisms 
and Cell Cultures (Deutsche Sammlung für Mikroorganismen und Zellkulturen, DSMZ). All 
cell lines were cultured under the conditions recommended by the respective depositor and are 
listed in Table 2-1. For L3.6pl cells cultureware was coated with collagen G 
(0.001% collagen/PBS). 
Primary HUVEC (human umbilical vein endothelial cells; single donor) were purchased from 
PromoCell and cultured in Endothelial Cell Growth Medium (PromoCell) containing the 
following supplements: 2% FCS, 0.4% ECGS, 0.1 ng/ml EGF, 1 ng/ml bFGF, 90 µg/ml 
heparin, 1 µg/ml hydrocortisone.  
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Table 2-1: Cell lines and culture media. 
Cell Line Species Type Medium Supplements 
A431 human epidermoid carcinoma MEM 10 % FBS 
1% NEAA 
A549 human lung carcinoma DMEM 10% FBS 
CHO-K1 Chinese hamster ovary  F12 10% FBS 
COS-7 African green monkey kidney  DMEM 10% FBS 
HCT-116 human colon carcinoma McCoy’s 5A 
(modified)  
10% FBS 
HEK293T/17 human embryonal kidney DMEM 10% FBS 
HepG2 human hepatocellular carcinoma DMEM 10% FBS 
HL-60 human acute myeloid leukemia RPMI-1640 10% FBS 
K562 human chronic myeloid leukemia 
in blast crisis 
RPMI-1640 10% FBS 
KB-3.1 human cervix carcinoma DMEM 10% FBS 
 
KB-V.1 human cervix carcinoma (MDR) MEM 15% FBS 
1% NEAA 
L3.6pl human pancreatic cancer 
(established in nude mice; 
pancreas to liver) 
RPMI-1640 10% FBS 
1 % pyruvate 
1% NEAA  
L-929 murine  
(mouse) 
connective tissue 
fibroblast 
RPMI-1640 10% FBS 
MRC5 human lung fibroblast DMEM 10% FBS 
NIH/3T3 murine  
(mouse, Swiss mouse) 
embryo DMEM 10% NCS 
Ptk-2 Potorous tridactylis kidney MEM 10% FBS 
1% NEAA 
SH-SY5Y human neuroblastoma DMEM 20% FBS 
SW480 human colon adenocarcinoma RPMI-1640 5% FBS 
U-2 OS human osteosarcoma McCoy’s 5A 
(modified) 
10% FBS 
U937 human histiocytic lymphoma RPMI-1640 10% FBS 
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2.1.4 CELL CULTURE MEDIA AND REAGENTS 
Table 2-2: Cell culture media and supplements. 
Reagent Description Manufacturer 
DMEM high glucose medium, contains 
glutamine and sodium bicarbonate 
Sigma-Aldrich, Taufkirchen, 
Germany 
Endothelial Cell 
Growth Medium  
Endothelial Cell Basal Medium and 
Supplement Mix 
PromoCell, Heidelberg, Germany 
F12 contains glutamine, sodium pyruvate, 
and sodium bicarbonate, Gibco® 
Invitrogen, Karlsruhe, Germany 
MEM  contains glutamine and sodium 
bicarbonate 
Sigma-Aldrich, Taufkirchen, 
Germany 
McCoy’s 5A 
(modified) 
high glucose medium, contains 
glutamine and bacto-peptone, Gibco® 
Invitrogen, Karlsruhe, Germany 
RPMI-1640 contains glutamine and sodium 
bicarbonate 
Sigma-Aldrich, Taufkirchen, 
Germany 
FBS defined FBS, heat inactivated, EU 
approved (FBS ‘GOLD’) 
PAA, Pasching, Austria 
NCS heat inactivated PAA, Pasching, Austria 
NEAA 100x solution Sigma-Aldrich, Taufkirchen, 
Germany 
sodium pyruvate 100 mM solution, sterile-filtered Sigma-Aldrich, Taufkirchen, 
Germany 
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Table 2-3: Other reagents.   
Reagent Description Manufacturer 
Accutase  PromoCell, Heidelberg, Germany 
Cell freezing medium DMSO 1x Sigma-Aldrich, Taufkirchen, 
Germany 
Cryo-SFM  freezing medium HUVEC PromoCell, Heidelberg, Germany 
DMSO Hybri-MaxTM, sterile-filtered Sigma-Aldrich, Taufkirchen, 
Germany 
hydroxyurea  Sigma-Aldrich, Taufkirchen, 
Germany 
2-mercaptoethanol  Sigma-Aldrich, Taufkirchen, 
Germany 
MTT thiazolyl blue tetrazolium bromide Sigma-Aldrich, Taufkirchen, 
Germany 
PBS pH 7.4, without Ca2+/Mg2+ Sigma-Aldrich, Taufkirchen, 
Germany 
paraformaldehyde  Sigma-Aldrich, Taufkirchen, 
Germany 
Proteinase K from 
Tritirachium album 
≥ 30 U/mg Sigma-Aldrich, Taufkirchen, 
Germany 
Ribonuclease A  ~ 90 U/mg Carl Roth GmbH, Karlsruhe, 
Germany 
trypsin-EDTA 10x solution Sigma-Aldrich, Taufkirchen, 
Germany 
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2.1.5 BUFFERS 
Actin buffer (non-polymerizing; pH 8.0) 
Tris     5 mM 
CaCl2     0.2 mM 
ATP     0.2 mM 
DTT     1 mM 
 
The pH was adjusted with HCl. 
 
6x DNA loading dye 
bromophenol blue   0.25% (w/v) 
xylene cyanol blue   0.25% (w/v) 
87% glycerol    10% (v/v) 
EDTA     10 nM 
 
PBS (pH 7.45) 
sodium phosphates   10 mM 
KCl     2.68 mM 
NaCl     140 nM 
  
The buffer was prepared by dissolving one solid PBS tablet (Gibco®, Invitrogen) in 500 ml 
distilled water. The buffer was autoclaved and stored at room temperature.  
 
PCB (pH 7.8) 
Na2HPO4    192 mM 
citric acid    4 mM   
 
Solutions of 0.2 M Na2HPO4 and 0.1 M citric acid were prepared separately and mixed prior 
to use (192 parts Na2HPO4 and 8 parts citric acid). 
 
PEM (pH 6.6) 
PIPES     100 mM 
EGTA     1 mM 
MgSO4 • 7 H2O   1 mM 
 
The pH was adjusted with KOH and the buffer was stored at 4°C. For tubulin isolation, ATP 
and GTP were added directly prior to use as assigned in the Methods section.  
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50x TBE (pH 8.0) 
Tris     0.89 M 
boric acid    5.5% (w/v) 
EDTA     0.93% (w/v) 
 
The pH was adjusted with HCl. For electrophoresis 50x TBE was diluted with H2Odd. 
 
TMRM assay buffer (pH 7.35) 
NaCl     135 mM  
KCl     5.4 mM  
MgCl2      2 mM   
Glucose    10 mM  
CaCl2      2 mM   
HEPES    10 mM  
 
The pH was adjusted with 10 N NaOH and the buffer was stored at 4°C. 
2.1.6 ANTIBODIES  
All antibodies were diluted in PBS containing 10% FBS. 
Table 2-4: Primary and secondary antibodies. 
Antibody Description Dilution Manufacturer 
anti-β-actin rabbit monoclonal (clone: 
EP1123Y), IgG 
1:2000 Merck Millipore, 
Darmstadt, Germany 
anti-phospho-Histone 
H2A.X (Ser139) 
mouse monoclonal (clone:  
JBW301), IgG1  
1:400 Merck Millipore, 
Darmstadt, Germany 
anti-α-tubulin mouse monoclonal (clone: 
DM1A), IgG1 
1:2000 Sigma-Aldrich, 
Taufkirchen, Germany 
Alexa Fluor® 488 goat 
anti-mouse 
IgG (H + L), Molecular 
Probes® 
1:1000 Invitrogen, Karlsruhe, 
Germany 
Alexa Fluor® 488 goat 
anti-rabbit 
IgG (H + L), Molecular 
Probes® 
1:1000 Invitrogen, Karlsruhe, 
Germany 
Alexa Fluor® 555 goat 
anti-rabbit 
IgG (H + L), Molecular 
Probes® 
1:1000 Invitrogen, Karlsruhe, 
Germany 
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2.1.7 STAINING DYES 
Stock solutions of listed dyes (Table 2.5) were prepared and stored according to the 
manufacturer’s recommendations. 
Table 2-5: Staining dyes. 
Stain Manufacturer 
Acridine orange (hydrochloride hydrate) Sigma-Aldrich, Taufkirchen, Germany 
Acti-stainTM 555 phalloidin Cytoskeleton Inc., Denver, USA 
Giemsa stain Sigma-Aldrich, Taufkirchen, Germany 
HCS CellMaskTM Green Molecular Probes®, Invitrogen, Karlsruhe, Germany 
HCS CellMaskTM Red Molecular Probes®, Invitrogen, Karlsruhe, Germany 
Hoechst33342 Molecular Probes®, Invitrogen, Karlsruhe, Germany 
ethidium bromide Sigma-Aldrich, Taufkirchen, Germany 
propidium iodide Carl Roth GmbH, Karlsruhe, Germany 
2.1.8 CYTOSKELETAL PROTEINS 
Pyrene muscle actin from rabbit muscle and MAP-rich tubulin from porcine brain were 
purchased from Cytoskeleton Inc., Denver, USA. 
2.1.9 TECHNICAL EQUIPMENT AND CONSUMABLES 
Table 2-6: Equipment. 
Description Type Manufacturer 
balances Acculab Vicon Sartorius AG, Göttingen, Germany 
 Precisa XB220A Gravimetrics AG, Dietikon, 
Switzerland 
centrifuges  Heraeus Fresco 17 Thermo Fisher Scientific, Schwerte, 
Germany 
 5180R (rotor A-4-62) Eppendorf, Hamburg, Germany 
 Sorvall (rotor GSA) Thermo Fisher Scientific, Schwerte, 
Germany 
 Sorvall (rotor SS-34) Thermo Fisher Scientific, Schwerte, 
Germany 
CO2 incubator Innova CO-170 New Brunswick Scientific, Edison, 
USA 
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flow cytometer GUAVA® EasyCyteTM Plus Merck Millipore, Darmstadt, Germany 
freezing container Nalgene 5100 Cryo 1°C, 
‘Mr. Frosty’ 
Thermo Fisher Scientific, Schwerte, 
Germany 
gel documentation system Gel Doc 2000 Bio-Rad Laboratories GmbH, 
München, Germany 
hemocytometer Neubauer-improved 
(0.1 mm depth) 
Paul Marienfeld GmbH & Co., Lauda-
Köngshofen, Germany 
liquid nitrogen tank MVE TEC 3000 Broser, Frankenthal, Germany 
microscope (automated) Pathway 855 BD Biosciences, Heidelberg, Germany 
microscope (optical) ECLIPSE TS100 Nikon, Düsseldorf, Germany 
pipettors Pipetus® Hirschmann Laborgeräte, Eberstadt, 
Germany 
plate readers SpectraMax M5e Molecular Devices, Biberach, 
Germany 
 EL808 Bio-Tek Instruments Inc., Winooski, 
USA 
power supply Standard power pack P25 BiometraGmbH, Göttingen, Germany 
rotor mixer Blender GT 800 Rotor Lips Ltd., Uetendorf, 
Switzerland 
spectrophotometer DU7500 Beckmann Coulter, Fullerton, USA 
vacuum pump VACUSAFE comfort IBS Integra Biosciences, Fernwald, 
Germany 
Table 2-7: Consumables. 
Description Type Manufacturer 
6-well plates Costar® 6 Well, clear, flat bottom, 
sterile  
Corning Life Sciences Inc., Lowell, 
MA, USA 
 Corning® CellBIND® 6 Well, clear, 
flat bottom, sterile 
Corning Life Sciences Inc., Lowell, 
MA, USA 
96-well plates Corning® CellBIND® 96 Well, 
clear, flat bottom, sterile 
Corning Life Sciences Inc., Lowell, 
MA, USA 
 96 Well, clear, flat bottom, sterile Sarstedt AG & Co., Nümbrecht, 
Germany 
 96 Well imaging plates, black, clear 
bottom, flat bottom, sterile 
 
BD Biosciences, Heidelberg, 
Germany 
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384-well plates Corning® 384 Well, black, NBSTM 
surface, flat bottom 
Corning Life Sciences Inc., Lowell, 
MA, USA 
cell scrapper 24 cm, sterile TPP, Trasadigen, Switzerland 
culture flasks 25cm2 (T-25), filter cap 
 
75cm2 (T-75), filter cap 
Sarstedt AG & Co., Nümbrecht, 
Germany 
Sarstedt AG & Co., Nümbrecht, 
Germany 
serological pipettes Corning ® Costar® Stripette (2 ml, 
5 ml, 10 ml, 25 ml, 50 ml) 
Corning Life Sciences Inc., Lowell, 
MA, USA 
2.2 METHODS 
Methods marked with an asterisk (*) were applied by collaborators and are described in brief. 
2.2.1 SUBCULTIVATION OF CELLS 
All cell culture experiments were performed under sterile conditions and cells were cultured 
in a gas-controlled incubator in a water vapor saturated atmosphere at 5% CO2 and 37°C. 
Frozen aliquots of cells were stored in liquid nitrogen. For plating, the respective full growth 
medium was pre-warmed to 37°C, cryoampules were quickly defrosted, sterilized with 70% 
EtOH and cells were suspended in 10 ml growth medium. Suspension cells were washed once 
in complete medium, centrifuged for 5 min at 1,000 rpm (Eppendorf 5180R), resupended in 
10 ml complete medium and plated in T-25 culture flasks. The day after seeding of adherent 
growing cultures in T-25 flasks, medium was discarded and replaced by 10 ml fresh complete 
culture medium. For subcultivation, confluent cultures of adherent cells were either scrapped 
off or detached after washing with PBS by trypsin/EDTA and the reaction was stopped by 
adding the 10-fold volume of FBS-containing medium. Suspended cells were split in ratios of 
1:3 to 1:20 according to the depositor’s recommendations. Suspension cultures were directly 
diluted in fresh complete medium and cell densities were maintained at about 
1x105-2x106 viable cells/ml.  
2.2.2 CRYOPRESERVATION 
The cells were seeded in T-25 flasks and grown to ca. 70% confluency (adherent cultures) and 
approximately 5x105 viable cells/ml (suspension cultures), respectively. After detaching 
adherent cells as described in section 2.2.1, cells were collected by centrifugation for 5 min at 
room temperature at 1,200 rpm (Eppendorf 5180R), washed once with PBS and the cell pellet 
was resuspended in 500 μl freezing medium to achieve a final concentration of about 
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106 cells/ml. Cryoampules were cooled down at a constant rate of -1°C/min in a -80°C freezer 
(freezing container ‘Mr. Frosty’) and subsequently transferred for long-term vapor phase 
storage in a liquid nitrogen tank.  
2.2.3 PRIMARY CULTURES 
Single donor HUVEC were subcultivated once the cells reached 70-90% confluency in T-25 
culture vessels. HUVEC were washed with a small volume of PBS and 3 ml accutase solution 
was added. The culture vessel was placed back in a CO2 incubator for ca. 15 min and once 
HUVEC completely detached, cells were collected by centrifugation for 3 min at 1,000 rpm 
(Eppendorf 5180R). The pellet was resuspended in endothelial cell growth medium and cells 
were split in a ratio of 1:2 - 1:3. For cryopreservation, HUVEC were resuspended in Cryo-
SFM freezing medium at 106 cells/ml and cryoampules were cooled down at a constant rate of 
-1°C/min in a -80°C freezer (freezing container ‘Mr. Frosty’) and subsequently transferred for 
long-term vapor phase storage in a liquid nitrogen tank.  
2.2.4 VIABILITY ASSAY (MTT) 
Cells from actively growing cultures were harvested and seeded at 6x103 cells per well of 96-
well plates (CellBIND®surface) in 180 μl complete medium and treated after 2 h 
equilibration in a CO2 incubator with compounds in serial dilution. Each compound or extract 
was tested in duplicate as well as the internal MeOH control. After 5 d incubation, 20 μl of 
5 mg/ml MTT (thiazolyl blue tetrazolium bromide) in PBS was added per well and it was 
further incubated for 1-3 h (depending on the cell type) at 37°C.[214] The medium was then 
discarded and cells were washed with 100 μl PBS before adding 100 μl 2-propanol/10 N HCl 
(250:1) in order to dissolve formazan granules. The absorbance at 570 nm was measured 
using a microplate reader (EL808, Bio-Tek Instruments Inc.), and cell viability was expressed 
as percentage relative to the respective MeOH control. IC50 (or GI50) values were determined 
by sigmoidal curve fitting. 
For cytotoxicity testing of fractions derived from extract purification, cells were seeded at a 
higher density (1.2x104 cells per well) and treated with the samples dissolved in MeOH at 
concentrations that were adjusted according to the initially detected potency of the parent 
sample. MTT was added already after 2-3 d and plates were processed as described above. 
Toxicity was expressed relative to the respective MeOH control, which was set to 0% 
toxicity.   
 
Materials and Methods 
 
37 
2.2.5 GIEMSA STAINING 
CHO-K1 cells from actively growing cultures were harvested and seeded at 2x104 cells per 
well of 96-well imaging plates in 100 μl complete medium and directly treated with extract 
fractions. Following 48 h treatment, cells were gently washed with PBS, then with 
PBS/MeOH (1:1.5), and finally incubated for 10 min at room temperature with 200 µl MeOH 
per well. For staining, MeOH was removed and replaced by 50 µl Giemsa staining solution, 
After 2 min incubation at room temperature excess dye was washed off with tap water. 
Images were acquired in 200-fold magnification in the transmitted channel (BD Pathway 
855). 
2.2.6 CLONOGENIC SURVIVAL 
*L3.6pl cells at 70% confluence were treated for 4 h with compounds at the assigned 
concentrations. After the treatment, the cells were trypsinized and 104 cells/well were seeded 
in a 6-well plate. The freshly seeded cells were allowed to grow for 6 d, followed by crystal 
violet staining (0.5% crystal violet, 20% MeOH, 80% H2O) for 10 min at room temperature. 
After washing with tap water, cells were dried and pictures of the wells were taken. Crystal 
violet was redissolved with sodium citrate solution (50 mM sodium citrate, 50% EtOH, 
50% H2O) to measure the absorption at 550 nm in a SpectraFluor PlusTM (Tecan, Männedorf, 
Austria). For statistical analysis, the percentage of viable cells of the untreated control was set 
to 100%.  
2.2.7 APOPTOSIS MEASUREMENT 
*Apoptotic cell death was measured as described by Nicoletti et al.[215]. Briefly, L3.6pl cells 
were treated for 48 h with compounds in various concentrations as assigned. To assess 
caspase-independent apoptosis induction, 10 µM Q-VD-OPh (R&D Systems Inc.) was added 
2 h prior to compound addition. After treatment, cells were permeabilized with a Triton-
containing buffer and stained o/n with 50 µg/ml propidium iodide (PI) at 4°C. The cells were 
analyzed by flow cytometry and cells with hypoploid DNA (sub-G1 peaks) were considered as 
dead and quantified relative to the whole cell population.  
2.2.8 CELL CYCLE STUDIES 
Cells from actively growing cultures were harvested and seeded in 6-well plates in 5 ml of 
complete medium and, after an o/n equilibration, were treated with the compounds dissolved 
in MeOH at the appropriate concentrations and for the indicated time periods. Approximately 
Materials and Methods 
 
38 
106 cells were harvested by centrifugation, washed twice with PBS (phosphate-buffered 
saline, pH 7.4) and fixed in cold (-20°C) 80% MeOH. After an o/n fixation at -20°C, the cells 
were washed with PBS and further permeabilized with 0.1% saponin in PBS. For DNA 
labeling, the cells were resuspended in staining solution containing 20 µg/ml propidium 
iodide (PI) and 100 µg/ml ribonuclease A (RNase A) in PBS. The cells were stained for 
30 min at 37°C and analyzed on a GUAVA EasyCyte Plus flow cytometer. In total, 
104 events, excluding cell debris, were measured, and the data were processed using 
FlowJo v7.6.5 software (Tree Star Inc.). For cell cycle analysis and quantification of G1, S, 
and G2/M cell populations, the Dean-Jett-Fox algorithm was used. 
2.2.9 IMMUNOBLOTTING 
*L3.6pl cells were treated with compounds for the indicated time points and proteins were 
prepared from total cell lysates. Proteins were separated by SDS-PAGE[216] and transferred to 
nitrocellulose membranes via tank blotting. Nitrocellulose membranes were incubated with 
antibodies raised against Bcl-2 (Calbiochem), PARP (Calbiochem) or actin (Millipore). To 
detect the protein levels, the ECLTM detection system (Amersham Pharmacia Biotech, Little 
Chalfont, UK) or the Odyssey Infrared Imaging system version 2.1 (LI-COR Biosciences, 
Lincoln, NE, USA) was used.  
2.2.10 IMMUNOFLUORESCENCE 
Human U-2 OS osteosarcoma cells were seeded at 5x103 cells per well in 96-well imaging 
plates (BD Falcon). After an o/n equilibration, the cells were treated with extracts, fractions, 
or compounds at the appropriate concentrations and treatment periods indicated for each 
experiment. The cells were fixed with cold (-20 °C) acetone/MeOH (1:1) for 10 min. After 
washing with PBS, the cells were permeabilized with 0.01% Triton-X 100 in PBS. The 
following primary antibodies were used: α-tubulin mAb (Sigma), β-actin mAb (Millipore), 
and anti-phospho-Histone H2A.X mAb (Millipore). For labeling, cells were incubated with 
primary antibody for 45 min at 37 °C, followed by incubation with the secondary antibody 
(Alexa Fluor® 488 goat anti-mouse or anti-rabbit, and Alexa Fluor® 555 goat anti-rabbit; 
Molecular Probes) under the same conditions. After washing with PBS, a staining solution 
was applied for 10 min at room temperature that contained the nuclear stain Hoechst33342 
(5 µg/ml) and a whole cell stain (1 µg/ml HCS CellMaskTM Red or Green). The samples were 
imaged on an automated microscope (BD Pathway 855) suitable for high-content screening 
with appropriate filter sets for Alexa 488, TRITC, and Hoechst fluorescence. 
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2.2.11 ACTIN LABELING (PHALLOIDIN PROBE) 
Human U-2 OS osteosarcoma cells were seeded at 5x103 cells per well in 96-well imaging 
plates (BD Falcon). After 2 d equilibration, the cells were treated with compounds at the 
appropriate concentrations. After 4 h treatment, cells were washed with pre-warmed PBS 
(37°C) and fixed with cold (-20 °C) acetone/MeOH (1:1) for 10 min at room temperature. 
After washing with PBS, the cells were permeabilized with 0.01% Triton-X 100 in PBS. 
Actin microfilaments were then probed by adding 50 µl of an Acti-stain phalloidin working 
solution (100 nM, diluted with PBS). After 30 min incubation, the cells were washed with 
PBS and the nuclear stain Hoechst 33342 (5 µg/ml in PBS) was added for 10 min at room 
temperature. The samples were washed again with PBS and cells were imaged on an 
automated microscope (BD Pathway 855) with appropriate filter sets for TRITC and Hoechst 
fluorescence. 
2.2.12 TMRM STAINING 
U-2 OS cells from actively growing cultures were harvested and seeded at 8x103 cells/well in 
96-well imaging plates (BD Falcon) and after 1 d, cells reached approximately 60% 
confluency. Reference compounds dissolved in DMSO (10 mM) were added to the cells to 
achieve a final concentration of 200 nM. Following 12 h treatment, the cells were washed 
twice with PBS and 100 µl of a staining solution (50 nM TMRM and 5 µg/ml Hoechst33342 
in assay buffer) was added. The cells were stained for 30 min at 37°C and after washing with 
assay buffer the samples were examined on an automated microscope (BD Pathway 855) in 
200-fold magnification with appropriate filter sets for rhodamine and Hoechst.  
2.2.13 ACRIDINE ORANGE STAINING 
U-2 OS cells from actively growing cultures were harvested and seeded at 5x103 cells/well in 
96-well imaging plates (BD Falcon; ‘culture plate’) and after 2 d, cells reached approximately 
80% confluency. Extracts and fractions were dissolved in MeOH and a 96-well ‘sample plate’ 
(Sarstedt) was prepared by evaporation of appropriate amounts of the samples. Dried extracts 
and fractions were re-dissolved in 120 µl pre-warmed McCoy’s 5A complete medium and the 
medium of the culture plate was replaced by 100 µl of the sample plate. Following 4 h 
treatment, the cells were washed with PBS and 75 µl of a staining solution (5 µg/ml AO and 
10 µg/ml Hoechst33342 in PBS) was added for 15 min. After staining at 37°C, cells were 
washed with PBS and imaged on an automated microscope (BD Pathway 855) in 200-fold 
magnification with appropriate filter sets for green/red fluorescence and Hoechst.  
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2.2.14 HCS STUDIES 
All analyses were performed in AttoVision v1.6.2. The presented values were generated on a 
single cell basis and averaged over the complete sample (well). For the analysis of 
microtubules and actin filaments, a dual mask (Cyto-Nuc-Dual) for the cytoplasm and nuclei 
was used in the HCS CellMaskTM and Hoechst channels, respectively, and the assigned 
parameters were calculated in either one of these ROIs (regions-of-interest) as indicated. In an 
unbiased but supervised approach, an experimental test set was generated for both, tubulin- 
and actin-disrupting effects, and it was found that the standard deviation of fluorescence of 
either cytoskeletal protein is among the most optimal parameters to describe induced effects. 
For the DSB analyses, a polygon nuclear mask was used in the Hoechst channel, and γH2A.X 
fluorescence was calculated within this ROI. In HCS experiments using either AO or TMRM 
as a probe, a dual mask (Cyto-Nuc-Ring) was applied. The first segment (nuclei) was 
generated in the Hoechst channel and as a second segment (‘cytoplasm’) a ring was generated 
around the former nuclear segment. Intensity parameters for AO and TMRM were calculated 
within this ring around nuclei. 
2.2.15 DETECTION OF DNA LADDERING 
Human HL-60 leukemia cells were seeded at a concentration of 105 or 2x105 cells/ml in 6-
well plates (5 ml per well). After 2 d, compounds dissolved in MeOH were added at the 
indicated concentrations and cells were treated for either 24 or 48 h. DNA fragments were 
extracted from apoptotic HL-60 cells in phosphate-citrate buffer (PCB, pH 7.8) as described 
by Gong et al.[217] Cells were harvested by centrifugation (1,200 rpm, 4°C, 10 min; Eppendorf 
5180R), the cell pellet was resuspended in 1 ml cold PBS, and the cell suspension was 
transferred drop wise into 10 ml 70% EtOH (-20°C). After o/n fixation at -20°C, cells were 
again harvested (1,200 rpm, 4°C, 10 min; Eppendorf 5180R) and EtOH was removed 
thoroughly. The extraction was performed by resuspension in 40 µl PCB buffer (pH 7.8) and 
30 min incubation at room temperature. After centrifugation (2,500 rpm, 5 min; Eppendorf 
5180R), the supernatant was treated with 3 µl 0.25% Nonidet NP-40 and 3 µl of 1 mg/ml 
RNase A in H2Odd. Following 30 min incubation at 37°C, 3 µl of 1 mg/ml proteinase K in 
H2Odd was added and samples were further incubated for 30 min at 37°C. The extracted DNA 
was loaded onto an agarose gel (1.7%) and separated by 4 h of electrophoresis at 4 V/cm 
using 0.5x TBE buffer. The resulting bands were stained with ethidium bromide and detected 
under UV light. 
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2.2.16 TUBULIN ISOLATION 
Microtubule proteins were isolated from porcine brain tissue as described previously.[218] All 
works were performed at 4°C except for the polymerization phases. Blood vessels and fat rich 
compartments of brains (approximately 600 g initial weight) were removed and the tissue was 
homogenized (Blender GT 800) in 900 ml PEM buffer containing 63 µl mercaptoethanol. 
After centrifugation at 13,000 rpm for 90 min at 4°C (Sorvall GSA) 0.1 mM GTP and 2.5 mM 
ATP was added to the supernatant. The solution was pre-warmed for 30 min at 37°C and a 
10% saccharose solution (37°C) was added as the bottom layer. Following centrifugation at 
13,000 rpm for 45 min at 37°C (Sorvall GSA), the resulting pellet was resuspended in 75 ml 
ice-cooled PEM buffer containing 1 mM GTP and the tubulin pellet was homogenized. For 
complete depolymerization, the solution was incubated for 30 min on ice and subsequently, 
debris was removed by centrifugation at 18,000 rpm for 30 min at 4°C (Sorvall SS-34). The 
supernatant was incubated for 15 min at 37°C and tubulin pellets were collected by 
centrifugation at 18,000 rpm for 30 min at 37°C (Sorvall SS-34). Purified tubulin (including 
MAPs) was either stored at -80°C or directly used in turbidimetric assays. 
2.2.17 IN VITRO TUBULIN POLYMERIZATION STUDIES 
Tubulin polymerization was analyzed in a turbidimetric assay.[219] The samples (200 μl, 
10 μM tubulin) in PEM polymerization buffer containing 1 mM GTP were filled into ice-
cooled cuvettes. These cuvettes were then placed in a water-jacketed cuvette holder in a diode 
array photometer (Beckman spectrophotometer DU7500) and rapidly warmed to 37°C. The 
absorbance at 350 nm in the presence and absence of drugs is proportional to the degree of 
tubulin polymerization. 
2.2.18 TRANSMISSION ELECTRON MICROSCOPY 
MAP-enriched tubulin from porcine brain tissue (70% tubulin, 30% microtubule-associated 
proteins; Cytoskeleton, Inc.) was adjusted to 12 μM tubulin with PEM buffer containing 
1 mM GTP and polymerized for 30 min at 37°C in the presence or absence of drugs. *For 
negative staining, thin carbon support films were prepared by indirect sublimation of carbon 
on freshly cleaved mica. Samples were then absorbed to the carbon film and negatively 
stained with 2% (w/v) aqueous uranyl acetate (pH 4.5). After air drying, samples were 
examined in a Zeiss TEM 910 at an acceleration voltage of 80 kV and at calibrated 
magnifications using a line grid replica. Images were recorded digitally with a Slow-Scan 
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CCD-Camera (ProScan, 1024x1024, Scheuring, Germany) with ITEM-Software (Olympus 
Soft Imaging Solutions, Münster, Germany). 
2.2.19 IN VITRO ACTIN POLYMERIZATION STUDIES 
Fluorescence-based actin polymerization assays were performed using pyrene muscle actin 
(Cytoskeleton, Inc.) according to the supplier’s protocol with minor modifications. Test 
compounds were dissolved in non-polymerizing buffer (5 mM Tris-HCl pH 8.0, 0.2 mM 
CaCl2, 0.2 mM ATP, 1 mM DTT) and mixed with pyrene actin diluted in the same buffer to 
give a final concentration of 20 µM chondramide and 5 µM actin. Samples were prepared in 
black, low-volume 384-well plates (Corning, NBSTM surface). The fluorescence at 405 nm 
(excitation at 360 nm) was scanned every 30 s for 85 min at 37°C on a microplate reader 
(Spectramax M5e, Molecular Devices). Experiments were performed in duplicates and the 
average relative fluorescence of polymerizing pyrene actin is given. Slopes were calculated in 
the linear range of kinetic measurements.  
2.2.20 CULTIVATION OF CHONDROMYCES SP. SBCM007 
*Strain SBCm007 was cultivated in VY/2 Media (5 g/L Baker’s Yeast, 1 g/L CaCl2). A fed-
batch cultivation was carried out in a 13 L bioreactor (filled with 8 L VY/2 and inoculated 
with 500 ml shake flask culture. For maintenance of pH a 0.2 M KOH and a 0.1 M H2SO4 
solution was used. The feed solution consisted of 100 g/L Baker’s Yeast and 1 g/L CaCl2. 
After depletion of the batch media 200 ml of a XAD/water solution was added and a constant 
feeding rate of about 0.15 ml/min was adjusted. To replace chlorine by bromine the CaCl2 
was substituted by the same amount of KBr. 
2.2.21 EXTRACT PREPARATION AND PRE-FRACTIONATION 
*For crude extract preparations cells and XAD were extracted separately with MeOH. For 
activity testing a pre-fractionation with silica gel 60 (Merck KGaA Darmstadt, Germany) was 
applied. The column was filled with a hexane/silica gel slurry loaded with methanolic raw 
extract on kieselguhr and subsequently eluted with 2 column volumes hexane, CHCl3 and then 
stepwise increasing (10%) CHCl3/MeOH fractions up to 100% MeOH. For purification of 
compounds a pre-fractionation with Sephadex LH-20 (Amersham Biosciences Uppsala, 
Sweden) was carried out with a column volume of 500 ml. Approximately 200 mg methanolic 
crude extract were loaded and subsequently eluted with MeOH; fractions of 8 ml were 
collected and used for semi-preparative HPLC purification. 
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2.2.22 SEMI-PREPARATIVE HPLC 
*Measurements were conducted on a Dionex HPLC system (Famos autosampler, P680 pump, 
TCC100 thermostat, and PDA100 detector), equipped with a Phenomenex Luna C18, 
250x4.6 mm, 5 µm dp column. Separation was achieved by variable linear gradients using (A) 
H2O and (B) ACN at a flow rate of 2.5 ml/min and 25°C. The gradient started at 5-60 % B 
with a 0.5 min hold and increased to 100% B in a variable time frame. UV data was acquired 
at 220 and 280 nm. The sample was injected by µl-pick-up technology with a H2O/ACN 
(50:50 v/v) mixture as supporting solvent. A maximum of 75 µl sample was injected before 
manual fraction collection. 
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RESULTS 
3.1 BIOLOGICAL CHARACTERIZATION OF PRETUBULYSINS 
Pretubulysin and its derivatives were synthesized and provided by the group of Prof. 
Kazmaier (Institute for Organic Chemistry, Saarland University). 
3.1.1 DETERMINATION OF GI50 VALUES 
Initially, the biological activity of pretubulysin and its direct precursor molecules from total 
synthesis were compared to the natural parent compounds tubulysins A and D. The growth 
inhibitory potential was assessed in tetrazolium salt-based assays (MTT) after 5 d treatment of 
cells with the compounds in serial dilution (Figure 3-1 and Table 3-1a). 
 
Figure 3-1: Chemical structures of tubulysins A and D, pretubulysin, and precursors. 
The amino acid composition of shorter pretubulysin precurors (analogs I-VI) is given 
in brackets. 
Tubulysin DTubulysin A
Pretubulysin Analog I
(missing propionate of Tup)
Analog II
(MepIleTuv)
Analog III
(MepIleMe‘Val‘)
Analog IV
(MepIleMeVal)
Analog V
(MepIle)
Analog VI
(Mep)
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Table 3-1a: GI50 values of natural tubulysins, synthetic pretubulysin, and its precursors. 
Compound[a] GI50 value[b] [nM] 
Tubulysin A 0.23 
Tubulysin D 0.02 
Pretubulysin 5.81 
Analog I 9600 
Analog II 14200 
Analog III 6500 
Analog IV > 25000 
Analog V > 25000 
Analog VI > 25000 
Table 3-1b: GI50 values of natural tubulysins, synthetic pretubulysin, and pretubulysin derivatives. 
Compound[a] GI50 value[c] [nM]
Tubulysin A 0.23 
Tubulysin D 0.04 
Pretubulysin 0.84 
2-Desmethyl-pretubuylsin 4.93 
N-Methylsarcosine variant 4700 
2,3-Didehydro-pretubulysin ethyl ester 487 
2,3-Didehydro-pretubulysin 240 
Oxazole-pretubulysin methyl ester 10.03 
Oxazole-pretubulysin 1.55 
Triazole-pretubulysin methyl ester >1500 
Triazole-pretubulysin 644 
Phenyl-pretubulysin methyl ester 420 
Phenyl-pretubulysin 119 
Pretubulysin-n-butylamide 40.48 
Pretubulysin-propargylamide 87.78 
Methylproline variant 164 
Pipecolic acid variant 1073 
‘Tuv’ Variant I 1.48 
‘Tuv’ Variant II 0.86 
‘Ile’ Variant I 46.16 
‘Ile’ Variant II 5.06 
‘Ile’ Variant III 121 
‘Ile’ Variant IV >5000 
[a] For chemical structures see Figure 3-1 and 3-2. [b]/[c] Compounds were tested in serial dilution for 
5 d on [b]L-929 cells (mouse subcutaneous connective tissue) or [c]human U-2 OS cells (osteosarcoma). 
Viability was assessed in an MTT assay. GI50 values were determined by sigmoidal curve fitting and 
calculated as the average of two independent measurements. 
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Other structural modifications of the pretubulysin core structure are displayed in Figure 3-2 
and corresponding GI50 values are given in Table 3-1b. 
 
   
modification sites
of pretubulysin
2-Desmethyl-pretubulysin N-Methylsarcosine variant
2,3-Didehydro-pretubulysin ethyl ester 2,3-Didehydro-pretubulysin
Oxazole-pretubulysin methyl ester Oxazole-pretubulysin
Triazole-pretubulysin methyl ester Triazole-pretubulysin
Phenyl-pretubulysin methyl ester Phenyl-pretubulysin
Pretubulysin-propargylamide Pretubulysin-n-butylamide
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Figure 3-2: Chemical structures of pretubulysin derivatives. 
Chemical variations of the pretubulysin core structure (highlighted in grey) were 
realized at N-terminal Mep, C-terminal Tup, the thiazole heterocycle of Tuv, and 
additionally, alkylation patterns of Ile and Tuv were varied.  
GI50 values for tubulysins A and D are in accordance with previous reports, and were 
determined to be in a mid picomolar to low nanomolar range.[192] The activity of pretubulysin 
was comparable to that of the parent compounds tubulysins A and D (low nanomolar range). 
However, with shorter chain analogs bioactivity was nearly abolished, and for single 
MepIleMeVal, MepIle, and Mep building blocks (Analog IV-VI in Figure 3-1) GI50 values 
were not determinable in the assay’s concentration range. Interestingly, analog III, that lacks 
already the thiazole ring of Tuv, still shows a reasonable growth inhibitory activity (GI50 of 
6.5 µM), which is even higher than determined for the MepIleTuv building block (analog II; 
GI50 of 14.2 µM). 
The 2-desmethyl derivative was approximately by factor 6 less potent than pretubulysin, and 
the 2,3-didehydro variants, either as free carboxylic acid or ethyl ester, by factor 600 and 300, 
Methylproline variant Pipecolic acid variant
‚Tuv‘ Variant I ‚Tuv‘ Variant II
‚Ile‘ Variant I ‚Ile‘ Variant II
‚Ile‘ Variant III ‚Ile‘ Variant IV
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respectively. When the C-terminal carboxylic acid group was replaced by an n-butylamide or 
propargylamide functional group, GI50 values were in the mid nanomolar range and hence, by 
factor 50 and 100, respectively, higher than the value for pretubulysin itself. However, 
variations of the N-terminal Mep are much less tolerated. By replacing N-Mep with 
methylproline, pipecolic acid (in variant where N-methyl in Tuv is replaced by an N-ethyl 
group), or methylsarcosine potency decreased approximately by factor 200, 1300 and 5600, 
respectively, compared to pretubulysin.  
In general, potency of derivatives, where the thiazole heterocycle was substituted by either a 
phenyl or triazole group, was strongly diminished resulting in GI50 values in the high 
nanomolar range, and the same compounds as methyl esters were at least by factor 3 less 
active than the free acid analogs. Solely oxazole derivatives exhibited GI50 values in the low 
nanomolar range; 1.55 nM for the free acid and 10.03 nM for the respective methyl ester. 
Different alkylation patterns at the N-terminus of Tuv (‘Tuv’ variants) do not seem to have a 
major impact on the bioactivity of pretubulysin, whereas in ‘Ile’ variants replacement of the 
sec-butyl group in L-Ile by a methyl group (GI50 > 5 µM) or a bulky phenyl group (‘Ile’ 
variant III; GI50 = 121 nM) leads to significantly reduced potency. Substitution of the sec-
butyl functional group by iso-butyl (GI50 = 46.2 nM) or iso-propyl (GI50 = 5.1 nM) was less 
relevant with regards to bioactivity. Nevertheless, potency compared to pretubulysin was 
reduced by factor 50 and 6, respectively. 
The parent compounds tubulysins A and D, pretubulysin, and some selected pretubulysin 
derivatives were tested in a larger panel of various cancer and non-cancerous cell lines (Table 
3-2). No certain specificity towards type of tissue or organism was observed, although fast-
dividing human leukemia cell lines appear to be more sensitive towards tubulysin and 
pretubulysin treatment. On average, pretubulysin is by factor 10 and 100 less potent than 
tubulysins A and D, respectively, and exhibits throughout the panel GI50 values in the low 
nanomolar range. Furthermore, pretubulysin is active on an MDR cancer cell line (KB-V.1; 
GI50 = 40.8 nM). The same is true for oxazole-pretubulysin (GI50 = 52.1 nM), which in 
general, exhibits a ca. 3-fold reduced potency compared to pretubulysin. With the 2-
desmethyl derivative potency is further reduced approximately by factor 10. ‘Tuv’ variants 
and ‘Ile’ variant II, however, are comparable active to pretubulysin itself, with 2- to 3-fold 
increased average activity for ‘Tuv’ variants and 2-fold decreased activity for the ‘Ile’ variant 
II. As mentioned earlier, the pretubulysin analog III (MepIleMe’Val’) lacking the thiazole 
ting of Tuv, still has a reasonable activity on the three tested cell lines with GI50 values of 
around 8 µM. 
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Table 3-2: GI50 values of selected derivatives[c] on several cell lines. 
Cell 
line[a] 
GI50 values[b] [nM] 
Tub. A Tub. D Pretub. Desm.-pretub. 
Analog 
III 
Oxaz.-
pretub. 
‘Tuv’ 
Var. I 
‘Tuv’ 
Var. II 
‘Ile’ 
Var. II 
A431 0.12 0.014 1.85 0.52 n.d. n.d. n.d. n.d. n.d. 
A549 0.11 0.007 6.49 47.57 n.d. 18.11 n.d. n.d. n.d. 
CHO-K1 1.13 0.11 n.d. n.d. 5030 n.d. n.d. n.d. n.d. 
COS-7 0.095 0.041 1.69 14.68 n.d. 30.80 n.d. n.d. n.d. 
HCT-116 0.32 0.036 2.27 n.d. n.d. n.d. 0.55 0.21 2.62 
HEK293T 0.059 0.012 0.34 2.56 n.d. 0.67 n.d. n.d. n.d. 
HepG2 0.14 0.008 0.96 13.34 2400 2.55 n.d. n.d. n.d. 
HL-60 0.012 0.007 0.045 0.60 1250 0.049 n.d. n.d. n.d. 
K562 0.47 0.027 0.52 3.81 n.d. 0.37 n.d. n.d. n.d. 
KB-3.1 0.19 0.022 3.46 40.10 n.d. 5.37 n.d. n.d. n.d. 
KB-V.1 n.d. n.d. 40.83 n.d. n.d. 52.06 n.d. n.d. n.d. 
L-929 0.23 0.020 5.81 61.01 6500 11.17 n.d. n.d. n.d. 
NIH/3T3 n.d. n.d. 11.78 n.d. n.d. 11.33 n.d. n.d. n.d. 
SH-SY5Y 0.25 0.013 0.91 4.42 n.d. n.d. n.d. n.d. n.d. 
SW480 0.024 0.005 0.31 4.82 n.d. 1.50 n.d. n.d. n.d. 
U-2 OS 0.23 0.041 0.84 4.93 12600 1.55 1.48 0.86 5.06 
U937 0.004 0.001 0.12 0.63 n.d. 0.52 n.d. n.d. n.d. 
[a] Compounds were tested in serial dilution for 5 d on various cancer and non-cancerous cell lines. 
A431: human epithelial carcinoma; A549: human lung carcinoma; CHO-K1: Chinese hamster ovary; 
COS-7: African green monkey kidney; HCT-116: human colon carcinoma; HEK293T: human kidney; 
HepG2: human hepatocellular carcinoma; HL-60: human acute promyelocytic leukemia; K562: human 
chronic myelogenous leukemia; KB-3.1: human cervical carcinoma; KB-V.1: KB-3.1 derivative 
(MDR); L-929: mouse subcutaneous connective tissue; NIH/3T3: mouse embryonic fibroblasts; SH-
SY5Y: human neuroblastoma; SW480: human colon adenocarcinoma; U-2 OS: human osteosarcoma; 
U937: human histiocytic lymphoma. [b] Viability was assessed in an MTT assay and GI50 values were 
determined by sigmoidal curve fitting and calculated as the average of two independent measurements; 
n.d.: not determined. [c] For chemical structures see Figure 3-1 and 3-2. Tub.: Tubulysin; Pretub.: 
Pretubulysin; Desm.: 2-Desmethyl; Oxaz.: Oxazole; Var.: Variant. 
3.1.2 LONG-TERM SURVIVAL OF CANCER CELLS  
The following experiment was done by our collaboration partner at LMU Munich (Prof. 
Vollmar; Pharmaceutical Biology). Highly metastatic human L3.6pl pancreatic cancer cells 
were pre-treated with either tubulysin A or pretubulysin at different concentrations for 4 h. 
Cells were washed, detached, seeded, and further incubated for 6 d. The relative number of 
colonies formed by the cells was assessed by crystal violet staining and expressed as 
percentage clonogenic survival relative to the control, which was set to 100% (Figure 3-3). 
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Figure 3-3: Inhibition of clonogenic survival by tubulysin A and pretubulysin. 
L3.6pl cells were stimulated for 4 h and then seeded at low confluence. After 6 d, cells 
were stained with crystal violet, and absorbance was measured at 550 nm (n = 3; 
*p≤0.05 Anova/Dunnett).  
Over the 6 d treatment period, both compounds inhibited the clonogenic survival of L3.6pl 
cells. Tubulysin A reduced the relative number of colonies to approximately 40% at a 
concentration of 1 nM and at higher concentrations the number was further reduced to ca. 
10%. However, higher concentrations of pretubulysin were needed to observe this effect to 
the same extent. Pre-treatment with 50 nM pretubulysin reduced the number of L3.6pl 
colonies to approximately 30%.  
3.1.3 TRIAZOLE-PRETUBULYSIN TOOL COMPOUND 
In the course of chemical syntheses, a triazole-pretubulysin derivative was prepared that lacks 
the Tup moiety. Instead, coumarin 460 (or coumarin 1, coumarin 47) is coupled via an alkyl 
linker directly to the triazole heterocycle (Figure 3-4).  
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Figure 3-4: Chemical structure of the triazole-pretubulysin tool compound. 
A triazole-pretubulysin derivative was prepared that bears a coumarin 460 functional 
group. Given absorption and emission maxima refer to ethanolic solution. The 
fluorescent probe was used in live cell studies.  
Prior to the use in live cell imaging studies, GI50 values of triazole-pretubulysin coumarin 
were determined in an MTT assay. Human HCT-116 colon carcinoma and human U-2 OS 
osteosarcoma cells were treated with the compound in serial dilution for 5 d resulting in GI50 
values of 0.45 µM and 0.53 µM, respectively. Although these values are by three orders of 
magnitude higher than those determined for pretubulysin, activity is still good enough so that 
the tool compound could be applied in live cell studies. Since tubulysins target microtubules 
and lead to their depolymerization, the biological functionality of the fluorescent probe was 
first tested in immunofluorescence (IF) experiments (Figure 3-5). 
 
Figure 3-5: Microtubule depolymerization in U-2 OS cells by triazole-pretubulysin coumarin. 
Human U-2 OS osteosarcoma cells were either left untreated (left image) or treated for 
48 h with 10 µg/ml of the tool compound (right image). Microtubules are displayed in 
green (IF on α-tubulin) and Hoechst-stained nuclei in blue.  
Triazole-pretubulysin coumarin clearly leads to the fragmentation of nuclei, enlargement of 
cells, and the depolymerization of microtubules and hence, was expected to be a valuable tool 
in live cell imaging studies on microtubule dynamics.  
Triazole-pretubulysin coumarin
Coumarin 460
Absorption λmax: 373 nm
Emission λmax:450 nm
10 µg/ml
Triazole-pretubulysin coumarin 
Control
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Ptk-2 potoroo kidney cells were plated in 96-well imaging plates and grown until 80% 
confluence. The cells were loaded with 1 µg/ml triazole-pretubulysin coumarin and directly 
imaged on an automated microscope in the Hoechst channel for 12 h every 30 min. Cellular 
uptake of the probe was seen as early as 30 min after treatment. Since only a small portion of 
the tool compound accumulated in cells by that time, residual compound in the culture 
medium led to strong background fluorescence. After 1 h, small vesicles became visible, that 
were present in all cells and after prolonged incubation (images are shown after 6 h, 9 h, and 
12 h) these vesicles were more pronounced and somewhat accumulated mainly around the 
nuclei. After 12 h, the time-lapse experiment was stopped and cells were fixed and 
permeabilized. By probing α-tubulin in IF experiments it was observed that Ptk-2 cells were 
strongly affected by the treatment with triazole-pretubulysin coumarin. Compared to control 
cells microtubules were not yet completely depolymerized, but an enlargement of cell bodies 
and a higher density of microtubules around the nuclear periphery was seen, both effects 
being typically observed prior to complete microtubule depolymerization (Figure 3-6). 
 
 
Figure 3-6: Live cell imaging study in Ptk-2 cells with triazole-pretubulysin coumarin. 
80% confluent Ptk-2 potoroo kidney cells were loaded with 1 µg/ml of the tool 
compound and imaged over a 12 h treatment period in Hoechst channel (upper panel). 
After 12 h, the cells were fixed. Images of the lower panel show IF images of 
microtubules either of the untreated control or triazole-pretubulysin coumarin treated 
Ptk-2 cells. 
Interestingly, a microtubular localization of triazole-pretubulysin coumarin was not observed 
at any time point. Among cellular compartments, vesicles observed upon tool compound 
treatment most resembled lysosomes. Thus, Ptk-2 cells were treated for 12 h with the probe, 
1 h                                         6 h                                        9 h                                   12 h
Control Triazol-pretubulysin coumarin 
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washed, and counterstained with acridine orange (AO). The dye specifically accumulates in 
acidic compartments (mainly lysosomes) and consequently exhibits a strong red fluorescence. 
An overlay of coumarin and AO fluorescence images confirmed a co-localization of the tool 
compound and lysosomes of Ptk-2 cells (Figure 3-7).  
 
Figure 3-7: Localization of triazole-pretubulysin coumarin in lysosomes. 
Ptk-2 cells were incubated with 1µg/ml tool compound for 12 h. Lysosomes were 
stained with acridine orange and images were recorded in the Hoechst and red 
fluorescence channel. Displayed are identical image sections of a sample dual-stained 
with the tool compound (left) and acridine orange (right).  
3.1.4 MITOTIC ARREST 
As for other tubulin-targeting drugs, antimitotic tubulysins induce a G2/M cell cycle arrest. In 
an initial experiment with mouse L-929 subcutaneous connective tissue cells, pretubulysin 
and tubulysin A were tested (Figure 3-8). The cells were treated at approximately 60% 
confluency with the compounds at concentrations near their respective GI90 values and further 
incubated for 24 h. Cells were collected by centrifugation, fixed and permeabilized, and DNA 
was labeled with propidium iodide (PI) as described in the Methods section. The DNA 
content was determined by flow cytometric measurements (FCM) on a Guava EasyCyte Plus 
system. Data was processed in FlowJo v7.6.5 software and cell cycle histograms were 
analyzed according to Dean-Jett-Fox algorithm (Table 3-3). 
As expected, both compounds are able to halt cells in the G2/M phase already after 24 h 
treatment. Similarly to results from growth inhibition experiments (GI50 value determination), 
pretubulysin is ca. 10-fold less potent than the reference compound tubulysin A. 
Approximately 26% of control cells are in G2/M and 40% in G1 phase of the cell cycle. Upon 
treatment with tubulysin A the G2/M population steadily increases with higher concentrations 
and at finally 12 nM tubulysin A 45% of cells accumulate in G2/M, whereas the G1 population 
decreases to ca. 27%. For a similar effect (31% in G1 and 47% in G2/M) L-929 cells were 
Coumarin fluorescence Lysosomal staining
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treated with pretubulysin at a final concentration of 150 nM. However, a less pronounced 
antimitotic effect (29% in G2/M) could already be observed at a concentration of 30 nM.  
 
 
Figure 3-8: G2/M cell cycle arrest in L-929 cells treated with tubulysin A or pretubulysin.  
L-929 cells were either left untreated (control) or treated for 24 h with tubulysin A and 
pretubulysin at the assigned concentrations. Cells were analyzed after PI staining by 
FCM. Histograms of gated populations (excluding debris) were obtained by Dean-Jett-
Fox algorithm in FlowJo v7.6.5 software. 
Table 3-3: Calculated percentage of L-929 cells in G1, S, and G2/M phase of the cell cycle.[a] 
% Cells 
Control Tubulysin A[b] Pretubulysin[b] 
- 2 nM 6 nM 9 nM 12 nM 30 nM 75 nM 110 nM 150 nM 
G1 40.5 39.1 32.8 35.2 26.7 41.2 38.1 32.2 30.7 
S 31.2 20.2 22.9 20.8 27.1 21.7 25.2 25.1 21.0 
G2/M 26.3 39.5 39.8 43.2 45.4 29.4 30.6 36.9 46.6 
[a] Corresponding histograms are displayed in Figure 3-8. Percentages were calculated in FlowJo 
v7.6.5 software. [b] L-929 cells were treated for 24 h with compounds at the assigned assay 
concentrations. 
Growth inhibition experiments revealed that some shorter chain pretubulysin analogs exhibit 
GI50 values in the low to mid micromolar range (analogs I-III in Figure 3-1). The 
MepIleMe’Val’ analog (III), although lacking the thiazole heterocycle, still shows a 
significant effect on several cell lines, with human HL-60 acute promyelocytic leukemia cells 
being the most sensitive (GI50 = 1.25 µM) towards pretubulysin analog III treatment. The 
Tubulysin A
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potency of analog III was even higher than that of the MepIleTuv analog (II). However, it was 
not clear whether the effect is cytostatic (antimitotic) or rather due to unspecific cytotoxicity. 
For this reason, HL-60 cells were treated with analog III at its approximate GI90 concentration 
(10 µM) for 48 h and cell cycle histograms were determined (Figure 3-9). 
 
 
Figure 3-9: G2/M cell cycle arrest in HL-60 cells treated with pretubulysin analog III.  
Cell cycle histograms of control cells (light grey) and HL-60 cells treated for 48 h 
with 10 µM pretubulysin analog III (dark grey) as determined by PI staining and 
FCM. Percentages of cells in G1 and G2/M phase of the cell cycle are given and were 
determined by Dean-Jett-Fox algorithm in FlowJo v7.6.5 software.  
In control HL-60 cells, approximately 50% of cells were in G1 and 23% in G2/M phase. 
Following treatment with the small precursor molecule led to a significant increase of cells in 
G2/M phase (70%) and in parallel, to a decrease of the G1 population (23%). These results 
suggest that also the MepIleMe’Val’ analog is able to destabilize microtubules and in turn, 
leads to an antimitotic (G2/M cell cycle arrest) effect.  
The effects of tubulysin A, pretubulysin, and pretubulysin analog III were also directly 
compared in cell cycle studies. Human HepG2 hepatocellular carcinoma cells were treated 
with the compounds for 24 h (Figure 3-10 and Table 3-4).  
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Figure 3-10: G2/M cell cycle arrest in HepG2 cells treated with tubulysin A, pretubulysin, or 
pretubulysin analog III.  
HepG2 cells were treated for 24 h with compounds at varying concentrations as 
indicated. Cells were analyzed after PI staining in FCM and histograms of gated 
populations (excluding debris) were prepared in FlowJo v7.6.5 using Dean-Jett-Fox 
algorithm. Arrows in cell cycle histograms of analog III-treated cells indicate sub-G1 
populations. 
All three compounds are able to halt HepG2 cells in the G2/M phase after 24 h of treatment. 
Similar to the results from the initial growth inhibition experiments with HepG2 cells, the 
antimitotic activity of pretubulysin is comparable to that of the reference compound tubulysin 
A (GI50 = 0.14 nM and 0.96 nM for tubulysin A and pretubulysin, respectively). The results 
are also in accordance with data generated from L-929 cells (Figure 3-8).  
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Table 3-4: Calculated percentage of HepG2 cells in G1, S, and G2/M phase of the cell cycle.[a] 
% 
Cells 
Ctrl. Tubulysin A[b] Pretubulysin[b] Analog III (MepIleMe’Val’)[b] 
- 50 nM 
100 
nM 
200 
nM 
50 nM 
100 
nM 
200 
nM 
0.5 
µM 
5 µM 10 µM 20 µM 
G1 53.3 9.0 4.8 3.5 41.8 15.4 16.2 47.4 49.2 35.6 23.5 
S 21.9 11.9 10.0 8.8 12.5 14.5 10.9 23.9 6.8 13.8 8.6 
G2/M 21.7 72.6 77.7 81.6 44.0 68.4 70.2 26.4 37.4 41.1 58.9 
[a] Corresponding histograms are displayed in Figure 3-10. Percentages were calculated in FlowJo 
v7.6.5 software. [b] HepG2 cells were treated for 24 h with compounds at the assigned concentrations. 
Approximately 22% of the control HepG2 cells are in G2/M phase and 53% in G1 phase. The 
G2/M population increases to approximately 70% or 82% after 24 h treatment with 200 nM 
pretubulysin or tubulysin A, respectively. However, nearly full cell cycle inhibition was 
already achieved in cells treated with 50 nM tubulysin A (73% in G2/M), whereas with 
pretubulysin a concentration-dependent effect was observed (44-70% in G2/M at different 
concentrations). Simultaneous to increasing G2/M populations, the G1 population decreases 
from 53% to 4% or 16% of the total number of measured cells treated with either 200 nM 
tubulysin A or pretubulysin, respectively. Similar to results with HL-60 cells (Figure 3-9) an 
induction of G2/M cell cycle arrest was observed in HepG2 cells treated with the pretubulysin 
precursor compound (analog III). At a final concentration of 5 µM, nearly 40% of all viable 
cells accumulated in G2/M phase. However, at higher drug concentrations (10 and 20 µM), 
the percentage of viable cells in G2/M further increased to up to 60% in parallel with an 
emerging sub-G1 population, which most likely reflects late apoptotic cells in which the DNA 
has already been degraded (Table 3-4 and Figure 3-10). 
Complementary to FCM results, typical cellular events induced by antimitotic drugs were 
observed in human U-2 OS osteosarcoma and potoroo Ptk-2 kidney cells. Treatment of cells 
with 25 nM pretubulysin for 24 h resulted in an abnormal accumulation of microtubules 
around the periphery of nuclei. At higher concentrations (50 nM) microtubules were 
completely depolymerized and most of the cells showed fragmented nuclei. In addition, 
normal mitotic cells, which were present in the control population, were no longer observed. 
Instead, cells with abnormal multipolar spindle pole structures were present (Figure 3-11). 
However, these effects account for a pronounced G2/M cell cycle arrest as cells are not able to 
divide anymore.  
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Figure 3-11: Typical cellular events upon pretubulysin treatment.  
Human U-2 OS ostosarcoma cells (upper panel) were treated for 24 h with 
pretubulysin at the assigned concentrations. Microtubules were visualized by IF 
staining of α-tubulin (pseudocolor green) and nuclei were stained with Hoechst33342 
(pseudocolor blue). Arrows indicate the abnormal accumulation of microtubules 
(25 nM) and cells with completely depolymerized microtubules and fragmented nuclei 
(50 nM). Images of dividing potoroo Ptk-2 kidney cells (middle and lower panel) were 
prepared likewise by IF. Cells were either left untreated or treated with 50 nM 
pretubulysin for 24 h. 
3.1.5 APOPTOSIS INDUCTION 
The late apoptosis measurements and immunoblot analyses mentioned in this paragraph were 
done by our collaboration partner at LMU Munich (Prof. Vollmar; Pharmaceutical Biology). 
According to a modified protocol described by Nicoletti et al.[215], apoptosis induction by 
tubulysin A and pretubulysin in human L3.6pl pancreatic cancer cells was assessed by PI 
staining of cells and subsequent FCM. In brief, treated cells are permeabilized with 
Triton-X 100 containing buffer and DNA is stained with PI. In late apoptotic cells, a so-called 
DNA laddering can be observed due to caspase-3 activated DNase. Small DNA fragments can 
25 nM 50 nM
Control Pretubulysin
mitotic cell
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multipolar spindle
(Pretubulysin)
tubulin                 DNA                      merge
tubulin                 DNA                      merge
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then diffuse through the nuclear membrane and in FCM analysis a sub-G1 population (DNA 
content < 2n) is observed. This population is quantified and serves as a measure for apoptotic 
cells with fragmented DNA. Here, L3.6pl cells were treated with tubulysin A and 
pretubulysin and apoptotic cells were quantified after 48 h (Figure 3-12). 
 
Figure 3-12: Induction of apoptosis in L3.6pl cells (Nicoletti assay).  
Human pancreatic cancer cells were treated for 48 h with varying concentrations of 
tubulysin A or pretubulysin. The percentage of apoptotic cells in the whole cell 
population was determined by PI staining (n = 2; *p ≤ 0.05 Anova/Dunnett).  
Both compounds already induced apoptosis at a concentration of 1 nM (ca. 20%) and at 
higher concentrations the percentage of apoptotic cells in the whole cell population increased 
to approximately 50% with either compound.  
It was already reported that treatment of KB-3.1 cells with tubulysin A leads to DNA 
laddering[220] and the same effect could be clearly confirmed for pretubulysin and one of its 
derivatives, 2-desmethyl pretubulysin. Complementary to the Nicoletti assay, human HL-60 
acute promyelocytic leukemia cells were treated for 24 and 48 h with pretubulysins and 
extracted chromosomal DNA was separated by agarose gel electrophoresis. Resulting DNA 
bands were stained with ethidium bromide and detected under UV light (Figure 3-13). 
Cleavage of chromosomal DNA in distinct fragment, as a hallmark of apoptosis, was induced 
with either compound after 24 h and 48 h treatment. At the same concentrations (30 nM and 
75 nM), DNA laddering caused by pretubulysin treatment was more pronounced compared to 
analogous 2-desmethyl pretubulysin samples.  
In an additional experiment it was found that the induction of apoptosis, as demonstrated by 
DNA laddering and emerging sub-G1 populations, is partly caspase-dependent. L3.6pl cells 
were treated with pretubulysin and tubulysin A for 48 h and the percentage of apoptotic cells 
was again assessed after PI staining in FCM. The broad spectrum caspase inhibitor Q-VD-
OPh reduced drug-induced apoptosis from approximately 46% to 26% and from 39% to 27% 
for tubulysin A and pretubulysin, respectively (Figure 3-14). 
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Figure 3-13: DNA laddering in HL-60 cells treated with pretubulysins.  
HL-60 cells were either left untreated or treated with pretubulysin and 2-desmethyl 
pretubulysin at the assigned concentrations and time period. Chromosomal DNA was 
extracted and typical fragments (DNA laddering) were separated by agarose gel 
electrophoresis. 
 
Figure 3-14: Caspase-dependent induction of apoptosis in L3.6pl cells (Nicoletti assay).  
Human pancreatic cancer cells were treated for 48 h with 10 nM tubulysin A or 
pretubulysin in conjunction with 10 mM caspase inhibitor Q-VD-OPh. The percentage 
of apoptotic cells in the whole cell population was determined by PI staining (n = 3; 
*p ≤ 0.05 Anova/Dunnett).  
Molecular mechanisms of mitotic arrest mentioned in section 3.1.4, are often found to trigger 
signaling towards the mitochondrial apoptosis pathway. For instance, routine screening of a 
myxobacterial compound library revealed all microtubule-destabilizers that were included in 
the library (disorazol and tubulysin derivatives) as effective modulaters of the mitochondrial 
membrane potential (Figure 3-15). 
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Figure 3-15: Mitochondrial membrane potential (MMP) in U-2 OS cells treated with antimitotics. 
In routine HCS, 90% confluent U-2 OS cells were treated with myxobacterial 
compounds at a final concentration of 200 nM for 12 h. Mitochondria were labeled 
with TMRM (pseudocolor red) and nuclei with Hoechst33342 (pseudocolor green). 
Images were acquired on a BD Pathway855 automated microscope and subsequently 
processed in AttoVision v1.6.2. Images show representative results from control cells 
and cells treated with tubulysin A or disorazol A. The relative MMP was calculated 
based on TMRM fluorescence intensity in the cytoplasmic segment. Bars represent the 
mean ± SEM of all cellular segments within a well. 
The reduction of MMP, as depicted by diminished TMRM fluorescence of mitochondria, is 
generally considered as an initial and irreversible step towards apoptosis. All microtubule-
destabilizing compounds in the library significantly reduced the MMP in U-2 OS cells after 
12 h treatment at a final concentration of 200 nM to approximately 50-70% of the control.  
One of the key players in mitochondrial apoptosis is the proto-oncoprotein Bcl-2 (B cell 
lymphoma 2) because its phosphorylation status is linked to cellular redox status, cell growth 
and particulary, regulation of apoptosis. Immunoblot analyses demonstrated that antiapoptotic 
Bcl-2 is inactivated, i.e. phosphorylated, upon treatment with tubulysin A and pretubulysin 
(Figure 3-16A). Human L3.6pl pancreatic cancer cells were treated with 10 nM of either 
compound, which resulted in transiently enhanced levels of phosphorylated Bcl-2 (pBcl-2) 
after 8 and 24 h treatment. Highest pBcl-2 levels were detected after either 24 h tubulysin A 
treatment or 8 h of pretubulysin treatment.  
In addition, treatment of L3.6pl cells with tubulysin A or pretubulysin leads to cleavage of 
poly(adenosine diphosphateribose) polymerase (PARP), which is a substrate of caspase-3 and 
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functions in DNA repair (Figure 3-16B). PARP cleavage was detectable after 24 h treatment 
with both compounds and the effect was even more pronounced after 48 h. 
 
Figure 3-16: Immunoblot analysis of L3.6pl cells treated with tubulysin A and pretubulysin.  
Human pancreatic cancer cells were treated for the indicated time points with 10 nM 
tubulysin or 10 nM pretubulysin. Lysates were immunoblotted for A) Bcl-2 and pBcl-
2 or B) for PARP; β-actin served as a reference for the quantification of protein levels.  
3.1.6 HCS STUDIES  
For comparative high-content screening (HCS) studies the following compounds were 
selected: tubulysins A and D, pretubulysin, pretubulysin analog III, disorazol A, and 
epothilone B. Human U-2 OS cells were treated with the compounds for 24 h or 48 h at final 
concentrations that were adjusted according to respective GI50 values. 
In order to assess microtubule disruption and apoptotic events, α-tubulin was probed by 
immunofluorescence, nuclei were stained with Hoechst33342, and the whole cell stain HCS 
CellMaskTM Red was added to facilitate subsequent segmentation of the cytoplasmic region. 
Most apparently, enlargement of cells, fragmentation of nuclei, and rearrangements of the 
microtubule structures were found. For quantification, a cytoplasm-nuclei dual mask was 
applied to generate the respective segments for every cell within all wells (Figure 3-17). 
Analyses were performed on a single cell basis and averaged over the complete sample. 
Throughout all HCS experiments the SEM increased with increasing concentrations of the 
compounds, which was due to a larger portion of apoptotic cells and therefore more 
heterogeneous cell populations mainly with regards to cell size. 
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Figure 3-17: Schematic segmentation process of HCS image data.  
Nuclear segments are based on Hoechst33342 fluorescence (left upper panel) and 
cytoplasmic segments are generated around each nucleus based on HCS CellMaskTM 
Red fluorescence (right upper panel). The obtained masks are then overlaid in the 
respective fluorescence channel for analysis (lower panel; nuclear mask in 
Hoechst33342 channel and cytoplasmic mask in Alexa488 channel).  
The enlargement of cells and fragmentation of nuclei were determined in AttoVision v1.6.2 
by calculating the area of cytoplasmic and nuclear segments, respectively. In accordance with 
growth inhibition induced by all of the tested compounds, the cell bodies (cytoplamic area, 
Figure 3-18) were significantly enlarged in a concentration-dependent manner as a result of 
the compounds’ cytostatic activity. Epothilone B, the only microtubule stabilizer in the test 
panel, yielded the same macroscopic effects as the other microtubule destabilizers. Treatment 
with increasing concentrations of tubulysin A and pretubulysin led to a steady increase of 
average cell size. However, also upon treatment with tubulysin D, disorazol A, and 
epothilone B, cells enlarged but a slight drop was observed at the highest concentrations 
tested. Image data dereplication revealed a relatively large number of rounded-up, late 
apoptotic cells in these samples. Interestingly, treatment with 50 µM pretubulysin analog III 
also induces the enlargement of cells. 
The average size of nuclei (Figure 3-19) determined in the same experiment is in accordance 
with the results from cytoplasmic area calculations. Not only nuclear size increased with 
increasing concentrations of the antimitotics but also the relative number of fragmented 
nuclei. Since these could not be resolved as single fragments by image segmentation, 
fragmented nuclei also contributed to higher average values of the nuclear area. In late 
apoptotic cells (at highest concentrations of tubulysin D, disorazol A, and epothilone B), 
α-tubulin
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nuclei
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chromatin condensation was observed which resulted in very high values for average nuclear 
fluorescence intensity (data not shown) and decreased nuclear area. 
  
Figure 3-18: Cytoplamic area of U-2 OS cells treated with antimitotic compounds. 
Human U-2 OS osteosarcoma cells were treated for 24 h with the compounds at 
assigned concentrations. Cells were fixed, probed on α-tubulin, and stained with 
Hoechst33342 and HCS CellMaskTM Red. Bars represent the mean cytoplasmic area ± 
SEM of all cellular segments within a well as determined in AttoVision v1.6.2. 
 
Figure 3-19: Nuclear area of U-2 OS cells treated with antimitotic compounds. 
Cells were treated and analyzed as in the experiment on cytoplasmic area (Figure 3-
18). Bars represent the mean nuclear area ± SEM of all cellular segments within a well 
as determined in AttoVision v1.6.2. 
For the analysis of microtubule disruption by HCS several parameters were determined using 
statistical methods that are most suitable to describe antimitotic phenomena based on 
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microtubule fluorescence (data not shown). Among these parameters, the standard deviation 
(SD) of tubulin fluorescence in the cytoplasmic segments seemed to be the most robust 
parameter and was therefore calculated as a measure for microtubule disruption (Figure 3-20).  
 
Figure 3-20: Microtubule disruption in U-2 OS cell treated with antimitotic compounds. 
Representative images of human U-2 OS osteosarcoma cells treated with 
epothilone B, pretubulysin, or its small precursor (upper panel). Cells were treated and 
analyzed as in the experiment on cytoplasmic area (Figure 3-18). Bars represent the 
mean SD of tubulin fluorescence in the cytoplasmic segment ± SEM of all cellular 
segments within a well as determined in AttoVision v1.6.2 (lower panel). 
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The more uniform tubulin appears in the cells, the lower the SD is, i.e., lowest SD values 
were observed for cells with completely depolymerized microtubules. For all microtubule 
destabilizing compounds, the SD of tubulin fluorescence peaks at intermediate concentrations 
used in the HC assay. This first maximum value is followed by a decline at higher 
concentrations, and for tubulysins A and D a second peak was observed. Upon image data 
dereplication it was apparent that an increase in tubulin fluorescence SD was linked to initial 
microtubule depolymerizing effects that are characterized by a greater number of mitotic cells 
with abnormal spindle pole structures and a higher density of interphase microtubules around 
the nuclear periphery in most cells. Increasing concentrations led to complete microtubule 
depolymerization (decline in SD) and a second peak of tubulin fluorescence SD at highest 
concentrations, as for tubulysins A and D, was caused by cell debris. For the microtubule 
stabilizer epothilone B, a continuous increase of fluorescence SD was observed. At a final 
concentration of 500 nM the SD slightly falls off, which is most likely due to the very 
pronounced microtubule stabilizing effect. 
In a study on DNA double-strand breaks (DSBs), human U-2 OS osteosarcoma cells were 
treated as in the aforementioned assays but for 48 h instead of 24 h. Cells were probed on 
phosphorylated histone H2A.X (γH2A.X), which is a marker for DSBs, by immunostaining, 
and nuclei were stained with Hoechst33342. The fluorescence intensity of γH2A.X was 
determined within the nuclear segments and averaged over the respective samples (Figure 3-
21). All tested antimitotics led to large γH2A.X foci that were exclusively associated with 
already fragmented nuclei or cells with condensed chromatin as exemplarily shown for 
epothilone B treated U-2 OS cells. For all samples, fluorescence intensity of γH2A.X 
basically increased with increasing concentrations, although a decline in intensity was 
observed for tubulysins A and D, and pretubulysin. As a positive control, cells were treated 
for 4 h with hydroxurea (HU), which starves the DNA polymerase at the replication forks for 
dNTPs and thus, induces DSBs. HU-induced DSBs appeared to be evenly distributed in the 
nuclear region as small γH2A.X foci in a concentration-dependent manner. 
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Figure 3-21: Histone H2A.X phosphorylation in U-2 OS cell treated with antimitotic compounds. 
Human U-2 OS osteosarcoma cells were treated for 48 h with the compounds at 
assigned concentrations. Cells were fixed, probed on γH2A.X, and nuclei were stained 
with Hoechst33342. Bars represent the mean intensity of γH2A.X within the nuclear 
segment ± SEM as determined in AttoVision v1.6.2 (upper panel). Representative 
images of human U-2 OS osteosarcoma cells treated for 48 h with 0.5 mM 
hydroxyurea or 100 nM epothilone B (pseudocolor blue: DNA; pseudocolor green: 
γH2A.X; lower panel).  
3.1.7 IN VITRO POLYMERIZATION STUDIES 
Electron micrographs displayed in this section were prepared by our collaboration partner at 
HZI Braunschweig (Prof. Rohde, group: Molecular Mechanisms of Streptococci). 
Previous experiments revealed that potency of pretubulysin is reduced approximately by 
factor 10 compared to the parent compound tubulysin A. GI50 values of pretubulysin analog 
III, which also acts by destabilizing microtubule structures, are at least one order of 
magnitude higher (low micromolar range) than those of pretubulysin itself. Cell-free in vitro 
experiments were performed in order to assess whether tubulysin A and synthetic 
pretubulysins exhibit similar tubulin-binding potencies without the cell membrane acting as a 
natural barrier. As a reference, the absorbance at 350 nm of 10 µM microtubule protein in 
polymerization buffer with and without 1 µM tubulysin A was recorded over time 
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(Figure 3-22). The addition of the antimitotic drug led to an approximately 50% reduction of 
built-up microtubules. Electron micrographs, which were prepared in parallel, revealed 
perfect tubular structures and rather long microtubules in the untreated control. However, 
upon pre-treatment with 1 µM tubulysin A a smaller number of shorter and disrupted 
microtubules were observed. The residual microtubules were either fragmented and/or the 
tubular structure was broken up as indicated by arrows in electron micrographs of 
Figure 3-22. 
 
Figure 3-22: In vitro inhibition of tubulin polymerization by tubulysin A. 
Tubulysin A (1 µM) was added to a preparation of 10 µM tubulin protein, and the 
absorbance was measured over time at 350 nM. The maximum value of the untreated 
control was set to 100% (upper left panel). Corresponding electron micrographs of the 
control (upper right panel) and the sample co-incubated with tubulysin A (lower 
panel) are given. Arrows indicate fragmented and/or broken up microtubular 
structures. 
The results are in accordance with previous reports on tubulysin A.[220] Furthermore, it was 
shown that pretubulysin can inhibit microtubule formation in vitro in a dose-dependent 
manner and can also depolymerize already assembled microtubules (Figure 3-23). Addition of 
1 µM pretubulysin to the tubulin protein preparation (pre-assembly) led to an approximate 
50% reduction in microtubule formation. The polymerization was further reduced with higher 
pretubulysin concentrations. As revealed by electron microscopy, treatment with 5 µM 
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pretubulysin led to completely destroyed microtubules as only single protein blocks were 
found. When pretubulysin was added post-assembly, higher concentrations were needed to 
reduce the number of already built-up microtubules to the same extent than in the pre-
assembly experiment. Approximately 2 µM pretubulysin was needed to reduce the amount of 
microtubules by ca. 50%. At higher concentrations no further depolymerization could be 
observed in time course experiments. In addition, the electron micrograph recorded of a 
sample treated with 5 µM pretubulysin post-assembly revealed that microtubules are 
significantly disrupted but still not fully depolymerized.  
 
 
Figure 3-23: In vitro inhibition of tubulin polymerization by pretubulysin. 
Varying concentrations of pretubulysin were added to a preparation of 10 µM tubulin 
protein either pre-assembly (upper panel) or after microtubule assembly (lower panel; 
the arrow indicates the time point of drug addition) and the absorbance was measured 
over time at 350 nM. The maximum values of the untreated controls were set to 100%. 
Electron micrographs of tubulin treated pre- or post-assembly with 5 µM pretubulysin 
are given.  
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The small precursor molecule (pretubulysin analog III) was also able to inhibit in vitro 
microtubule formation (Figure 3-24). Compared to pretubulysin its activity is approximately 
10-fold reduced; either 20 µM of analog III or 2 µM of pretubulysin were needed to inhibit 
polymerization by about 60-70%. Furthermore, electron micrographs revealed that treatment 
with either 2 µM pretubulysin or 25 µM pretubulysin yields similar results with respect to 
microtubule disruption, as depicted by the shortened microtubules and the perturbed tubular 
structure relative to the control. 
 
 
Figure 3-24: In vitro inhibition of tubulin polymerization by pretubulysin analog III. 
Pretubulysin (2 µM) and its analog III (20 and 200 µM) were added pre-assembly to a 
preparation of 10 µM tubulin protein and the absorbance was measured over time at 
350 nM. The maximum value of the untreated control was set to 100%. Electron 
micrographs of tubulin treated with 2 µM pretubulysin or 25 µM pretubulysin 
precursor are given.  
3.2 DISCOVERY OF NEW CHONDRAMIDES AND INITIAL SAR STUDIES 
Fermentation and extract preparation, chromatographic steps, purification of chondramides 
and their structural elucidation mentioned in this section were performed by S. Hüttel in our 
research group. 
3.2.1 CYTOSTATIC ACTIVITY OF SBCM007 CRUDE EXTRACT 
In routine screening of methanolic crude extracts from shake flask cultivations of the newly 
discovered Chondromyces sp. strain SBCm007, no significant antibacterial or antifungal 
activity was discovered. However, the extract exhibited a potent activity against a human 
leukemia cell line with an IC50 value of 0.54 µg/ml (Figure 3-25).  
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Figure 3-25: Inhibition of HL-60 cells by SBCm007 crude extract. 
Human HL-60 promyelocytic leukemia cells were treated with Chondromyces sp. 
SBCm007 crude extract in serial dilution and incubated for 3 d. Viability was assessed 
in an MTT assay and was calculated relative to the internal control. The IC50 value 
was determined by sigmoidal curve fitting as average of two independent 
measurements.  
In order to elucidate whether this result comes from rather acute cytotoxic effects or is caused 
by cytostatic compounds present in the crude extract cells were screened on typical 
morphological alterations. Apparently, at concentrations around the determined IC50 value, 
cells enlarged, which can already be regarded as a growth inhibitory (cytostatic effect). 
Nevertheless, Chinese hamster ovary CHO-K1 cells were treated with the crude extract at its 
IC50 and 10-fold IC50 concentration for 48 h, and for better visualization cells were stained 
with Giemsa (Figure 3-26).   
 
Figure 3-26: Inhibition of cytokinesis after treatment with SBCm007 crude extract. 
CHO-K1 cells were treated for 48 h with the crude extract of Chondromyces sp. 
SBCm007 at assigned concentrations. Images of Giemsa-stained cells were obtained 
by transmitted light microscopy. Red arrows indicate multinucleated cells.  
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Interestingly, a quite unique phenotype characterized by bi-or even multinucleated cells was 
observed. At a concentration of 0.5 µg/ml most of the CHO-K1 cells appeared to be intact but 
some cells were binucleated. At 10-fold higher concentrations, the cell membrane was 
significantly affected and even multinucleated cells (up to four nuclei) were observed. 
3.2.2 TARGET-SPECIFIC ACTIVITY IN THE CRUDE EXTRACT 
Strains of the genus Chondromyces are described as producers of various secondary 
metabolites with partly cytostatic activity[221], and dereplication of LC-MS data against our in-
house database revealed the presence of chondramides A~D in SBCm007 crude extracts 
(Figure 3-27).   
 
Figure 3-27: Strain SBCm007 produces chondramides. 
Base peak chromatogram (BPC) of the crude methanolic extract (from adsorber resin 
AmberliteTM XADTM 16) of Chondromyces sp. SBCm007 as analyzed by HPLC-MS in 
positive ionization mode.  
Chondramides A~D were found to be quite abundant in the extract and eluted at a retention 
time of approximately 9 min in the presented chromatogram. These metabolites are usually 
active in the mid-nanomolar range on cultured mammalian cells and exhibit moderate activity 
against yeast.[194] Still, it was surprising that IC50 values of the crude extract on leukemia cells 
were only by 2-3 orders of magnitude higher than GI50 values reported for pure compounds.  
In addition to general bioactivity studies, crude extract-treated cells were probed on other, 
more specific, determinants of cytotoxicity. Since it was already reported for chondramides 
that these NPs act by stabilizing actin filaments[209], CHO-K1 cells were treated and 
subsequently analyzed by fluorescence microscopy using IF labeling on β-actin (Figure 3-28). 
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Figure 3-28: Actin condensation in CHO-K1 cells. 
CHO-K1 cells were either left untreated or treated for 24 h with chondramide A as a 
reference or SBCm007 crude extract. Nuclei were stained with Hoechst33342 
(pseudocolor red) and actin was visualized by IF on β-actin (pseudocolor green). 
Arrows indicate dividing cells in the control population and the box marks a 
representative multinucleated cell with actin lumps of the crude extract-treated 
sample.  
Although the expected actin pattern (condensed filaments) and multinucleated cells were 
observed in CHO-K1 cells that were treated with SBCm007 crude extract slight differences, 
which mainly manifested in the overall shape of the cells, were found compared to cells that 
were treated with chondramide A as a reference. Thus, human U-2 OS osteosarcoma cells 
were used in subsequent studies since these rather large cells have an epithelial adherent 
morphology and have been shown to be excellently suited for a wide variety of microscopy-
based assays, in particular, HCS applications. It was found that, besides influences on overall 
cell shape, actin lumps, nuclear condensation, and multinucleation, also lysosomal integrity 
was disturbed, as displayed by a less acidic lysosomal pH (Figure 3-29). 
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1 µg/ml SBCm007 crude extract
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Figure 3-29: Increased lysosomal pH in U-2 OS cells. 
U-2 OS cells were either left untreated or treated for 4 h with chondramide B or 
SBCm007 crude extract. Acidic lysosomes (pseudocolor red) were stained with 
acridine orange and green fluorescence of this dye is observed in the cytosol 
(displayed in grey). The small insert images display corresponding effects on the actin 
filaments as determined by IF on β-actin (pseudocolor green); nuclei were stained with 
Hoechst33342 (pseudocolor red).   
Lysosomal membrane permeabilization (LMP) is induced by a plethora of intra- and 
extracellular stimuli and is the key step in the lysosomal death pathway. Upon LMP, 
cathepsins and other hydrolases are released from the lysosomes in the cytosol, which in turn, 
trigger the mitochondrial pathway of apoptosis. Additionally, release of these hydrolases may 
also directly lead to cell death due to digestion of proteins in the cytosol.[222] The 
metachromatic fluorophor acridine orange (AO) is a lysosomotropic weak base and thus, 
accumulates preferentially in acidic compartments, i.e. lysosomes, where it exhibits a bright 
red to orange fluorescence. However, lower intracellular concentrations of AO (nuclear and 
cytosolic) are characterized by a green fluorescence, whereas the fluorescence intensity may 
increase upon lysosomal disruption, in parallel to a decrease in granular red fluorescence.[223] 
Here, it could be demonstrated that upon 4 h treatment of U-2 OS cells with SBCm007 crude 
extract, the lysosomal pH was significantly increased (induction of LMP) as indicated by an 
increase in green nuclear and cytosolic AO fluorescence and a decrease in red lysosomal AO 
fluorescence. This effect could not be attributed to chondramide-related cellular events. In the 
same experiment, chondramide B was used as a reference compound and although the cellular 
shape and actin condensation resemble effects observed with crude extract-treated cells no 
direct influence on the lysosomal pH was determined. 
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3.2.3 HCS ON LYSOSOMAL INTEGRITY 
Since the induction of LMP observed in crude-extract treated cells could not be explained by 
the presence of any known compound, the extract was fractionated by size-exclusion 
chromatography (SEC) and resulting fractions were tested in an HCS assay on lysosomal 
integrity (Figure 3-30). As determined by HPLC-MS, chondramides A~D were mainly 
present in SEC fractions 23-28 and strongest LMP induction was found with samples 20-22. 
 
 
Figure 3-30: Induction of LMP in U-2 OS by SBCm007 fractions obtained by SEC. 
U-2 OS cells were either left untreated or treated for 4 h with SBcm007 crude extract 
or fractions derived from SEC. Cells were stained with AO and Hoechst33342 and 
analyzed by HCS. The AO fluorescence ratio green/red is calculated based on average 
values from all cells within a well. Error bars display ± SD of green fluorescence 
within the cytoplasmic segment. Main chondramide fractions are marked in dark blue. 
Exemplary images recorded in red fluorescence channel are given for the untreated 
control and cells treated with either SEC fraction 21 or 23. 
These results again demonstrated a chondramide-independent effect on LMP. Solely in SEC 
fraction 23 an overlap of both effects, disruption of cellular shape as induced by 
chondramides and a slight increase in lysosomal pH as induced by unknown metabolites, was 
observed.   
In addition, the crude extract of Chondromyces sp. SBCm007 was fractionated by column 
chromatography (silica gel) and samples were likewise subjected to HCS assays on lysosomal 
pH (Figure 3-31). Here, chondramides A~D were mainly found in silica gel fractions C and D 
and interestingly, also strongest effects with respect to LMP induction were observed in these 
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fractions. However, silica fraction E did not contain considerable amounts of chondramides 
but was also active in the HCS assay. 
 
Figure 3-31: Induction of LMP in U-2 OS cells by SBCm007 silica gel fractions. 
U-2 OS cells were either left untreated or treated for 4 h with SBcm007 crude extract 
or silica gel fractions derived thereof at a final concentration of 50 µg/ml. Cells were 
stained with AO (pseudocolors green/red) and Hoechst33342 (pseudocolor blue) and 
analyzed by HCS. The AO fluorescence ratio green/red is calculated based on average 
values from all cells within a well. The dashed line indicates the value of the control. 
Error bars display ± SD of green fluorescence within the cytoplasmic segment. Main 
chondramide fractions are marked in dark blue. 
For secondary purification via RP-HPLC the most active primary fractions determined in 
HCS assay were chosen, i.e. SEC fraction 22 and silica gel fraction C. Although the latter 
contains significant amounts of cytostatic chondramides, deconvolution of differential effects 
was considered to be practicable using HCS (Figure 3-32). 
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Figure 3-32: HCS on LMP with RP-HPLC fractions of SEC fraction 22 and silica gel fraction C. 
Assigned primary fractions were further separated by RP-HPLC and samples were 
collected in 1 min intervals. Obtained RP-HPLC fractions were tested using U-2 OS 
cells that were stained with AO and Hoechst33342 after 4 h treatment. The AO 
fluorescence ratio green/red is calculated based on average values from all cells within 
a well. Error bars display ± SD of green fluorescence within the cytoplasmic segment. 
Chondramide-containing fractions are marked in dark blue. Exemplary images 
recorded in red fluorescence channel are given for the untreated control and cells 
treated with HPLC sample min40 derived from silica gel fraction C. 
Unfortunately, the bioactivity with respect to LMP induction found in SEC fraction 22 could 
not be tracked down to a further purified RP-HPLC fraction. None of the samples showed a 
significant effect on the lysosomal pH. Nevertheless, with HPLC fractions of silica gel 
fraction C, actin-polymerizing effects, as determined in an analogous HCS experiment on 
actin filaments, and LMP induction could be clearly separated. Despite this success, 
compounds responsible for the de-acidification of lysosomes could not be isolated in the 
course of this study. This shortcoming may be explained by the very low abundance of the 
respective metabolites in the crude extract, which also did not allow for a precise definition of 
target masses.  
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3.2.4 BIOACTIVITY-GUIDED ISOLATION OF NEW CHONDRAMIDES 
In addition to HCS on lysosomal integrity, primary fractions derived from column 
chromatography (silica gel) of Chondromyces sp. SBCm007 crude extract were generally 
evaluated for cytotoxic effects in a tetrazolim salt-based viability assay (Figure 3-33).  
 
Figure 3-33: Relative toxicity of primary silica gel fractions on U-2 OS cells. 
Human U-2 OS osteosarcoma cells were either left untreated or treated for 48 h with 
SBcm007 silica gel fractions at a final concentration of 50 µg/ml. Viability was 
assessed in an MTT assay and the value of the control was set to 0% toxicity. Error 
bars display ± SD of three independent measurements. Main chondramide fractions 
are marked in dark blue. The insert image displays the assay read-out for fractions A-
H; the darker the wells the more MTT was reduced and the more viable cells are.  
The presence of known chondramides A~D, as analyzed by HPLC-MS, could be clearly 
confirmend in fractions C and D and in addition, a modest toxicity (<20%) was found in silica 
fractions A and B, and I-M. The activity in fractions A/B might be explained by the 
insufficient separation of chondramides by column chromatography and thus, minute amounts 
of chondramides might also be present in these fractions. However, this cannot explain the 
toxicity found with fractions I-M. Therefore, silica gel fractions were subjected to additional 
HCS studies. In first instance, it was of interest whether toxicity of fractions A/B in fact 
comes from known chondramides and thus, alterations of cellular and nuclear shape and actin 
filaments were assessed (Figure 3-34). Surprisingly, actin polymerizing effects were found in 
all silica gel fractions, although viability assays based on tetrazolium salt reduction (Figure 3-
33) and MS analysis confirmed the presence of known chondramides only in fractions C and 
D. The HCS images were segmented and analyzed as described for assays on microtubules 
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(see section 3.1.6) and again, the standard deviation of cytoskeletal fluorescence in the 
cytoplasmic segment turned out to be most suitable for the characterization of actin 
polymerization.  
 
Figure 3-34: Actin polymerization in U-2 OS cells treated with SBCm007 silica gel fractions. 
U-2 OS cells were either left untreated or treated for 24 h with SBcm007 crude extract 
or silica gel fractions derived thereof at a final concentration of 25 µg/ml. Cells were 
immunostained on β-actin and nuclei were stained with Hoechst33342. Cytoplasmic 
actin fluorescence standard deviation was analyzed on a single cell basis as average 
value per well. The dashed line indicates the value of the control. Error bars display ± 
SD of actin fluorescence standard deviation. Fractions containing chondramides A~D 
are marked in dark blue. The image shows actin lumps (indicated by a red arrow) upon 
treatment with fraction G.  
Initially, some of the silica fractions were further fractionated by RP-HPLC and subjected to 
HC screening. Indeed, in all cases the active HPLC fractions could be defined (as exemplarily 
shown for fractionated silica fraction G, Figure 3-35) and narrowed down to an elution time 
frame of 4-5 min within a total run length of 54 min. This in turn, enabled the definition of 
target masses and the subsequent purification of these metabolites. Candidate compounds 
were subjected to full structural elucidation using MS and NMR techniques and were thereby 
identified as novel chondramide derivatives, exhibtiting some structural features, which are 
not described for members of the chondramide family so far. In total, 14 new structures were 
identified by NMR and the amounts of 11 new chondramides were sufficient enabling the 
biological characterization of these derivatives (Figure 3-36 and Table 3-5).  
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Figure 3-35: Bioactivity in secondary RP-HPLC fractions of silica gel fraction G. 
Silica gel fraction G was separated by RP-HPLC and samples were subjected to HCS 
on actin filaments using U-2 OS cells. Cells were immunostained on β-actin 
(pseudocolor green) and nuclei were stained with Hoechst33342 (pseudocolor blue). 
Actin-targeting compounds eluted between min31 and min34. 
Encouraged by the discovery of new chondramides, HR-MS data of crude extracts were 
extensively evaluated and the analysis was guided by the hypothesis that novel derivatives 
could exist which might be highly variable in terms of substitution of the peptide part and/or 
altered in the polyketide part of the molecule. Indeed, additional 24 different derivatives could 
be detected based on the combined evaluation of HR-MS, isotope pattern and tandem-MS 
fragmentation. 
Briefly summarized, novel chondramide scaffolds include analogs that are phosphorylated or 
glycosylated at the aryl group on C7’, halogenated (chlorine or bromine) at C6’ and/or at C5’’ 
of tryptophan, and/or altered in the polyketide moiety by incorporation of a different starter 
unit.  
 
Figure 3-36: Chondramide core structure. 
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Table 3-5: Chondramides produced by Chondromyces sp. SBCm007. 
[a] The chondramide scaffold is given in Figure 3-36. Listed are derivatives, which were purified from 
SBcm007 extracts and were confirmed by NMR. *Known chondramides; †no biological evaluation. 
[b] Planar structure of the carbohydrate moieties: 
 
3.2.5 DETERMINATION OF GI50 VALUES OF CHONDRAMIDES 
The biological activity of the newly discovered chondramides was compared to the already 
described chondramide derivatives A~C. The growth inhibitory potential was assessed in 
tetrazolium salt-based assays (MTT) after 5 d treatment of cells with the compounds in serial 
dilution (Table 3-6). For the evaluation, a small panel of cancer cell lines (U-2 OS, HCT-116, 
C6H9O7:
C15H24NO12:
Derivative[a] R1 R2 R3 R4 R5 
Chondramide A* OMe H OH H Me 
Chondramide B* OMe Cl OH H Me 
Chondramide C* H H OH H Me 
Chondramide D†* H Cl OH H Me 
Chondramide A3 OMe H OH Cl Me 
Chondramide A4 OMe Cl OH Cl Me 
Chondramide A6 OMe Cl P H Me 
Chondramide A8 OMe Cl P Cl Me 
Chondramide A9 OMe H C6H9O7[b] Cl Me 
Chondramide A10 OMe Cl C6H9O7[b] Cl Me 
Chondramide A3 (linear)† OMe H OH Cl Me 
Chondramide A10 Variant† OMe Cl C15H24NO12[b] Cl Me 
Bromo-Chondramide A3 OMe H OH Br Me 
Bromo-Chondramide C3 H H OH Br Me 
Propionly-Chondramide C1 H H OH H Et 
Propionyl-Bromo-
Chondramide C3 H H OH Br Et 
Chondramide E2† OH Cl OH H Me 
Chondramide E4 OH Cl OH Cl Me 
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KB-3.1, and the MDR cell line KB-V.1), wildtype fibroblast cell lines (L-929 and MRC5), 
and primary cells (HUVEC) were used. 
Table 3-6: GI50 values[a] [nM] of chondramides. 
[a] Compounds were tested in serial dilution for 5 d on various cell lines and viability was assessed in 
an MTT assay. GI50 values were determined by sigmoidal curve fitting and calculated as the average 
of two independent measurements. n.a.: not active up to 10 µM; w.a.: weak activity in the range of 5-
10 µM. [b] For chemical structures see Figure 3-36 and Table 3-5. Chondr.: Chondramide; Prop.: 
Propionyl. [c] HCT-116: human colon carcinoma; U-2 OS: human osteosarcoma; KB-3.1: human 
cervical carcinoma; KB-V.1: human cervical carcinoma (MDR); L-929: mouse subcutaneous 
connective tissue fibroblasts; MRC5: human lung fibroblasts; HUVEC: human umbilical vein 
endothelial cells. 
Already described chondramides A~C exhibited GI50 values in the mid nanomolar range on 
all tested cell lines without any apparent specificity for certain cell lines. Newly discovered 
chondramides A3, A4, A6, and A8 were likewise active suggesting that neither chlorination at 
C6’ nor phophorylation on C7’of the aryl moiety has a great impact on overall potency. 
Contrary, glycosylation at C7’ is not tolerated and for chondramides A9 and A10 GI50 values 
could not be determined in the assay’s concentration range. Also chondramide E4, bearing a 
chlorine at C6’ and a hydroxyl at C2’ instead of a methoxy group or hydrogen, was 
approximately by one order of magnitude less active than chondramide reference compounds 
(A~C). Brominated chondramides were, in general, active in the low nanomolar range but 
interestingly, bromo-chondramide C3 and its propionyl analog displayed a slightly higher 
Chondramide 
derivative[b] 
Cell Line[c] 
HCT-116 U-2 OS KB-3.1 KB-V.1 L-929 MRC5 HUVEC 
A 48.9 27.1 50.5 38.0 90.9 63.8 43.7 
B 30.1 20.8 40.7 56.4 80.8 20.9 30.7 
C 33.7 25.6 36.8 85.8 87.3 26.1 34.0 
A3 28.6 46.7 63.5 85.7 72.8 38.0 50.5 
A4 44.4 26.4 56.8 83.1 67.6 12.7 52.5 
A6 60.9 51.6 49.3 23.1 44.6 25.9 67.7 
A8 49.3 33.2 13.4 58.1 56.2 7.6 24.1 
A9 n.a. n.a. n.a. w.a. w.a. w.a. n.a. 
A10 n.a. n.a. w.a. w.a. w.a. n.a. n.a. 
Br-Chondr. A3 42.9 37.7 74.5 11.2 69.4 44.5 23.7 
Br-Chondr. C3 17.7 4.8 46.8 23.8 14.0 57.7 44.4 
Prop.-Chondr. C1 42.1 15.1 56.3 22.7 30.0 71.9 54.6 
Prop.-Br-Chondr. C3 17.2 9.0 38.0 31.9 23.0 129.8 50.2 
E4 378.8 351.9 627.2 251.5 554.8 479.7 207.4 
Results 
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potency on cancer cell lines and a less toxic effect on human non-cancerous cells compared to 
chondramides A~C.  
In addition to GI50 determination, the actin-targeting mechanism was confirmed for all tested 
derivatives in human U-2 OS osteosarcoma cells as exemplarily shown for propionyl-
chondramide C3 and bromo-chondramide C3 (Figure 3-37). 
 
 
Figure 3-37: Actin polymerization induced by novel chondramides. 
Human U-2 OS osteosarcoma cells were either left untreated or treated for 4 h with 
chondramides at a final concentration of 100 nM. Actin was labeled with Acti-
Stain555-phalloidin (pseudocolor red) and nuclei were stained with Hoechst33342 
(pseudocolor blue).  
3.2.5 IN VITRO ACTIN POLYMERIZATION 
Since the GI50 values for some of the new derivative were significantly different to those 
determined for chondramides A~C, all compounds were evaluated in a cell-free system on 
actin polymerization. Especially glycosylated chondramides A9 and A10, which lost potency 
by at least three orders of magnitude (GI50 values >10 µM), might eventually exhibit higher in 
vitro potency than suggested by the cell-based assay. For better comparability compounds 
were grouped as follows: chondramides with GI50 values >100 nM (Figure 3-38), brominated 
derivatives (Figure 3-39), and other chondramides with mid nanomolar activity (Figure 3-40).  
The studies were performed using pyrene-labeled rabbit muscle actin[224] at a concentration of 
5 µM under non-polymerizing (low salt) conditions. In a pre-evaluation study with reference 
compounds chondramide A~C it was found that a final concentration of 20 µM of the 
polymerization inducers gave best results, thus, every chondramide derivative was tested 
under these conditions and fluorescence of pyrene-actin was followed over 85 min at 37°C. 
For chondramides A and B saturation was observed after approximately 30 min and also 
chondramides C potently induces actin polymerization in vitro. As indicated by the cell-based 
growth inhibition studies, the glycosylated chondramide A9 does not exihibit any actin-
polymerizing effect under the tested conditions. Nevertheless, glycosylated chondramide A10 
Control                                      Chondramide A                        Bromo-Chondramide C3        Propionyl-Bromo-
Chondramide C3
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shows a slow increase in G-actin polymerization, which is significantly less pronounced than 
observed for reference compounds chondramides A~C. Chondramide E4 was by one order of 
magnitude less potent compared to chondramides A~C with regards to its GI50 values, a fact, 
which might also partly be explained by its decreased ability to polymerize actin.  
 
 
Figure 3-38: Induction of G-actin polymerization by chondramides with reduced cytostatic potency. 
Chondramides were applied at a final concentration of 20 µM and fluorescence 
intensity of pyrene-actin (5 µM) was measured at 37°C for 85 min, every 30 s, at an 
emission wavelength of 405 nm (excitation at 360 nm). Curves represent the average 
of two independent experiments.  
Brominated chondramide C3 derivatives, which were, by tendency, the most active 
derivatives in terms of cancer cell inhibition, were only poorly active in actin polymerization 
studies. However, it is also noticeable that bromo-chondramide A3, the least potent amongst 
the brominated analogs, quickly polymerizes G-actin, with similar efficacy as chondramides 
A and B. Futhermore, chondramides A3, A6, A8, and propionyl-chondramide C1, although 
having GI50 values comparable to chondramides A~C, show a significantly reduced actin-
polymerizing effect, merely chondramide A4 is similarly potent in the cell-free system. Table 
3-7 summarizes the relative effects on G-actin polymerization. 
 
Chondramide A
Chondramide B
Chondramide C
Chondramide A9
Chondramide A10
Chondramide E4
0 500 1000 1500 2000 2500 3000 3500 4000 4500 5000
0
100
200
300
400
500
re
la
tiv
e f
lu
or
es
ce
nc
e i
nt
en
sit
y [
a.
u.
]
time [s]
Results 
 
86 
 
Figure 3-39: Induction of G-actin polymerization by brominated chondramides. 
Chondramides were applied at a final concentration of 20 µM and fluorescence 
intensity of pyrene-actin (5 µM) was measured at 37°C for 85 min, every 30 s, at an 
emission wavelength of 405 nm (excitation at 360 nm). Curves represent the average 
of two independent experiments.  
 
 
Figure 3-40: Induction of G-actin polymerization by several chondramide derivatives. 
Chondramides were applied at a final concentration of 20 µM and fluorescence 
intensity of pyrene-actin (5 µM) was measured at 37°C for 85 min, every 30 s, at an 
emission wavelength of 405 nm (excitation at 360 nm). Curves represent the average 
of two independent experiments.  
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Table 3-7: Summarized values for G-actin polymerization. 
Compound relative slope [RFU per min][a] 
Chondramide A 14.7 ± 0.20 
Chondramide B 11.8 ± 0.14 
Chondramide C 8.3 ± 0.08 
Chondramide A3 4.5 ± 0.08 
Chondramide A4 12.0 ± 0.10 
Chondramide A6 1.9 ± 0.06 
Chondramide A8 2.7 ± 0.06 
Chondramide A9 0.2 ± 0.04 
Chondramide A10 2.9 ± 0.05 
Bromo-Chondramide A3 13.2 ± 0.08 
Bromo-Chondramide C3 5.1 ± 0.07 
Propionyl-Chondramide C1 3.9 ± 0.06 
Propionyl-Bromo-Chondramide C3 2.8 ± 0.06 
Chondramide E4 6.2 ± 0.12 
[a] Corresponding curves are displayed in Figures 3-38, 3-39, and 3-40. The slope ± SD (increase of 
relative fluorescence units per minute) was calculated for each sample in the linear range of the curve.  
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DISCUSSION 
4.1 PRETUBULYSIN AS POTENTIAL NOVEL LEAD STRUCTURE 
This section deals with results from the biological evaluation of pretubulysin. Structure-
activity relationships of several synthetic derivatives, apoptotic mechanisms induced by 
pretubulysin and its putative application as molecular probe in studies on microtubule 
assembly are discussed in detail. Due to only a minor loss in activity of pretubulysin 
compared to two intensely studied parent compounds (tubulysins A and D) and since the 
typical supply issue encountered with natural products can be circumvented, pretubulysin 
might emerge as novel lead structure in tumor therapy. 
4.1.1 STRUCTURE-ACTIVITY RELATIONSHIP OF TUBULYSINS AND PRETUBULYSINS 
Within the myxobacteria tubulysins are frequently produced but restricted to the suborder 
Cystobacterineae. Thus, these compounds were found in strains of the genera Angiococcus, 
Archangium, Cystobacter, and Stigmatella. Nine tubulysin derivatives were initially described 
from myxobacterial strains Archangium gephyra Ar 315 and Angiococcus disciformis An d48 
(Figure 4-1). Tubulysins were found by bioactivity-guided isolation because of a superior 
cytotoxicity of the respective myxobacterial extracts on mouse L-929 fibroblast cells. Isolated 
derivatives were completely inactive against bacteria and yeast but exhibited moderate 
activity against some filamentous fungi. However, GI50 values determined on several cell 
lines were in the low picomolar to low nanomolar range and by this, tubulysins surpass the 
growth inhibition potential of other antimitotics, such as epothilones, vinblastine, and taxol, 
by a factor of 20-1000.[192, 225]  
The antiproliferative potential of tubulysins correlates well with their lipophilicity so that 
tubuphenylalanine derivatives, being rather lipophilic, are generally by one order of 
magnitude more potent than corresponding tubutyrosine analogs. The 11-acyloxy side chain 
on Tuv seems to play only a minor role although within the two groups (Tup and Tut 
derivatives) analogs with a 3-methylbuturyl side chain (tubulysins D and A) are the most 
active and analogs with an acetyl side chain (tubulysins H and I) are the least active. 
Interestingly, in vitro tubulin polymerization inhibition was approximately constant with all 
derivatives leading to the conclusion that preferential cellular uptake of more lipopholic 
tubulysins, in part, explains their greater potency in cell-based assays on growth 
inhibition.[225] Similar results were obtained in a recent study on several tubulysin analogs, 
which were obtained from mixtures of natural Tut type tubulysins via TFA-mediated 
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formation of an N-acyliminium ion within the Tuv segment. Upon treatment of this 
intermediate species with either alcohols, thiols, or nitriles the respective N-acyl-N,O-acetals, 
N-acyl-N,S-thioacetals, or N,N’-diacyl-aminals were formed and derivatives with varying 
alkyl side chain at the N,O- or N,S-acetals exhibited very similar GI50 values on human cancer 
cells that were all in the low nanomolar range.[226]  
 
 
Figure 4-1: Natural tubulysins isolated from myxobacterial strains. 
Archangium gephyra produces tubulysin A (2-4 mg/L) and as minor components 
tubulysins B, C, G, and I with a p-hydroxyphenyl residue (Tut). Angiococcus 
disciformis produces phenyl analogs (Tup) D, E, F, and H (all ca. 0.5 mg/L).  
Because of tubulysins’ distinct structure and high potency, these compounds have attracted 
considerable synthetic interest. Total synthesis efforts towards tubulysins revealed the 
introduction of the acid and base labile N,O-acetal functionality present on the Tuv fragment 
in a cluster of other sterically demanding groups, such as the O-acetate group at Tuv-C5, and 
stereochemical requirements of the C-terminal γ-amino acid as most challenging.[196, 227] 
Several reports on the synthesis of tubulysin fragments have been published[228, 229, 230], 
whereas introduction of the labile N,O-acetal at the Tuv amino group was not achieved until 
2006, when Peltier et al.[201] published the first total synthesis of tubulysin D with an 13% 
overall yield over 16 synthetic steps. Another series of tubulysins (tubulysins U-Z) without 
the N,O-acetal ester fragment, was the subject of several synthetic studies. Tubulysin U, 
which lacks the N,O-acetal functionality, and tubulyisn V, which additionally bears a 
hydroxyl instead of an acetate at Tuv-C5, can be prepared by total synthesis in reasonable 
quantities.[231, 232, 233] Evaluation of their antiproliferative activity revealed that these 
derivatives are less active by several orders of magnitude (in the low to high nanomolar 
range) compared to other natural tubulysins. However, syntheses around tubulysins U and V 
D-Mep L-Ile Tuv Tup / Tut Tubulysin R1 R2
A OH CH2CH(CH3)2
B OH CH2CH2CH3
C OH CH2CH3
D H CH2CH(CH3)2
E H CH2CH2CH3
F H CH2CH3
G OH CH=C(CH3)2
H H CH3
I OH CH3
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enabled important SAR insights. Tubulysin U is by two orders of magnitude more active than 
tubulysin V revealing the great impact of the acetylated Tuv segment. It was also found that 
the absolute stereochemistry of the Tuv-C5 functional group is important since epi-tubulysin 
V (a stereoisomer of tubulysin V) is by factor of 30 to 45 less potent than the natural 
variant.[234] Other stereoisomers of Tuv in tubulysin D (5-epi-, 7-epi, and 5,7-di-epi-tubulysin 
D) basically revealed a similar relationship. Inverted configuration at either Tuv-C5 or Tuv-
C7 lead to a decreased potency (mid nanomolar range), whereas 5,7-di-epi-tubulysin D was 
essentially inactive.[235] On the contrary, a Tut-C2 epimer of tubulysin B exhibited equal 
potency to the corresponding natural tubulysin.[236] In addition, growth inhibitory studies with 
tubulysin V variants that all bear a ketone group at Tuv-C5 and an acyclic N-Mep, displayed 
the importance of the stereogenic α-methyl group in Tup; the desmethyl variant was active in 
the high nanomolar range, whereas the dimethyl and methyl variants were essentially inactive 
with GI50 values in the mid micromolar range or even not active up to 50 µM, 
respectively.[234] Complementary to tubulysin U and V derivatives with a secondary amine in 
the Tuv segment, Wipf and Wang[237] synthesized a desacetoxytubulysin with a simple N-
methyl group in 20 steps and 2.1% overall yield. This replacement was not essential for the 
antiproliferative activity resulting in GI50 values in the low nanomolar range, comparable to 
the tubulin-binder vinblastine. Replacement of N-Mep by N-methylsarcosine, however, 
significantly lowered potency by approximately two orders of magnitude. Similar to the 
reported epi-tubulysin V, the natural (R)-configuration of the acetate on Tuv-C5 in the 
desacetoxy variant is preferred with regards to in vitro tubulin assembly inhibition but 
exhibits nearly equal potency in cell-based studies than its diasteromer.[238]  In desmethyl and 
dimethyl Tup derivatives of tubulysin (secondary amine instead of N,O-acetal and Tuv-C5 
keto group) the role of the N-terminus was probed. Replacing the natural N-Me-D-Pip in 
either a Tup-C2 desmethyl or dimethyl variant by N-Me-D-Pro reduced the antiproliferative 
activity approximately by factor 10, whereas dimethyl analogs were generally more potent. 
However, the natural D-configuration and the N-methyl group on either Mep or MePro 
appeared to be essential for biological activity.[239, 240]  
In summary, as exemplified by comprehensive SAR studies on tubulysin D analogs by the 
Ellman group[241, 242], various modifications can be introduced on the C-terminus of tubulysins 
with only modest loss in antiproliferative activity. By retaining only the phenethyl or γ-
carboxy group of the Tup fragment, derivatives were still active in the low nanomolar range. 
Interestingly, also an N-methyl analog and the truncated tripeptide lacking Tup were 
considerably active. Thus, this site seems to be appropriate for further modifications or the 
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attachment of functionality, such as fluorophors or targeted antibodies. Contrary, 
modifications of the N-terminus seemed to be only tolerated, in terms of potent 
antiproliferative activity of derivatives, when a basic tertiary amine is still present. Variants 
with a simple N-acetyl group or completely lacking Mep lost activity by three orders of 
magnitude. Furthermore, neither the O-acetyl group of Tuv nor the N,O-acetal side chain were 
significantly influencing biological activity.[241]  
Figure 4.2 summarizes the aforementioned basic SAR conclusions with tubulysin A as the 
core structure. 
 
 
 
Figure 4-2: Structure-activity relationships of tubulysins. 
Tubulysin A, which is displayed as the core structure, exhibits antiproliferative 
activity in the mid picomolar range on various cancer cell lines. Several studies on 
either natural tubulysins or synthetic derivatives accounted for important SAR 
conclusions. A highly simplified overall conclusion is that variations of the N,O-acetal 
of Tuv and simplifications of the C-terminal amino acid are very well tolerated, 
whereas variation of the N-terminal Mep has a much higher impact.  
In addition to great achievements in the course of synthetical surveys, the biosynthesis of 
tubulysins was the subject of several comprehensive studies. The biosynthetic gene cluster for 
tubulysin synthesis was first identified in A. disciformis An d48 by transposon mutagenesis 
and molecular analysis revealed that the secondary metabolites are assembled by a 
multienzyme PKS/NRPS hybrid system that consists of five NRPS modules and two PKS 
replacement of Tut by Tuv
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 ca. 10-fold increased potency
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missing γ-carboxylic acid group
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(2 orders of magnitude in 
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modules. In this study of the biosynthetic machinery, a precursor of tubulysin was postulated 
for the first time; this precursor is released from the last module in the assembly line, the 
type I PKS TubF. The enzyme-free precursor, referred to as ‘pretubulysin’, would then 
undergo oxidation and acylation reactions to form the natural product (cf. Figure 1-13). 
However, no candidate gene encoding the respective enzymes for oxidation and acylation 
could be identified and confirmed.[243] The gene cluster also contains a cyclodeaminase-
encoding gene, tubZ, which is putatively involved in the formation of the starter unit pipecolic 
acid. The gene was inactivated in strain An d48 to probe its function, and it was expected that 
tubulysin production would be completely abolished. Astonishingly, tubulysin production in 
an An d48-tubZ- mutant strain was only reduced to approximately 3% of the wild-type level. 
Furthermore, the proposed pretubulysin could be detected in substantial amounts in the 
mutant strain and, after reanalysis, in minute amounts in the wild-type strain. Despite growing 
A. disciformis on a larger scale, pretubulysin could not be isolated in sufficient amounts for 
further development. Therefore, the total synthesis of pretubulysin was initiated, and the 
biosynthetic hypothesis was finally proven by comparing synthetic and naturally occurring 
pretubulysin via mass spectrometry and NMR.[202] The biological characterization of 
pretubulysin, which can be obtained synthetically in gram-scale quantities, was the subject of 
this thesis.[203, 244] Having a practical chemical synthesis in hands, other even more simplified 
pretubulysin analogs were prepared and their biological activity was evaluated using a panel 
of different cell lines. In initial growth inhibition experiments, it turned out that pretubulysin 
was active in a low to sub-nanomolar range against various cell lines from different origin and 
tissue, including colon, hepatocellular, and cervical carcinoma, and exhibits a mean GI50 value 
of ca. 1.6 nM on cancer cell lines. Thus, based on GI50 values, pretubulysin is, on average, 
only a factor of 10 or 100 less active than naturally occurring tubulysin A (mean GI50 of 
0.17 nM) and tubulysin D (mean GI50 of 0.02 nM), respectively. Furthermore, a significant 
antiproliferactive activity on Pgp-overexpressing MDR cell lines (here: KB-V.1) was found 
for pretubulysin, as already reported for the natural parent compounds[192] (Table 3-2). 
Antiproliferative testing in mouse L-929 cells of a series of pretubulysin derivatives with 
shorter chain at the C-terminus and reference compounds (Figure 3-1 and Table 3-1a) again 
revealed that tubulysins D and A exhibit GI50 values in the picomolar range, whereas 
pretubulysin was approximately 20-fold less active (5.8 nM). However, activity was nearly 
abolished in all other analogs. Pretubulysin analog I in which the propionate group of Tup 
was missing (9.6 µM) or analog II in which the C-terminal amino acid was missing 
completely (14.2 µM) were by three orders of magnitude less potent than pretubulysin. 
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Contrary, for tubulysin D derivatives that resemble pretubulysin analog I and II a nanomolar 
activity was detected[241]. However, it has to be taken into account that the natural tubulysin D 
is already by two orders of magnitude more potent than pretubulysin with a GI50 value of 
20 pM in L-929 cells. Interestingly, the MepIleMe’Val’ derivative in which Val is replaced by 
the C2-prolonged homolog (γ-amino acid; pretubulysin analog III) exhibited slightly 
increased activity relative to analog II (MepIleTuv), with a GI50 value of 6.5 µM against 
L-929 mouse cells. This finding is particularly striking since analog III completely lacks the 
two aromatic rings of pretubulysin. This compound was therefore tested on three cancer cell 
lines (Table 3-2) and GI50 values were determined to be in the micromolar range. By 
tendency, human HL-60 promyelocytic leukemia cells were the most sensitive towards 
pretubulysin analog III treatment (GI50 of 1.25 µM), which is accordance to the results from 
other tubulysins and pretubulysins. However, single Mep, MepIle, and MepIleMeVal building 
blocks did not inhibit L-929 cells at concentrations up to 25 µM.  
Other pretubulysin derivatives with variations of the N- and C-terminus, thiazole ring of Tuv, 
and of aliphatic side chains on Ile-C2 and the tertiary amine of Tuv were evaluated in growth 
inhibition experiments using human U-2 OS osteosarcoma cells (Figure 3-2 and Table 3-1b). 
As determined with other cell lines, pretubulysin is active in the low nanomolar range (GI50 of 
0.84 nM). On the C-terminus of the molecule different variations were probed. The 2-
desmethyl variant was still active in a low nanomolar range (4.93 nM). Thus, potency was 
reduced approximately by factor 10, as additionally determined in a larger panel of various 
cell lines (Table 3-2). However, a dehydrogenation of C2-C3 in Tup was shown to have a 
much higher impact. 2,3-didehydro-pretubulysin, either as free acid or ethyl ester, exhibited 
GI50 values in the high nanomolar range, which depicts a lowered potency compared to 
pretubulysin by at least three orders of magnitude. Other variations of the C-terminal amino 
acid (pretubulysins with propargylamide or n-butylamide functionalities instead of the γ-
carboxylic acid functional group in Tup) led to GI50 values in the mid nanomolar range, i.e. 
50- to 100-fold reduced potency. It has been reported that variations of N-Mep generally have 
a higher impact on the molecule’s potency than variations of the C-terminal amino acid. 
Indeed, N-methylsarcosine-pretubulysin was essentially inactive (GI50 of 4.7 µM) and its 
potency is comparable to the aforementioned MepIleTuv (analog II) or MepIleMe’Val’ 
(analog III) derivatives that completely lack N-terminal Tup. Likewise, the methylproline 
derivative is by two orders of magnitude less potent than pretubulysin (GI50 of 164 nM) and a 
pipecolic acid variant lacking the N-methyl group is even by three orders of magnitude less 
active (GI50 of 1.1 µM). Next, the influence of the thiazole ring in pretubulysin was assessed 
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and it turned out that substitution by either a phenyl or triazole functionality is not tolerated 
very well. Respective free carboxylic acid or methyl ester analogs were active in the high 
nanomolar to low micromolar range. Phenyl-pretubulysin exhibited a GI50 value of 119 nM on 
U-2 OS cells and triazole-pretubulysin was even 5-fold less active (644 nM). Corresponding 
methyl ester analogs further reduced potency approximately by factor 5. Solely a replacement 
of the thiazole by an oxazole ring did not impact potency (GI50 of 1.55 nM) and the 
corresponding methyl ester was also still active in the low nanomolar range (10.0 nM). Upon 
testing of oxazole-pretubulysin in a larger panel of cell lines it could be shown that this 
derivative is equally potent to pretubulysin. Another series of pretubulysins was available that 
varied in the alkylation pattern of the tertiary amine in Tuv or the Ile-C2. Replacing the N-Me 
group by either an allyl or ethyl group did not influence pretubulysin’s potency and GI50 
values were still in the low nanomolar range (1.5 nM and 0.9 nM, respectively). This is in 
accordance to SAR conclusions from natural tubulysins bearing an N,O-acetal group, whereas 
it was found that variations of this position are mostly very well tolerated with regards to full 
bioactivity. On the other hand, the influence of aliphatic groups on Ile-C2 seems to be mostly 
controlled by the sterical demand of these groups. The 2-isopropyl variant has comparable 
antiproliferative potency than pretubulyin that bears a 2-sec-butyl group instead. However, a 
2-isopropyl variant loses activity by approximately one order of magnitude (GI50 of 46 nM) 
and Ile-C2-benzyl-pretubulysin was inactive up to a concentration of 5 µM.  
By tendency, SAR conclusions from pretubulysin testing (Figure 4-3) resemble those from 
previously reported studies on natural tubulysins (cf. Figure 4-2). In brief, variation of the C-
terminus (on the γ-carboxy side chain of Tut) was somewhat tolerated with only a minor loss 
in activity, whereas N-terminal Mep appeared to be crucial for a nanomolar activity. Solely 
substitution of Mep with MePro was tolerated to some extent. The thiazole ring of Tuv might 
be replaced by an oxazole without impacting pretubulysin’s potency, but phenyl and triazole 
are disadvantageous. Regarding aliphatic side chains, variations of the tertiary amine in Tuv 
and Ile-C2 substitution are tolerated, whereas bulky groups at the latter position significantly 
reduce potency. In addition, with systematically shortened analogs (starting from the C-
terminus) potency was significantly reduced by three order of magnitude and single 
MepIleMeVal building blocks were inactive up to 25 µM. Nevertheless, some of the 
variations appeared to have a greater impact with regards to biological activity than reported 
for e.g. tubulysin D, which might, in part, be explained by pretubulysin’s per se 100-fold 
reduced potency compared to tubulysin D.  
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Figure 4-3: Structure-activity relationships of pretubulysins. 
Pretubulysin, which shows antiproliferative activity in the low nanomolar range, is 
displayed as the core structure. Determination of the growth inhibitory potential of 
several synthetic derivatives allowed for important SAR conclusions. In addition to 
reported results from tubulysins, the role of the thiazole ring of Tuv was assessed in 
pretubulysin.  
A way to assess SAR of NPs is not only via total synthesis and chemical derivatization but 
may also include screening for natural derivatives. In the case of tubulysins, a multitude of 
further natural tubulysin derivatives has been discovered in A. disciformis An d48 and 
Cystobacter sp. SBCb004 producer strains by using elaborate HPLC-MS analyses. It was 
found that many steps in the biosynthetical pathway do not go to completion and especially 
post-assembly reactions appeared to be relatively inefficient.[245] In addition to these naturally 
produced derivatives, the ca. 40 kb core biosynthetic tubulysin gene cluster lacking acyl 
transfer and oxidation functions was recently reconstituted, and heterologous expression was 
achieved in two different host systems. This result paves the way for the production of 
another generation of bioactive tubulysin metabolites by genetic manipulations.[246] 
4.1.2 PRETUBULYSIN LEADS TO MITOTIC ARREST AND APOPTOSIS INDUCTION 
Tubulysins are active on a wide variety of cancer cell lines from different origins and tissues, 
including lung, colon, cervix, ovarian, prostate, breast, and leukemia cancer lines, as 
determined in the NCI-60 test panel. Moreover, potency of tubulysins on Pgp-overexpressing 
MDR cell lines (e.g. KB-V.1 and HCT-15) remains extraordinary high and equals the activity 
on corresponding non-MDR cell lines (e.g. KB3.1 and HCT-116).[192, 196, 199] Emerging 
multidrug resistance of cancer cells is common with many antimitotic agents but nevertheless, 
chemotherapeutics of this class are particularly successful in clinical applications. The MDR 
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phenotype may also include overexpression of other efflux pumps (e.g. MDR-1), upregulation 
of key players in apoptosis (e.g. antiapoptotic Bcl-2), post-translational modifications, and the 
expression of different tubulin phenotypes.[167] Thus, there is an increasing demand for novel 
microtubule inhibitors in order to circumvent already established resistance.  
In pre-clinical MoA studies with tubulysin A it was found that the NP has salient antimitotic 
and antiangiogenic properties, which may translate into clinically useful anticancer 
features.[199, 220] The tubulysin-induced depolymerization of microtubules was assessed on a 
biochemical and cellular level, revealing that tubulysin noncompetitively inhibits vinblastine 
binding to microtubules and also to a minor extent inhibited colchicine binding, which 
suggested a binding mode for tubulysin at the peptide site[247], in close proximity to the vinca 
site of the Vinca domain on β-tubulin. As a consequence of irreversible microtubule 
depolymerization, eukaryotic cells accumulated in G2/M phase of the cell cycle, which 
ultimately led to the induction of apoptosis, as specified by caspase-3 activation, nuclear 
fragmentation, and DNA laddering.[220] Furthermore, cord formation and chemotaxis assays 
with primary cells (HUVEC) suggest a strong antiangiogenic effect of tubulysin A.[199] 
Angiogenesis describes the formation of new small blood vessels in vivo, which plays a role 
in the growth of solid tumors[248] and antiangiogenic properties have also been found for other 
antimitotic agents, such as the microtubule-stabilizer paclitaxel, and have been linked to the 
cytostatic effect, which is mediated by the initiation of the intrinsic (mitochondrial) apoptosis 
pathway.[249] In a current study, it could be shown that pretubulysin exhibits antiangiogenic 
properties at a similar level than tubulysin A and additionally, led to a dramatic reduction of 
tumor growth and vascular density without any obvious toxicity in an ectopic murine 
xenograft model with hepatocellular HUH7 carcinoma cells.[204] Other pre-clinical in vivo 
data of tubulysins was likewise encouraging, although toxic side effects delayed further 
development. In order to improve the therapeutic index of highly cytotoxic tubulysins, several 
targeting strategies, such as ligand-coupling (targeting folate receptors)[250], delivery via 
nanoparticles[251], and peptide dendrimers[252] have been applied.  
Here, some of the underlying mechanisms of pretubulysin’s cytostatic activity were evaluated 
and a summary is given in Figure 4-4, which displays a schematic overview of the induced 
cellular and molecular changes that were found in the course of this study.  
In growth inhibition experiments, pretubulysin exhibited GI50 values in the low nanomolar 
range on various cultured mammalian cells, and thus, was only 10- to 100-fold less active 
than the parent compounds tubulysins A and D, respectively. Additionally, pretubulysin was 
able to inhibit growth of the Pgp-overexpressing MDR cell line KB-V.1, as it was already 
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described for natural tubulysins[192] (Table 3-2). As pretubulysin was most likely acting on the 
same target than tubulysins, its influence on the microtubule architecture was probed (Figure 
3-11). While at high dosages of pretubulysin (50 nM) a complete disruption of microtubules, 
i.e. depolymerization, was observed in human U-2 OS osteosarcoma cells following 24 h 
treatment, at a lower dosage microtubules were not directly disrupted in their overall structure 
but abnormally accumulated around the nuclear periphery. 
In fact, it has been shown for the microtubule destabilizer vinblastine, that a stabilizing effect 
can be observed at low concentrations by its ability to suppress dynamic mechanisms at the 
high-affinity binding sites at the end of microtubules.[253] The same effect might explain the 
abnormal accumulation of interphase microtubules in pretubulysin-treated cells, which 
resembles a local stabilization. In addition, an HCS experiment (Figure 3-20) revealed that 
this phenomenon also occurred when U-2 OS cells were treated for 24 h with other 
microtubule-destabilizing agents (tubulysins A and D, disorazol A). Following segmentation 
of the nuclear and cytoplasmic area (Figure 3-17), the standard deviation of tubulin 
fluorescence was calculated within the latter segment, which is an indicative parameter of 
microtubule disruption. At concentrations near the respective GI50 value of the antimitotics, an 
increase in microtubule fluorescence SD was observed that upon image data dereplication 
turned out to be caused by an initial stabilizing effect. This peak value was followed by a 
decline in tubulin fluorescence SD, which is indicative for a depolymerization of 
microtubules. A second peak was observed with tubulysins A and D that reflects rounded-up, 
late apoptotic cells for which automated analysis and calculation of decisive parameters 
partially fails. Interestingly, cells treated with the microtubule stabilizer epothilone B led to 
similar results, although values for tubulin fluorescence SD were generally higher and a 
maximum value was achieved not until more-than-10-fold higher concentrations than the 
compound’s GI50 value, reflecting maximal stabilization of microtubules. At higher 
concentrations cells died, which is represented by lower SD values.  
In addition to the described cell-based studies, it could be demonstrated in in vitro 
experiments that pretubulysin is able to inhibit the polymerization of tubulin protein and 
induce depolymerization of built-up microtubules, in a manner similar to that of tubulysin A 
(Figure 3-22 and 3-23). The absorbance of microtubule protein at 350 nm was measured over 
time and addition of either 1 µM tubulysin A or 1 µM pretubulysin led to an approximately 
50% reduction in tubulin polymerization. This result is in accordance to previous studies 
where it was reported that, although GI50 values on mammalian cell cultures differ by up to 
three orders of magnitude, the in vitro potency of natural tubulysins is barely affected.[225] 
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Furthermore, inhibition of tubulin polymerization by pretubuylsin was dose-dependent; at a 
concentration of 3.4 µM only ca. 25% polymerization was observed and electron micrographs 
of samples that were incubated with 5 µM pretubulysin revealed that microtubules are fully 
destroyed. However, higher concentrations of pretubulysin needed to be applied to 
depolymerize already built-up microtubules. Using a concentration of 1.5 µM, still 80% of 
intact microtubules were present, and even with 3.8 µM pretubulysin the post-assembly 
addition did not lead to a full depolymerization also reflected by electron micrographs of 
samples incubated with 5 µM of the drug. These results imply that pretubulysin rather binds 
to tubulin protein subunits than to filamentous tubulin and thus, sequestration of tubulin 
prevents microtubule assembly. 
As expected for a microtubule-destabilizing drug, abnormal multipolar spindles were 
observed in pretubulysin-treated cell populations (Figure 3-11). Since the dynamic nature of 
microtubules is a prerequisite for cellular division and chromosome segregation during 
mitosis pretubulysin and tubulysin A were evaluated in cell cycle studies (Figure 3-8 and 3-
10; Table 3-3 and 3-4). The mitotic spindle is attached to the two opposing centrosomes, with 
the minus-ends of the microtubules attaching to the poles, and the plus-ends extending away 
from them.[254] Microtubule-targeting drugs generally function by repressing the highly 
dynamic processes during and prior to chromosome segregation, thus, inhibiting 
metaphase/anaphase transition, blocking mitosis, and ultimately inducing apoptosis.[167] 
Tubulysin A exhibited GI50 values of 0.23 nM and 0.14 nM, and GI50 values determined for 
pretubulysin were 5.81 nM and 0.96 nM on mouse L-929 fibroblasts and human HepG2 
hepatocellular carcinoma cells, respectively (Table 3-2). By this, pretubulysin was 
approximately by one order of magnitude less potent than the natural parent compound. By 
tendency, a similar difference in potency was observed in cell cycle studies. Treatment of 
L-929 cells for 24 h with either 12 nM tubulysin A or 150 nM pretubulysin resulted in the 
accumulation of ca. 45% of all viable cells in the G2/M phase. In untreated control samples, 
only ca. 25% of cells were in G2/M. However, already lower concentrations (2 nM for 
tubulysin A and 30 nM for pretubulysin) were sufficient to observe a slight increase of the 
G2/M population (30-40% of viable cells) without a significant effect on the G1 population. In 
a cell cycle experiment with HepG2 cells equal concentrations of both antimitotics were 
applied (50, 100, and 200 nM) and cells were treated for 24 h. In the control population, ca. 
20% of viable cells were in the G2/M phase and 50% were in G1 phase. At the lowest 
concentration of tubulysin already a significant accumulation of cells in the G2/M phase was 
observed (> 70%) and the relative number only slightly increased with increasing 
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concentrations. When HepG2 cells were treated with 50 nM pretubulysin the G2/M population 
increased to ca. 45% and simultaneously the portion of cells in G1 decreased to 40%. At the 
two higher concentrations similar effects than with 50 nM tubulysin were observed, with ca. 
70% of viable cells in G2/M and 15% in G1. In conclusion, pretubulysin is a potent antimitotic 
agent, whereas treated cells are halted in the G2/M phase of the cell cycle efficiently at 
concentrations around 100 nM after 24 h.   
In general HCS studies on morphological alterations it was found that all antimitotic agents in 
the test panel (tubulysins A and D, pretubulysin, disorazol A, and epothilone B) led to 
significantly enlarged cells and nuclei following 24 h treatment at concentrations near the 
respective GI50 values (Figure 3-18 and 3-19). In the case of pretubulysin, the cytoplasmic 
and nuclear area was increased by nearly 30% at concentrations between 50 nM and 500 nM. 
Furthermore, detailed analysis of pretubulysin-treated cells, but also cells treated with the 
other drugs, revealed nuclear fragmentation (multiple micronuclei) and cells with condensed 
chromatin, both being typical hallmarks of apoptosis. In addition, cells were probed on 
phospho-histone γH2A.X (Figure 3-21), which is widely used as a marker for DSBs because 
H2A.X is phosphorylated on serine residue 139 within seconds after the induction of 
DSBs.[255] As a result, no direct DSB induction by the antimitotic compounds at sublethal 
concentrations was detected, instead, large γH2A.X foci were exclusively associated with 
already fragmented nuclei leading to the assumption that enhanced phosphorylation is 
probably triggered by downstream apoptotic signaling as a consequence of DNA 
fragmentation. It is quite possible that the aforementioned effects on nuclei are the 
consequence of the so-called ‘mitotic catastrophe’, a type of cell death which results from 
deficient cell cycle checkpoints and cellular damage[256] and in particular, is observed with 
microtubule-targeting agents.[257] Complementary to these macroscopic effects on nuclei, it 
was found that pretubulysin and its 2-desmethyl variant induce DNA laddering as determined 
by agarose gel electrophoresis (Figure 3-13). In human HL-60 promyelocytic leukemia cells, 
that were treated for 24 h or 48 h with both drugs at a final concentration of 30 nM or 75 nM, 
a typical DNA ladder was observed, as it was already found for tubulysin A-treated KB-3.1 
cells[220]. Both, nuclear fragmentation and DNA laddering are specific hallmarks of late 
apoptosis (programmed cell death) and were likewise observed for other antimitotics, such as 
paclitaxel.[258, 259] Indeed, following 48 h treatment approximately 40-50% of human L3.6pl 
pancreatic cancer cells were found to be apoptotic due to treatment with either 10 nM 
tubulysin A or 10 nM pretubulysin (Figure 3-12). However, the inhibition of effector caspases 
did not necessarily protect the cells against cell death (Figure 3-14). When cells were co-
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incubated with the broad-spectrum caspase inhibitor Q-VD-OPh the amount of late apoptotic 
cells with already permeabilized membrane decreased from initially 40-50% to only 
approximately 25% and by this, pretubulysin-induced apoptosis is only partly caspase-
dependent. This caspase-independent ‘apoptosis-like’ cell death was also found to be induced 
by other microtubule-targeting compounds, such as paclitaxel, epothilone B, or 
combretastratin-A4.[260, 261, 262] It might be speculated that these processes are of lysosomal 
origin involving the release of proteolytic enzymes in the cytosol that may either act directly 
on key cellular substrates or in concert with caspases.[263]  
Nevertheless, an involvement of mitochondria could clearly be confirmed for several 
microtubule-destabilizing agents of myxobacterial origin, as these all induced an increase of 
mitochondrial outer membrane permeability (MOMP) and thus, a loss of mitochondrial 
membrane potential (MMP) (Figure 3-15). Following loss of MMP, cytochrome-c is released 
from mitochondria, which interacts with Apaf-1 (apoptotic protease activating factor) and 
procaspase 9, which in turn, activates the caspase cascade, and finally, DNA is fragmented, 
whereas these effects are mainly modulated by proteins of the Bcl-2 family. However, also 
caspase-independent apoptotic signaling cascades can be triggered via mitochondria, for 
instance by the release of AIF (apoptosis-inducing factor), which translocates to the nucleus 
and induces DNA fragmentation trough interaction with other factors.[264]  
In this study, one of the key players of the intrinsic (mitochondrial) apoptosis pathway was 
found to be modulated by treatment of cells with either 10 nM tubulysin A or 10 nM 
pretubulysin (Figure 3-16). Transiently enhanced levels of phosphorylated Bcl-2 (pBcl-2) in 
human L3.6pl pancreatic cancer cells were already observed after 8 h treatment, and highest 
levels were detected either after 24 h or 8 h treatment for tubulysin A and pretubulysin, 
respectively. Although the specific signaling events that are commonly induced by 
antimitotics, which lead to inactivation, i.e. phosphorylation, of antiapoptotic Bcl-2, are only 
fairly understood, it is evident that phosphorylation is accomplished by cellular mechanisms 
involving different kinases, such as JNK and ERK1/2.[265] However, Bcl-2 prevents apoptosis 
by abrogating cytochrome-c release and the subsequent activation of caspases.[266] As a proof 
of principle, it could be shown that treatment of L3.6pl cells with either tubulysin A or 
pretubulysin (Figure 3-16) led to cleavage of PARP, which is a substrate of caspase-3 and 
functions in DNA damage detection and repair.[267] Cleaved PARP was already detectable 
after 24 h and the effect was even more pronounced following 48 h treatment with either drug. 
In summary, it could be demonstrated that pretubulysin shares common characteristic to other 
antimitotic agents and in particular, acts in similar manner as its parent compound 
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tubulysin A. Following an initial formation of abnormal spindle pole structures and cell cycle 
arrest, apoptosis is triggered at least in part via the intrinsic (mitochondrial) pathway, which 
culminates in fragmented DNA and cell death (Figure 4-4). 
 
 
Figure 4-4: Schematic representation of cellular events triggered by pretubulysin. 
Due to pretubulysin’s primary action on microtubules cells are arrested at the 
metaphase/anaphase transition and as part of the ‘mitotic catastrophe’ the 
mitochondrial apoptosis pathway is initiated as displayed by a loss of MMP. 
Following phosphorylation of antiapoptotic Bcl-2, cytochrome-c is released from 
mitochondria that triggers the caspase cascade activation and finally, nuclear damage 
and cell death. Events displayed in grey were not directly studied in the course of this 
thesis. 
4.1.3 SMALL PRECURSOR MOLECULES DESTABILIZE MICROTUBULES 
As determined by NMR structural analyses on the tubulin-bound conformation of tubulysin A 
in aqueous solution, the thiazole ring of Tuv (via the nitrogen atom) and the aromatic ring of 
Tut form a basal platform upon which the N,O-acetal side chain of Tuv packs to form a 
hydrophobic core. The O-acetyl group on Tuv-C5 and the remaining backbone towards N-
Mep protrude from this region. Based on these results, authors concluded that the 
hydrophobic skeleton described by the thiazole ring, the Val side chain of Tuv, the Ile side 
chain, and a tertiary amine on the N-terminus are essential for full bioactivity, whereas N-
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Mep, the γ-carboxy group of Tut, and the N,O-acetal functionality are dispensable.[268] These 
conclusions are basically in accordance to previous SAR data based on biological activity (cf. 
chapter 4.1.1). Furthermore, pretubulysin’s high potency is even more definite since most 
important determinants of biological activity, in terms of tubulin-binding, are still present in 
this simplified precursor of tubulysin. 
Here, it was found that a pretubulysin precursor (analog III), which lacks the aromatic rings of 
Tup and Tuv, still exhibits a considerable biological activity in cell-based studies with GI50 
values in the low nanomolar range on several cell lines (Table 3-2). However, it was not clear 
whether this is due to a rather nonspecific cytotoxic effect. In HCS studies (Figures 3-18 to 3-
21) it was then found that pretubulysin analog III induces all typical morphological changes in 
human U-2 OS cells, which were also found with tubulysins A and D and pretubulysin, and 
generally, these are typical effects observed with microtubule-destabilizing agents. Most 
importantly, following 24 h treatment, a destabilizing effect of microtubules was observed at 
concentrations as low as 5 µM, which is specified in the HCS assay by an increased value of 
the standard deviation of microtubule fluorescence due to a higher density of microtubules 
around the nuclear periphery. At 10-fold higher concentrations (50 µM) even a complete 
depolymerization of microtubules was observed, which clearly reflects a similar MoA than for 
the other tubulysins in the assay. By tendency, all compounds induced microtubule 
depolymerization at concentrations near their respective GI50 value and full depolymerization 
was achieved at 10-fold higher concentrations (Figure 3-20). Furthermore, typical hallmarks 
of apoptosis of antimitotic drugs were observed in HCS assays in cells treated with 
pretubulysin analog III, i.e. significant enlargement of cells (Figure 3-18) and nuclei (Figure 
3-19), and nuclear fragmentation. Both morphological changes are often associated with a 
preceding G2/M cell cycle arrest. In human HL-60 promyelocytic leukemia cells, which were 
most sensitive towards pretubulysin treatment, a nearly complete G2/M cell cycle arrest was 
observed after 48 h treatment with 10 µM pretubulysin analog III. The G1 population 
decreased from 49% to 16%, and simultaneously, the G2/M population increased from 23% to 
71% (Figure 3-9). However, when tubulysin A, pretubulysin, and pretubulysin analog III were 
directly compared in cell cycle studies with human HepG2 hepatocellular cells (Figure 3-10 
and Table 3-4), it was found that that effective concentrations are reflective of previously 
determined GI50 values. Tubulysin A (GI50 on HepG2: 0.14 nM) concentrations as low as 
50 nM led to a significantly increased G2/M population (> 70% of the total population) 
already after 24 h treatment, whereas a comparable effect with pretubulysin (GI50 on HepG2: 
0.96 nM) was only achieved when the assay concentration was 4-fold higher (200 nM). The 
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GI50 value of pretubulysin analog III was determined to be 2.4 µM on HepG2 cells, which 
displays a by three orders of magnitude reduced potency compared to full-length pretubulysin. 
Thus, in cell cycle studies, HepG2 cells were treated for 24 h with 0.5-20 µM pretubulysin 
analog III. Compared to the control cell population, already at the lowest concentration 
applied an increase of the G2/M population by ca. 5% was observed. At an assay 
concentration of 5 µM, nearly 40% of all viable cells accumulated in G2/M phase. However, 
at higher drug concentrations, the percentage of viable cells in G2/M further increased to up to 
60%, in parallel with an emerging sub-G1 population, which most likely reflects late apoptotic 
cells in which the DNA has already been degraded. This effect is a common hallmark for late 
apoptosis and is often linked to the typical DNA ladder observed in agarose gel 
electrophoresis of isolated chromosomal DNA.[269] As characterized by a clearly induced 
G2/M accumulation of viable cells, the small pretubulysin precursor (analog III), which is also 
able to destabilize microtubules, as observed in HCS experiments, in turn, leads to mitotic 
arrest in HepG2 cells. Nevertheless, the effect seems to be more nonspecific than that of 
pretubulysin itself, a difference that is reflected by a higher toxicity that is likely due to the 
greater than 100-fold-higher concentrations required to observe any effect on the cell cycle.  
The overall loss of potency with pretubulysin analog III by about three orders of magnitude 
compared to pretubulysin, the findings from cell cycle studies, and generally, missing decisive 
structural features (pretubulysin analog III lacks the complete C-terminal Tup and the triazole 
moiety of Tuv), are already indicative for a less efficient binding to tubulin protein. Natural 
tubulysins and pretubulysin exhibit only minor differences when it comes to inhibition of in 
vitro tubulin polymerization[203, 225], although potency varies by up to two orders of magnitude 
in cell-based growth inhibition experiments. However, it was found that 20 µM pretubulysin 
analog III are required to reduce tubulin polymerization (10 µM tubulin protein) to about 30% 
of the untreated control (Figure 3-24). In the same experiment, 2 µM pretubulysin were 
sufficient to yield a similar effect. Corresponding electron micrographs revealed that 
treatment with either 2 µM pretubulysin or 25 µM pretubulysin analog III cause similar 
effects with respect to microtubule disruption, as depicted by shortened microtubules and the 
perturbed tubular structure relative to the control (Figure 3-22 and 3-24). The activity of the 
shorter chain analog was approximately 10-fold reduced in the cell-free system and thus, it is 
likely that not only cellular uptake or reduced metabolic stability causes the loss of growth 
inhibition activity but also that binding affinity to purified tubulin is reduced, a conclusion 
which would be in accordance to NMR structural analyses of tubulin-bound tubulysin A.[268]  
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Even though the potency of the small pretubulysin precursor (analog III), which consists of 
only two out of the four original amino acids, was significantly reduced in all accomplished 
assays, the precursor molecule still exhibits a similar MoA than the parent compound 
pretubulysin, which is mainly characterized by microtubule disruption and an induction of 
mitotic arrest. These results suggest that pretubulysin might be further simplified and 
modified easily and attachment of various functional groups on the C-terminus appears 
manageable. Some reports on other further simplified and functionalized 
pretubulysins[270, 271, 272] have already been published and future synthetic approaches might 
aid in obtaining greater insight in the MoA of this compound family and allow the ‘fine-
tuning’ of the target binding, toxicity, and tumor specificity properties of pretubulysin. 
4.1.4 PRETUBULYSINS AS MOLECULAR PROBES  
Fluorophor-coupled conjugates of tubulin binding agents, such as BODIPY-vinblastine and 
BODIPY FL-paclitaxel are already employed mainly in in vitro studies with isolated tubulin 
but also in live cell studies, for instance as tools to determine transport functions of ABC drug 
transportes.[273] Incubation of living cells with the BODIPY conjugate of the microtubule 
destabilizer vinblastine results in a rather uniform fluorescence that is accumulated in the 
cytoplasmic region.[274] However, the bis-acetylated form of a paclitaxel (microtubule 
stabilizer) fluorophor conjugate was successfully applied to visualize distinct 
microtubules[275], which might be attributed to the fact that paclitaxel directly binds to 
polymeric tubulin rather than to monomeric subunits.  
Here, a triazole-pretubulysin was prepared that is functionalized by a coumarin 460 group, 
which was directly coupled via an aliphatic linker to the triazole moiety and by this, replaces 
Tup. The corresponding pretubulysin precursor (analog II, MepIleTuv) exhibited a GI50 value 
of 14.2 µM in mouse L-929 fibroblasts. However, the coumarin-coupled triazole analog was 
approximately by factor 10 more potent than the single MepIleTuv building block with GI50 
values in the low micromolar range. Nevertheless, this implies a reduced potency by 2-3 
orders of magnitude compared to the original pretubulysin.  
It was shown that the tool compound is able to completely destroy the microtubule 
architecture following 48 h treatment in a manner highly similar to pretubulysin (Figure 3-5). 
When assessing the cellular distribution of triazole-pretubulysin coumarin in live cell imaging 
studies (Figure 3-6) no localization could be observed up to 30 min of treatment. This might 
be attributed to a strong background fluorescence of the compound in the cell culture medium 
and unbound pretubulysin inside the cells, which significantly hampers image data analysis. 
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However, throughout the 30 min - 12 h experiment fluorescence was detected organized as 
small vesicles distributed within the cells and at later time points these vesicles were 
somewhat preferably found around the periphery of nuclei. Interestingly, similar results were 
obtained with a fluorophor-coupled tubulysin A construct (personal communication Dr. F. 
Sasse). Unfortunately, the used tool compound is incompatible with common fixation 
techniques so that no direct co-localization with microtubules could be assessed using 
immunostaining for α-tubulin. This issue might be circumvented by using tubulin-GFP fusion 
constructs for labeling of microtubules in living cells. However, post-immunostaining of 
microtubules revealed the typical phenotype with enlarged cells and a higher density of 
microtubules around the nuclear periphery, which is characteristically for a starting 
depolymerization effect. In order to determine the exact localization of the detected 
fluorescent vesicles, acridine orange (AO) staining of vital cells was applied (Figure 3-7). 
When accumulated in acidic lysosomes, this dye exhibits a characteristic orange to red 
fluorescence (λmax ca. 630 nm) and thus, emission maxima of coumarin (λmax ca. 450 nm) and 
AO are sufficiently separated. Surprisingly, an exact co-localization of the triazole-
pretubulysin tool compound and lysosomes was observed. Since lysosomal trafficking is 
mediated via interplay of microtubules, myosin, and actin[276] the appearance of a larger 
fraction of fluorescent spots around nuclei might, in part, be explained indirectly by a higher 
density of microtubules around the nuclear periphery in treated cells. This is also in 
accordance to the finding that depolymerization of microtubules affects the positioning of 
endosomal and lysosomal compartments.[277, 278] Interestingly, accumulation in acidic vesicles 
(endosomes, lysosomes, vesicles of the Golgi compartments) has also been described for a 
variety of other drugs (mostly lipophilic weak bases) as part of a detoxification mechanism of 
the cell or lysosomal trapping is a desired and essential property of a compound, as for 
instance with some antimalarial drugs that target parasite lysosomes.[279] However, in case of 
triazole-pretubulysin coumarin the lysosomal uptake might be favored due to the weak basic 
amine functionalities. Inside lysosomes the compound might become protonated and therefore 
trapped within the acidic compartment. Nevertheless, a certain amount of the overall 
compound load must contribute to microtubule depolymerization by binding to tubulin. Since 
this is most probably due to binding to monomeric subunits, local concentrations might be too 
low to be detectable by fluorescence microscopy in the presence of accumulated dye in 
lysosomes. In principle, it might also be possible that the tool compound very early in the 
process and irreversibly affects microtubule architecture and later on, is mostly accumulated 
in the acidic compartments. This would be in accordance to experiments with pretubulysin 
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and tubulysin A, which both inhibit the long term survival of pancreatic cancer cells over a 
6 d period after a rather short stimulation with the drugs (Figure 3-3). At nanomolar 
concentrations, both compounds were able to reduce the number of cancer cell colonies by at 
least 50%. However, the drawn conclusions are at this stage rather speculative and further 
efforts have to be undertaken to reveal pretubulysin’s cellular localization and details of its 
MoA.  
In an independent study, a second generation of pretubulysin tool compounds has been 
prepared. The pretubulysin core structure was functionalized by a benzophenone moiety, 
which replaces the phenyl group of Tut, and an additional propargylamine coupled to the C-
terminus. In target analysis studies, cells were labeled in situ by UV-induced cross-linking of 
the probe (via benzophenone) with respective binding partners and after cell lysis, a biotin tag 
was introduced by click chemistry via the alkyne group of the tool compound enabling 
enrichment and MS analysis of respective binding partners. Thus, it could be shown for the 
first time that pretubulysin exihibts a remarkably high affinity for β-tubulin. Interestingly, a 
similar approach was applied for fluorescence imaging studies, where it could be shown by 
co-staining of α-tubulin that the used tool compound disturbs microtubule structures. 
However, the covalently-linked fluorescent tool compound was also found to appear as little 
spots that were associated with microtubules, which only remotely resembled the structures 
observed in studies with triazole-pretubulysin coumarin, and authors concluded that these are 
monomeric tubulin units.[272]  
In summary, functionalized pretubulysins appear to be valuable tools for the elucidation of 
binding partners and cellular processes induced by this compound class. Future studies may 
focus on further optimization of the molecules in terms of maintaining original potency, 
elucidation of the exact localization and dynamics within cells, and tool compounds may also 
be applied for in-depth SAR studies by functionalization of various pretubulysin derivatives. 
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4.2 NEW CHONDRAMIDES WITH ALTERED ACTIVITY PROFILE  
Standardized crude extracts from myxobacteria were screened in the course of this thesis on 
their biological activity in whole cell viability assays with regards to antibacterial, antifungal, 
and cytotoxic properties. In a case study with Chondromyces sp. SBCm007, it was found that 
crude extracts were highly cytotoxic and furthermore, induced characteristic morphological 
changes in cultured mammalian cells. Thus, bioactivity-guided isolation was moved from 
classical approaches to high-content screening on defined targets. Dereplication using a 
targeted MS profiling approach[79] highlighted the presence of the actin-targeting cyclic 
depsipeptides chondramides A~D[194] that, in part, explained the strong cytotoxicity of the 
crude material. However, a multitude of novel chondramides derivatives was discovered by 
combining elaborate fermentation, screening, and HR-MS techniques. In particular, biological 
profiling of purified compounds revealed some brominated analogs as invaluable in terms of 
their higher potency on cancer cell lines and an altered affinity in actin polymerization studies 
compared to already described chondramides A~D. 
4.2.1 HIGH-CONTENT SCREENING IS APPLICABLE FOR CRUDE EXTRACTS 
With the advent of HCS it was expected that this technology might greatly facilitate the early 
drug discovery process and subsequent SAR - and toxicity studies. Due to the implementation 
of HTS in the R&D pipeline, primary screening has already been improved in terms of 
productivity. However, higher quality leads are most probably discovered in sophisticated, 
more focused and multiparametric whole cell screens using fluorescence as a read-out. 
Numerous probes have been developed that are commonly either based on labeling certain 
cellular components, indicating environmental signal transduction events, or intrinsical 
labeling of target molecules in living cells.[280] The advantages and disadvantages of both, 
HCS and HTS, are obvious when it comes to screening of large combinatorial or NP-based 
libraries. In the course of further miniaturization of assays and achievements in liquid 
handling and automation processes, HTS allows for very fast screening of large compound 
libraries, however, success rates with regards to marketing of new drugs did not meet 
expectations. Functional HCS assays, on the other hand, have the potential to yield more 
relevant hits, but cell culture techniques are generally time-consuming and difficult to handle 
at a scale required for HCS of large libraries.[281]  
Compared to the screening of pure compound libraries, application of HTS and HCS for crude 
extract bioactivity-guided isolation is even more challenging. Due to the inherent complexity 
of extracts, a significant interference with the assay read-outs is probable, which anticipates a 
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straight forward isolation of NCEs.[1] On the other hand, following traditional approaches 
(whole cell growth inhibtion screens) highly active compounds present in the extracts might 
mask other interesting bioactive metabolites.[105]  
In the course of the presented study it was found that a morphological ‘pre-screening’ of cells 
treated with cytotoxic crude extracts is essential as part of the decision-making process 
whether a sample is subjected to HCS. Early on in the bioactivity-guided isolation process 
extracts that induce specific morphological changes, which are indicative for a cytostatic 
effect, are prioritized over those that cause unspecific toxicity or precipitate. Bioactivities due 
to already known secondary metabolites can then be distinguished from those induced by 
NCEs in an initial HCS experiment by applying focused screens on the established cellular 
targets and putative other apoptotic events (Figure 4-5). 
 
 
Figure 4-5: Integration of HCS in bioactivity-guided isolation of NPs from crude extracts. 
Crude extracts that induce distinct effects in cultured mammalian cell are suitable for 
being further processed via HCS. The technology can thereby aid to distinguish 
cellular events that are caused by already described cytostatic NPs and novel NPs with 
different MoA. 
indicator cell line 
CHO-K1
 treatment with crude extracts
toxic effects             morphological change            precipitation
• known cytostatic compounds?
• cellular targets?
HCS
• assay(s) on established target(s) assays on other apotosis-related targets
discrimination of cytostatic effects of known metabolites
& putative NCEs with different MoA
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Here, crude extracts of Chondromyces sp. SBCm007 were found to be highly active in terms 
of cytotoxicity and furthermore, treated cells were enlarged and contained up to four nuclei 
per cell (Figure 3-25 and 3-26). In principle, these effects could have been attributed to the 
actin-targeting chondramides A~D produced by strain SBCm007 (Figure 3-27). Nevertheless, 
it was expected that other biological activities might be masked by the presence of the cyclic 
depsipetides and thus, the crude extract was subjected to further profiling in HCS 
experiments. Indeed, it could be demonstrated that besides a pronounced actin polymerization 
typically observed with chondramides, LMP (lysosomal membrane permeabilization) was 
induced upon treatment of U-2 OS cells with the crude material. The latter effect could not be 
attributed to the known chondramides (Figures 3-28 and 3-29).  
Following conventional bioactivity-guided isolation, the cytotoxicity of primary fractions was 
assessed in a tetrazolium salt-based viability assay (Figure 3-33). These results displayed 
again the strong cytostatic activity of chondramides being mainly present in two out of 
thirteen fractions. Without having the preliminary data from HCS profiling further processing 
of the crude extract would have probably been aborted since the viability assay failed to detect 
pronounced activities in ‘non-chondramide’ fractions. However, in the following, HCS 
revealed the superiority of image-based screening over conventional cytotoxicity screening. 
Applying the above mentioned primary fractions in HCS experiments on either lysosomal 
integrity (Figure 3-31) or actin filament disruption (Figure 3-32) revealed additional bioactive 
fractions. LMP was expected to be caused by novel metabolites but actin polymerization and 
an increase of lysosomal pH were not ideally separated in terms of active silica gel fractions. 
The crude material was also fractionated using SEC and in fact, distinct fractions that induce 
LMP were obtained (Figure 3-30). Although the effects on lysosomes were highly 
reproducible and distinct in the course of the screening campaign until the first fractionation 
step, LMP induction was not observed anymore in samples from secondary fractionation of a 
SEC fraction by RP-HPLC. Nevertheless, bioactivity was detected in HPLC fractions from a 
primary silica gel fraction (Figure 3-32). Unfortunately, NPs that act by inducing LMP could 
not be isolated in the course of this study, a shortcoming which can be attributed to very low 
abundance of the compounds; due to this, even the definition of target masses could not be 
accomplished for some fractions. Efforts to optimize cultivation conditions for the production 
of these metabolites by strain SBCm007 are currently ongoing. Encouragingly, it could be 
demonstrated recently in an independent study that the secondary metabolite profile observed 
from strain SBCm007 can be successfully diversified by means of gaseous composition 
variation in fermentation processes.[282] 
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Interestingly, actin polymerization activity was found troughout all primary fractions, even in 
those where the MTT viability assay failed to detect any toxicity (Figure 3-34). Following the 
general procedure already applied in bioactivity-guided studies on LMP induction, primary 
fractions were further separated by RP-HPLC, tested in HCS on actin polymerization and 
indeed, the effect on actin filaments could be attributed to distinct HPLC fractions containing 
masses (and corresponding fragmentation patterns) other than those of described 
chondramides. However, upon purification and full structural elucidation by NMR of the first 
putatively novel NPs, it turned out that strain SBCm007 produces new structural variants of 
the chondramide family (Figure 3-36 and Table 3-5). For instance, chondramide A10 was 
found to be glycosylated at C7’ and additionally bears a chlorine at C6’ of the aryl moiety. 
Despite being present only in minute amounts in the crude extracts compared to known 
chondramides, its potency was reduced by at least three orders of magnitude (GI50 > 10 µM). 
Nevertheless, chondramide A10 was highlighted by HCS assays from HPLC fractions due to 
its specific effects on actin filaments. This finding demonstrates the usefulness and 
applicability of the HCS screening approach for the rapid identification of low-abundance 
bioactive natural products.  
Encouraged by the discovery of some structural variants of chondramides, HR-MS data of 
crude extracts and fractions was screened again, assuming that novel chondramides might be 
highly variable in terms of structural features. In addition, supplementation of the culture 
broth with different halogens (e.g. replacement of NaCl by KBr) led to the production of new 
‘non-natural’ C6’-brominated chondramides. In summary, application of HCS for bioactivity-
guided isolation of NPs produced by Chondromyces sp. led to the discovery of altogether 35 
new chondramides variants. Furthermore, 11 of these new NP variants were characterized in 
terms of their bioactivity and results were invaluable for initial SAR conclusions. By 
combining HCS with sensitive analytical techniques for compound identification and 
structure elucidation, and elaborate production optimization to improve the yield of newly 
identified target compounds, it might be possible that significant numbers of novel scaffolds 
can be isolated from myxobacteria and other natural product sources that have been missed by 
previously applied conventional bioactivity-guided isolation approaches.  
4.2.2 STRUCTURE-ACTIVITY RELATIONSHIP OF CHONDRAMIDES 
Highly cytotoxic chondramides A~D were originally isolated from terrestrial strains of the 
species Chondromyces crocatus, and strain Cm c5 was found to be the most efficient producer 
so far (several mg per liter). On average, chondramides exhibited GI50 values in the low- to 
Discussion 
 
112 
mid nanomolar range on several mammalian cell lines and interestingly, also inhibited the 
growth of the Pgp-overexpressing MDR cell line KB-V.1.[194, 283] Similar to the structurally 
related jaspamide/jasplakinolide[206, 207] isolated from Jaspis sponge, chondramides target the 
actin cytoskeleton of mammalian cells and induce a hyperpolymerization of filaments, which 
culminates in the formation of large actin lumps, inhibition of cytokinesis, and cell death. 
Furthermore, both compound families share a common binding site on F-actin, similar to that 
of the mushroom toxin phalloidin, as observed in competition experiments.[208, 209]   
As mentioned previously, tubulin-targeting drugs are an integral part of the pharmacopoeia 
for cancer treatment, but also actin has been thought to be a valid target. However, no actin-
targeting drug is currently in clinical use.[168, 167] Jasplakinolide and chondramides have been 
considered for further preclinical evaluation although having a rather low therapeutic index, 
especially pulmonary hemorrhage induced by jasplakinolide hampered its clinical 
development.[284] Encouragingly, these NPs, unlike phalloidin, are cell-permeable and might 
prove to be excellent probes in studies on actin dynamics.[212] These considerations, in turn, 
fostered several synthesis studies and two independent reports on the total synthesis of 
chondramide C were published more than ten years after the discovery of the 
cyclodepsipeptides.[285, 211]  The synthesis studies enabled the configurational assignment of 
all stereogenic centers and additionally, accounted for important SAR insights. It was found 
that the stereochemistry at the C6-C7 region in the polyketide segment significantly impacts 
chondramide’s activity (efficacy was attenuated by 10- to 100-fold with two of the three 
additionally prepared diastereomers) presumably by populating an unfavorable conformation 
of the tripeptide part of the molecule.[285] This proposal was further substantiated by findings 
from ligand-ligand similarity studies of chondramide C and phalloidin in polymeric actin, 
made up of three independent actin subunits. In addition, interactions of the Trp side chain 
and the hydroxyl group of Tyr in the phalloidin cavity of actin were found.[211] Total synthesis 
of chondramide A, which contains 3-amino-2-methoxy-3-aryl propanoic acid instead of β-
tyrosine, confirmed the configuration at C2’ to be (2S,3S).[286] With modified synthetic 
analogs of this derivative it could be demonstrated that the aryl group is essential for activity 
but can be modified at the para-position by a variety of rather small substituents, such as a 
methyl group, fluorine, or a nitrile group. The biological activity of these derivatives was 
more or less comparable to natural chondramides, merely a C7’ phenyl analog and an amide 
derivative forfeit potency by 1-2 orders of magnitude, respectively[287], and substitution of the 
phenolic OH with other even bulkier groups was actually less tolerated.[288] Probing the 
influence on biological potency of other structural features of the chondramides scaffold it 
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was found that in general, the C6-C7 configuration, N-methylation of the tryptophan α-amino 
group, and the olefin geometry at C4-C5 have a ‘fine-tuning’ function although being 
essential for retaining full biological potency. Solely the stereochemical arrangement at C2 
had a great impact, as indicated by significantly reduced activity of (2R)-configured analogs 
compared to corresponding (2S)-isomers.[288] Figure 4.6 summarizes the aforementioned basic 
SAR conclusions with natural chondramide B as the core structure. 
 
 
Figure 4-6: Structure-activity relationships of synthetic chondramides. 
Chondramides A~D are active in the low- to mid nanomolar range on cultured 
mammalian cells. With natural derivatives neither the chlorination at C5’’ of Trp nor 
the methoxylation at C2’ significantly influences the biological activity of 
chondramides.  
Analysis of the biosynthetic machinery in strain Cm c5 revealed a PKS/NRPS gene cluster for 
the assembly of chondramides, which are comprised of three amino acids (Ala, N-MeTrp, and 
β-tyrosine or α-methoxy-β-tyrosine) and a polyketide chain. In addition to the expected genes 
for PKS and NRPS, a rare tyrosine aminomutase (CmdF) and a previously unknown 
tryptophan-2-halogenase (CmdE) were found to be encoded by the cluster and on the basis of 
structural similarity to jaspamide/jasplakinolide it was proposed that an unsual (R)-β-tyrosine 
moiety is incorporated.[289] In further biosynthesis studies this expectation was confirmed and 
it could also be demonstrated in vitro that the aminomutase CmdF directly converts L-α-
tyrosine into β-tyrosine with (R)-β-tyrosine as the kinetically preferred product.[290] The 
structural diversity of new chondramides derivatives from strain SBCm007 discovered in the 
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course of this thesis is most probably caused by a subset of enzymes absent from the original 
producer strain C. crocatus Cm c5. Halogenation at C6’ and glycosylation or phosphorylation 
at C7’ of the aryl moiety, hydroxylation of C2’, and an ethyl group at C7 of the polyketide 
segment are not present in originally described chondramides A~D. However, the described 
variations are incorporated independently from each other, except for the carbohydrate group 
at C7’, which can solely be found in combination with a halogenation at C6’; no glycosylated 
derivative without halogen at this position could be detected. 
The pressumed actin-polymerizing activity was found with all purified novel chondramides 
(Figure 3-37 displayes exemplary images of cells treated with medium concentrations of 
chondramides), and the effects resembled those described for jasplakinolide[291]. Upon 
treatment with rather low concentrations actin lumps were observed in the perinuclear region 
and at higher dosage, actin was nearly completely depleted from the central region of the 
cells, which exhibited an altered morphology in terms of cell shape and thick actin aggregates 
were found predominantely at the cell margins.  
GI50 values of chondramides were assessed in an MTT viability assay on a small panel of cell 
lines and human primary cells (Table 3-6). Except for the above mentioned glycosylated 
derivatives and chondramide E4, all chondramides were found to be active in the low- to mid 
nanomolar range, which is in accordance to previously reported values for reference 
compounds chondramides A~D.[194, 209] In general, chondramides exhibited no certain 
specificity with respect to origin and tissue of the tested cell lines; most derivatives were 
active in the two-digit nanomolar range on cancer cell lines, including the MDR cell line 
KB-V.1, non-cancerous cell lines, and HUVEC. A direct comparison of activity and 
substitution pattern reveals that bulky groups coupled to the hydroxyl moiety of the aryl 
residue, such as a carbohydrate moiety, generally weaken the activity in cell-based studies, a 
finding also supported by results from other groups.[287, 288] This relationship might be 
partially explained by the lower permeability of the eukaryotic cell membrane for more polar 
compounds. Nevertheless, a phosphate group seems to be tolerated. When comparing 
chondramide A6 (phosphorylated) with chondramide B, and chondramide A8 
(phosphorylated, C6’-chlorinated) with chondramide A4, average GI50 values are all in the 
range of 35 to 50 nM. On the other hand, derivatives with a carbohydrate residue 
(chondramides A9 and A10) were significantly less active in terms of growth inhibition and 
GI50 values were not determinable in the assay’s concentration range but are expected to be 
greater than 5 µM. Another structural feature which was not evaluated in previous SAR 
studies on synthetic chondramides is a hydroxylation at C2’. With regards to chondramides 
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A~D, which either bear a hydrogen or methoxy group at this position, C2’ substitution does 
not seem to impact potency. However, a hydroxyl group, as found in chondramide E4, 
significantly lowers activity by approximately one order of magnitude (GI50 values in the high 
nanomolar to low micromolar range). 
Most interestingly, brominated chondramide C3 analogs were clearly more active on cancer 
cell lines than on human non-cancerous cells and aside from that were generally more potent 
than all other tested derivatives. On average, the C6’-brominated analogs of chondramide C 
either bearing a methyl group at C7 of the polyketide backbone or an ethyl group (eventually 
derived by incorporation of a prolonged starter unit; propionyl-CoA instead of acetyl-CoA) 
were by factor two less toxic for human non-cancerous and primary cells than for human 
cancer cell lines. In comparison, chondramide C exhibits average GI50 values of 45 nM and 
30 nM on cancer cells and non-cancerous/primary cells, respectively. By this, the two most 
important derivatizations, in terms of shifting growth inhibitory activity towards cancer cell 
lines, seem to be the substitution at C6’ (halogen) and C7 (ethyl group). Figure 4-7 
summarizes the SAR conclusions based on GI50 values.  
 
 
Figure 4-7: Structure-activity relationships of novel chondramides based on GI50 values. 
Novel chondramides isolated from strain SBCm007 were active in the low- to mid 
nanomolar range. Only a carbohydrate moiety at C6’ and hydroxylation of C2’ 
negatively impact potency. Interestingly, an ethyl residue at C7 and bromine at C6’ 
seemed to shift specificity of chondramides towards cancer cell lines.  
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4.2.3 BIOLOGICAL AND BIOCHEMICAL DATA SUGGEST A PUTATIVE OFF-TARGET 
Based on the results from growth inhibition experiments (Table 3-6) it was assumed that the 
in vitro actin polymerization potency of chondramides might also differ significantly. Thus, 
compounds were grouped according to their respective GI50 values and activity patterns and 
actin polymerization was assessed. For this purpose, fluorescence of a 5 µM pyrene-labeled 
actin preparation, incubated with 20 µM chondramide, in non-polymerizing buffer (low salt 
conditions) was measured over time (Figure 3-38, 3-39, and 3-40; Table 3-7).   
It has already been proposed that chondramides, as well as the related 
jaspamide/jasplakinolide family share a common binding site on F-actin, similar to that of 
phalloidin.[208, 209] These compounds bind to actin filaments much more tightly than to actin 
monomer and shift the equilibrium (treadmilling) to favor filament formation over 
dissociation by lowering the critical concentration due to a decreased rate constant for subunit 
dissociation from the minus-end.[291, 292] This is also in accordance to live cell imaging studies 
using synthetical chondramide- and jasplakinolide probes, which were coupled to a BODIPY 
fluorophor. The dye-coupled depsipetides led to considerably weaker labeling of cytosolic G-
actin and highly dynamic actin structure (e.g. lamellipodia) than of static long-lived filament 
populations (e.g. stress fibers and arcs).[212] In addition, spontaneous hypernucleation of G-
actin as a result of bundling of very short actin filaments and subsequent actin polymerization 
are typically observed with the above mentioned actin-targeting drugs.[291] Here, it was 
assumed that spontaneous actin polymerization in vitro is either proportional to the 
determined cytostatic activity or might be influenced by cellular uptake of unequally 
substituted chondramides.  
The first test set comprised novel chondramides with GI50 values greater than 200 nM. 
Indeed, polymerization of G-actin was slowed down in comparison to chondramides A~C. As 
already indicated by GI50 values, chondramide E4 (C2’-hydroxyl) was the most active among 
these novel derivatives but exhibited an approximately 2-fold slower increase of pyrene-actin 
fluorescence compared to the reference compounds. For the glycosylated derivatives it seems 
likely that halogenation on the tryptophan residue (C5’’-Cl) can partly restore the ability to 
polymerize actin when directly comparing chondramides A9 and A10. The former does not 
exhibit any actin-polymerizing activity in vitro, whereas with the latter analog polymerization 
steadily increased. A similar relationship is observed for chondramides A3 and A4, where 
additional chlorination at C5’’ increased the polymerization rate even more drastically. 
Interestingly, chondramide A3 (C6’-Cl) and chondramide B (C5’’-Cl) differed significantly in 
their potency of inducing G-actin polymerization; the C6’-Cl analog was approximately by 
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factor three less active. However, this is not in accordance to determined GI50 values, which 
were highly comparable for both compounds. Also phosphorylated analogs A6 and A8 did not 
induce fast G-actin polymerization as suggested by their growth inhibitory potential. With 
average GI50 values of ca. 40 nM these derivatives were nearly as active as reference 
chondramides A~C. However, in vitro polymerization potency was approximately 5-fold 
reduced. This result may indicate that phosphorylated chondramides are taken up by living 
cells but the phosphate ester might be cleaved by intra- or extracellular phosphatases, which 
in turn, counteracts a hindered binding to actin as indicated by observations in the in vitro 
system. 
As mentioned above, a shifted growth inhibitory activity towards human cancer cells seemed 
to be mainly determined by C6’-bromine and C7-ethyl groups, as found in propionyl-bromo-
chondramide C3. Strikingly, this goes along with a ca. 5-fold weaker in vitro activity in actin 
polymerization studies compared to chondramide C.  
 
 
Figure 4-8: Overview of structure-activity relationships of novel chondramides. 
Novel chondramides isolated from strain SBCm007 were evaluated in cell-based and 
in vitro assays. Taken together, the results suggested a putative off-target. The affinity 
to this target appears to be mainly determined by the substitution pattern at C6’ and 
C7. Future synthetic approaches might aid to reveal off-target effects by lowering 
chondramide’s affinity to actin, putatively realized by replacement of tryptophan for 
another amino acid and omitting the C2’ methoxy group (highlighted by dashed 
circles).  
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Similar observations are made for derivatives where only bromine or an ethyl group is present 
(propionyl-chondramide C1 and bromo-chondramide C3), indicating that these substituents 
might disturb the affinity to actin or rather increase the affinity to a second putative target. 
The existence of this second target is even more probable since in vitro activity on actin can 
be restored to highest levels when the methoxy moiety is present in a brominated analog as 
shown for bromo-chondramide A3, indicating that induction of actin polymerization is 
actually not hindered by the halogen substituent. Interestingly, chondramide A3, which is the 
chlorinated analog of bromo-chondramide A3, seems to be less affine to G-actin than its 
counterpart. Unfortunately, no propionyl-chondramide C3 could be isolated to verify these 
findings.  
Figure 4-8 opposes SAR conclusions from cell-based studies to SAR from in vitro 
experiments and highlights possible modification sites for future off-target finding studies. In 
conclusion, substitution of tryptophan in the peptide backbone for another amino acid might 
lower the molecule’s affinity to actin and increase thereby availability of chondramides for 
other putative off-targets. Likewise, absence of the methoxy group at C2’ might aid to further 
weaken the affinity for actin. Based on a scaffold with C6’-bromination and C7-ethylation it 
should be possible to synthesize, with the already established and/or modified routes, 
molecules suitable for further SAR studies and subsequently evaluate both, target-related and 
off-target effects. Nevertheless, at this point, it remains to be proven whether chondramides 
really target other biomolecules than actin.  
4.2.4 DIVERSITY OF NATURAL PRODUCT SCAFFOLDS 
It is assumed that organisms, which are able to retain chemical diversity at low cost, are 
evolutionary favored[9]. With regard to this, it is not surprising that the host strain SBCm007 
further increases the small number of related chondramide derivatives by acquisition of a 
subset of additional enzymes that are not directly associated with the original biosynthetic 
gene cluster. By this, diversity in terms of chemical and physical properties of the compounds 
is increased with minimal additional energetic effort. In addition to chemical diversity per se, 
NPs are optimized in terms of possible protein interactions[25, 26] and considering three-
dimensional structure similarities of proteins, NPs are generally able to interact with a 
plethora of cellular targets that often leads to the modulation of various signaling 
pathways.[26, 27] Based on the aforementioned considerations, it seems to be rather unlikely 
that chondramides do not have a second or even multiple targets. Thus, it might be concluded 
that chondramides in general interact with putative off-targets to a certain extent, a 
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speculation which is strengthened by decisive structural elements of the newly discovered 
derivatives, which may indeed lead to higher affinity to alternative protein targets.  
These phenomena are also common to other drugs and regarded as beneficial since, e.g., an 
emerging multidrug resistance of many cancers is observed with current therapeutic 
approaches. Especially the application of targeted therapies, in contrast to conventional 
chemotherapy, which acts on all dividing cells, fostered a higher rate of resistance 
development. With the approval of new generation anticancer drugs, such as sorafenib, 
inhibition of several signaling pathways will eventually develop as state-of-the-art treatment 
or at least as promising alternative to conventional strategies[293]. Besides the desired targeting 
of several target proteins by the same compound, off-target cytotoxicity has often hampered 
the development of NPs into clinically useful agents. For instance the plant-derived non-
alkaloid toxin lignan podophyllotoxin acts by inhibiting tubulin polymerization but has severe 
toxic side effects. The further development of this drug then led to the discovery of a second 
target molecule, topoisomerase II, and the semisynthetic podophyllotoxin analog etoposide 
was developed for clinical use as topoisomerase II inhibitor.[294] 
In the case of the newly discovered chondramide derivatives both scenarios are conceivable: 
chondramides having a common second target, which remained so far undiscovered and/or 
the future synthesis of analogs that have improved properties with regards to exclusively 
targeting physiologically relevant proteins other than actin in cancer cells.   
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SUMMARY AND CONCLUSIONS 
Natural products remain the most productive source of novel lead structures for a variety of 
therapeutical applications. In the last decades, the fascinating order of Myxococcales 
(myxobacteria) has emerged as a highly valuable source of NPs as these bacteria produce a 
variety of secondary metabolites with unique structures that often exhibit a new mode-of-
action. Numerous myxobacterial metabolites have cytotoxic or cytotstatic properties and six 
distinct compound classes have been described to directly target the eukaryotic cytoskeleton. 
In the course of this study, myxobacterial compounds of two different classes were 
investigated by means of cell biological and in vitro methods. The antimitotic tubulysin 
precursor pretubulysin and some of its derivatives were biologically evaluated. In addition, 
high-content screening was implemented for the bioactivity-guided isolation of NPs from 
myxobacterial origin. This, in turn, resulted in the discovery of novel derivatives of actin-
targeting chondramides that were further characterized. 
5.1 PRETUBULYSINS 
Pretubulysin is a natural product that is found in several strains of myxobacteria in only 
minute amounts. It represents the first enzyme-free intermediate in the biosynthesis of 
tubulysins that undergoes post-assembly acylation and oxidation reactions. In the course of 
this study it could be demonstrated that pretubulysin inhibits the growth of cultured 
mammalian cells, as do tubulysins, which are already in advanced preclinical development as 
anticancer and antiangiogenic agents. The MoA of this highly potent compound class has 
been described and involves the depolymerization of microtubules, thereby inducing mitotic 
arrest. By total synthesis of pretubulysin, the supply issues with the naturally occurring 
derivatives can be circumvented and in contrast to tubulysin, pretubulysin is synthetically 
accessible in gram-scale quantities.  
Encouragingly, it was found that the simplified precursor of tubulysin is nearly equally potent 
to the parent compound as demonstrated by growth inhibition studies using a panel of cell 
lines from different origin and tissue. The testing of several other pretubulysin derivatives, 
which were either direct synthetic precursors or altered in the substitution pattern at various 
positions of the linear tetrapeptide, revealed important SAR insights, which were partly not 
covered in studies on tubulysins so far. As a result, tested derivatives were less potent than 
pretubulysin itself or merely equally active. Nevertheless, it was found that also highly 
simplified molecules, such as pretubulysin analog III that consists only of two out of the four 
original amino acids, still exibit a certain cytotoxicity in the micromolar range on mammalian 
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cell lines. Analyzing the antimitotic potential of pretubulysins in comparison to well-studied 
myxobacterial secondary metabolites that target microtubules (tubulysins, disorazol, and 
epothilone) it was found that all tested microtubule destabilizers show a highly comparable 
MoA by means of tubulin-related effects. Interestingly, although the activity of pretubulysin 
analog III was reduced by approximately three orders of magnitude compared to pretubulysin 
in growth inhibition experiments, this compound still can bind to tubulin in vitro and cause 
microtubule depolymerization in cell-based assays. However, these effects appeared to be 
more toxic than observed for pretubulysin itself as revealed by flow cytometric 
measurements.  
In more detailed studies it turned out that pretubulysin induces apoptosis in part via the 
intrinsic (mitochondrial) pathway as a result of mitotic block as depicted by a G2/M cell cycle 
arrest, and is also able to inhibit the long-term survival of cancer cells. Similarly to results 
from in vitro experiments, pretubulysin was comparably active to its parent compound 
tubulysin. Consequently, pretubulysin appears to be an ideal candidate for future development 
in preclinical trials and is a very promising early lead structure in cancer therapy as it exhibits 
common characteristics of other already established antimitotic compounds. In addition, SAR 
studies revealed possible modification sites of the core pretubulysin structure, which, in turn, 
might aid to develop improved pretubulysins and functionalized molecules for future in-depth 
preclinical evaluations. First attempts were already promising, as coumarin-tagged triazole-
pretubulysin was still active in the low micromolar range and in addition, did not lose its 
ability to depolymerize microtubules. However, results from live cell imaging studies cannot 
be definitely construed at this stage. With a synthetic route in hand, pretubulysin can be easily 
modified by means of further simplification and the attachment of various other functional 
groups. Future synthetic approaches will thereby aid in obtaining greater insight into the MoA 
of this compound family and will allow the ‘fine-tuning’ of the target-binding, toxicity, and 
tumor specificity properties of pretubulysin. 
5.2 CHONDRAMIDES 
Several bottlenecks in traditional bioactivity-guided isolation hamper the successful discovery 
of new chemical entities with potent bioactivity from natural sources. One issue is the 
presence of already decribed bioactive metabolites in e.g. bacterial extracts that might mask 
activities of other interesting NPs. By implementing high-content screening for bioactivity-
guided isolation with a focus on cytostatic compounds it was expected that the deconvolution 
of various observations, in terms of activity, might be greatly facilitated.  
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In the course of this study, extracts and fractions of Chondromyces sp. SBCm007 were 
subjected to in-depth HCS studies. Mainly two distinct biological effects were found: the 
polymerization of actin and a loss of lysosomal integrity. Compounds that induce the latter 
effect could not be isolated in the course of this work as these metabolites were produced in 
minute amounts only. Current work focuses on the production optimization with respect to 
these NPs. 
However, dereplication of LC-MS data against our in-house database revealed the presence of 
chondramides A~D in SBCm007 extracts and this could further be confirmed by means of 
cytotoxicity as depicted by conventional viability screening using mammalian cell lines. 
These cyclic depsipeptides are described to target actin filaments with a similar binding mode 
to the mushroom toxin phalloidin. Astonishingly, in HCS experiments, actin polymerization 
was found throughout all prepared fractions, also in the ‘non-chondramide’ samples for which 
viability screening failed to detect any pronounced activity. Thus, by the application of 
focused HC screens, over 30 novel chondramide derivatives were discovered from 
Chondromyces sp. SBCm007, some of which were present in minute amounts only. In 
addition, supplementation of the culture broth with potassium bromide afforded the 
production of brominated analogs. 
The initial biological profiling of 11 new derivatives in comparison to reference compounds 
(chondramides A~C) lead to important SAR conclusions. In particular, bromo-chondramide 
C3 and propionyl-bromo-chondramide C3 were the most active in cell-based studies, with 
GI50 values on human cancer cell lines in the low nanomolar range. Furthermore, these 
bromo-chondramides are in average by factor 2-4 less cytotoxic for non-cancerous human 
cells in comparison to average values on cancer cell lines. However, for these two compounds 
activity could not be exclusively explained by a strong actin polymerizing effect, as observed 
for instance with chondramides A and B in in vitro experiments. In fact, in vitro actin 
polymerization using brominated analogs showed an apparently different progression than 
observed for chondramides A~C as bromo-chondramides were much less active in the cell-
free system. For these reasons, a second cancer cell target for chondramides, other than actin, 
was proposed. This cellular target currently remains undiscovered and should be the subject 
of future investigations. 
In summary, HCS is highlighted as a valuable tool for bioactivity-guided isolation of NPs 
from crude bacterial extracts. Given the fact that the growth inhibitory activity on cancer cell 
lines of newly discovered bromo-chondramide C3 and propionyl-bromo-chondramide C3 
outcompetes that of described chondramides and that these derivatives were less potent on 
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non-cancerous human cells and less active in in vitro actin polymerization experiments, 
evidence for a putative off-target for this exciting class of NPs is provided. The results of the 
presented study can also aid the further SAR-guided development of chondramides either as 
molecular probes or pharmaceutical agents.  
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APPENDIX 
7.1 ABBREVIATIONS 
ABP  actin-binding protein 
ACC  acetyl CoA carboxylase 
ADC  antibody-drug conjugate 
ADP  adenosine diphosphate 
AIF  apoptosis inducing factor 
AO  acridine orange 
Apaf-1  apoptotic protease activating factor 1 
ARP  actin-related protein 
ATP  adenosine triphosphate 
a.u.  arbitrary units 
Bcl-2/pBcl-2 B cell lymphoma 2/phosphorylated B cell lymphoma 2 
bFGF  basic fibroblast growth factor (recombinant human) 
BODIPY FL boron-dipyrromethene fluorescein-like fluorescence 
BPC  base peak chromatogram 
γH2A.X phosphorylated histone H2A.X 
γ-TuRC γ-tubulin ring complex 
CD  cluster of differentiation 
CDK  cyclin-dependent kinase 
cf.  confer 
CF  cystic fibrosis 
Ctrl.  control 
Da  Dalton 
dd  double-distilled 
DMEM  Dulbecco’s modified eagle medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  deoxynucleoside triphosphate 
DSB  DNA double-strand break 
ECGS  endothelial cell growth supplement (bovine hypothalamic extract) 
EDTA  ethylene diamine tetraacetic acid 
e.g.  exempli gratia 
EGF  epidermial growth factor (recombinant human) 
EGTA  ethylene glycol tetraacetic acid 
EPS  exopolysaccharide 
ERK1/2  extracellular signal-regulated kinases 1/2 
F-actin  filamentous (or polymeric) actin 
FBS  fetal bovine serum 
FCM  flow cytometric measurement 
FCS  fetal calf serum 
G-actin  globular (or monomeric) actin 
GDP  guanosine diphosphate 
GFP  green-fluorescent protein 
GI50  half maximal growth inhibitory concentration 
GLP-1  glucagon-like peptide-1 
GTP  guanosine triphosphate 
HCS  high-content screening 
HIF-1  hypoxia-inducible factor-1 
HMG-CoA 3-hydroxy-3-methyl-glutaryl-coenzyme A 
HPLC  high-performance liquid chromatography 
HR-MS high-resolution mass spectrometry 
HTS  high-throughput screening 
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HU  hydroxyurea 
IC50  half maximal inhibitory concentration 
i.e.  id est 
IF  intermediate filament or immunofluorescence 
IgG (H+L) immunoglobulin G (heavy and light chains) 
Ile  isoleucin 
JNK  c-Jun N-terminal kinase 
LC  liquid chromatography 
LHRH  luteinizing hormone-releasing hormone 
LMP  lysosomal membrane permeabilization 
mAb  monoclonal antibody 
MAP  microtubule-associated protein 
Mb  mega base pairs 
MCAK  mitotic centromere-associated kinesin (kinesin-like protein KIF2C) 
MDR  multidrug resistant 
MDR-TB multidrug resistant tuberculosis 
MEM  minimum essential medium eagle 
Mep  N-methylpipecolic acid 
Me’Val’ methylvaline derivative in which Val is replaced by the C2-prolonged homolog (γ-
amino acid) 
MMP mitochondrial membrane potential 
MoA  mode-of-action 
MOMP  mitochondrial outer membrane permeability 
MRP  multidrug resistant protein 
MRSA  methicillin-resistant Staphylococcus aureus 
MS  mass spectrometry 
Mtb  Mycobacterium tuberculosis 
MTOC  microtubule-organizing center 
mTOR  mammalian target of rapamycin 
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NCE  new chemical entity 
NCS  newborn calf serum 
n.d.  not determined 
NEAA  non-essential amino acids 
NMR  nuclear magnetic resonance 
NP  natural product 
NRP  non-ribosomal peptide 
NRPS  non-ribosomal peptide synthetase 
o/n  overnight 
PARP  poly(ADP-ribose) polymerase 
PBS  phosphate-buffered saline 
PCB  phosphate-citrate buffer 
P-gp  P-glycoprotein 
PI  propidium iodide 
Pip  pipecolic acid 
PIP2  polyphosphoinositide 4,5-bisphosphate 
PIPES  piperazine-N,N′-bis(2-ethanesulfonic acid) 
PK  polyketide 
PKS  polyketide synthase 
Q-VD-OPh quinolyl-valyl-O-methylaspartyl-[-2, 6-difluorophenoxy]-methyl ketone 
R&D  research and discovery 
RFU  relative fluorescence units 
RNA  ribonucleic acid 
ROI  region-of-interest 
RPMI  Roswell Park Memorial Institute medium 
RTK  receptor tyrosine kinase 
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SAR  structure-activity relationship 
SD  standard deviation 
SEC  size-exclusion chromatography 
SEM  standard error of the mean 
TCM  traditional Chinese medicine 
TEM  transmission electron microscopy 
TFA  trifluoro acetic acid 
TMRM  tetramethyl rhodamine methyl ester 
Tup  tubuphenylalanine 
Tut  tubutyrosine 
Tuv  tubuvaline 
Val  valine 
V-ATPase vacuolar-type H+-adenosine triphosphatase 
v/v  volume-to-volume 
WT  wildtype 
w/v  weight-in-volume 
XDR-TB extensively drug-resistant tuberculosis 
XMAP215 microtubule-associated protein 215 kDa 
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